
<html lang="en"     class="pb-page"  data-request-id="f2042dde-2a72-4244-89fc-376537ca3daa"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.6b01634;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2017.60.issue-2;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin" /></meta><meta name="dc.Creator" content="Peter  Jones" /></meta><meta name="dc.Creator" content="R. Ian  Storer" /></meta><meta name="dc.Creator" content="Yogesh A.  Sabnis" /></meta><meta name="dc.Creator" content="Florian M.  Wakenhut" /></meta><meta name="dc.Creator" content="Gavin A.  Whitlock" /></meta><meta name="dc.Creator" content="Katherine S.  England" /></meta><meta name="dc.Creator" content="Takasuke  Mukaiyama" /></meta><meta name="dc.Creator" content="Christoph M.  Dehnhardt" /></meta><meta name="dc.Creator" content="Jotham W.  Coe" /></meta><meta name="dc.Creator" content="Steve W.  Kortum" /></meta><meta name="dc.Creator" content="Jill E.  Chrencik" /></meta><meta name="dc.Creator" content="David G.  Brown" /></meta><meta name="dc.Creator" content="Rhys M.  Jones" /></meta><meta name="dc.Creator" content="John R.  Murphy" /></meta><meta name="dc.Creator" content="Thean  Yeoh" /></meta><meta name="dc.Creator" content="Paul  Morgan" /></meta><meta name="dc.Creator" content="Iain  Kilty" /></meta><meta name="dc.Description" content="By use of a structure-based computational method for identification of structurally novel Janus kinase (JAK) inhibitors predicted to bind beyond the ATP binding site, a potent series of indazoles w..." /></meta><meta name="Description" content="By use of a structure-based computational method for identification of structurally novel Janus kinase (JAK) inhibitors predicted to bind beyond the ATP binding site, a potent series of indazoles w..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 4, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b01634" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01634" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b01634" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01634" /></link>
        
    
    

<title>Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b01634" /></meta><meta property="og:title" content="Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0031.jpeg" /></meta><meta property="og:description" content="By use of a structure-based computational method for identification of structurally novel Janus kinase (JAK) inhibitors predicted to bind beyond the ATP binding site, a potent series of indazoles was identified as selective pan-JAK inhibitors with a type 1.5 binding mode. Optimization of the series for potency and increased duration of action commensurate with inhaled or topical delivery resulted in potent pan-JAK inhibitor 2 (PF-06263276), which was advanced into clinical studies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b01634"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01634">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b01634&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b01634&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b01634&amp;href=/doi/10.1021/acs.jmedchem.6b01634" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 2</span><span class="cit-fg-pageRange">, 767-786</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/2" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b01591" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b01642" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Jones">Peter Jones</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-8637-9530" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=R.+Ian++Storer">R. Ian Storer</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span><span class="author-xref-symbol "><sup>â</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yogesh+A.++Sabnis">Yogesh A. Sabnis</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span><span class="author-xref-symbol "><sup>Â¶</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Florian+M.++Wakenhut">Florian M. Wakenhut</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span><span class="author-xref-symbol "><sup>â</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gavin+A.++Whitlock">Gavin A. Whitlock</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span><span class="author-xref-symbol "><sup>Ã</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Katherine+S.++England">Katherine S. England</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span><span class="author-xref-symbol "><sup>â</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Takasuke++Mukaiyama">Takasuke Mukaiyama</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span><span class="author-xref-symbol "><sup>â³</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christoph+M.++Dehnhardt">Christoph M. Dehnhardt</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span><span class="author-xref-symbol "><sup>â²</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jotham+W.++Coe">Jotham W. Coe</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steve+W.++Kortum">Steve W. Kortum</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jill+E.++Chrencik">Jill E. Chrencik</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David+G.++Brown">David G. Brown</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â</sup></span><span class="author-xref-symbol "><sup>â</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rhys+M.++Jones">Rhys M. Jones</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+R.++Murphy">John R. Murphy</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Thean++Yeoh">Thean Yeoh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Morgan">Paul Morgan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Iain++Kilty">Iain Kilty</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>â </sup>Medicine Design, <sup>â¡</sup>Pharmacokinetics, Dynamics and Metabolism, and <sup>Â§</sup>Inflammation and Immunology Research Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States</span></div><div class="aff-info" id="aff2"><span class="aff-text"><sup>â¥</sup>Medicine Design, and <sup>â¥</sup>Medicinal Sciences, Pfizer Inc., 445 Eastern Point Road, Groton, Connecticut 06340, United States</span></div><div class="aff-info" id="aff3"><span class="aff-text"><sup>#</sup>Worldwide Medicinal Chemistry, <sup>â</sup>Structural Biology and Biophysics, and <sup>â</sup>Pharmaceutical Sciences, Pfizer Ltd., Ramsgate Road, Sandwich, CT13 9NJ, U.K.</span></div><div class="corresp-info"><strong>*</strong>P.J.: e-mail, <a href="/cdn-cgi/l/email-protection#acdcc9d8c9de82c6c3c2c9df9eecdccac5d6c9de82cfc3c1"><span class="__cf_email__" data-cfemail="2252475647500c484d4c4751106252444b5847500c414d4f">[emailÂ protected]</span></a></div><div class="corresp-info"><strong>*</strong>R.I.S.: e-mail, <a href="/cdn-cgi/l/email-protection#2d444c43035e59425f485f6d4c5e595f4c574843484e4c034e4240"><span class="__cf_email__" data-cfemail="046d656a2a77706b7661764465777076657e616a6167652a676b69">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01634&amp;href=/doi/10.1021%2Facs.jmedchem.6b01634" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 2</span><span class="cit-pageRange">, 767â786</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 16, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>8 November 2016</li><li><span class="item_label"><b>Published</b> online</span>4 January 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 January 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b01634" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01634</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D767%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DPeter%2BJones%252C%2BR.%2BIan%2BStorer%252C%2BYogesh%2BA.%2BSabnis%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D2%26contentID%3Dacs.jmedchem.6b01634%26title%3DDesign%2Band%2BSynthesis%2Bof%2Ba%2BPan-Janus%2BKinase%2BInhibitor%2BClinical%2BCandidate%2B%2528PF-06263276%2529%2BSuitable%2Bfor%2BInhaled%2Band%2BTopical%2BDelivery%2Bfor%2Bthe%2BTreatment%2Bof%2BInflammatory%2BDiseases%2Bof%2Bthe%2BLungs%2Band%2BSkin%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D786%26publicationDate%3DJanuary%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b01634"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4275</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">28</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b01634" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Jones&quot;},{&quot;first_name&quot;:&quot;R.&quot;,&quot;last_name&quot;:&quot;Ian Storer&quot;},{&quot;first_name&quot;:&quot;Yogesh&quot;,&quot;last_name&quot;:&quot;A. Sabnis&quot;},{&quot;first_name&quot;:&quot;Florian&quot;,&quot;last_name&quot;:&quot;M. Wakenhut&quot;},{&quot;first_name&quot;:&quot;Gavin&quot;,&quot;last_name&quot;:&quot;A. Whitlock&quot;},{&quot;first_name&quot;:&quot;Katherine&quot;,&quot;last_name&quot;:&quot;S. England&quot;},{&quot;first_name&quot;:&quot;Takasuke&quot;,&quot;last_name&quot;:&quot;Mukaiyama&quot;},{&quot;first_name&quot;:&quot;Christoph&quot;,&quot;last_name&quot;:&quot;M. Dehnhardt&quot;},{&quot;first_name&quot;:&quot;Jotham&quot;,&quot;last_name&quot;:&quot;W. Coe&quot;},{&quot;first_name&quot;:&quot;Steve&quot;,&quot;last_name&quot;:&quot;W. Kortum&quot;},{&quot;first_name&quot;:&quot;Jill&quot;,&quot;last_name&quot;:&quot;E. Chrencik&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;G. Brown&quot;},{&quot;first_name&quot;:&quot;Rhys&quot;,&quot;last_name&quot;:&quot;M. Jones&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;R. Murphy&quot;},{&quot;first_name&quot;:&quot;Thean&quot;,&quot;last_name&quot;:&quot;Yeoh&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Morgan&quot;},{&quot;first_name&quot;:&quot;Iain&quot;,&quot;last_name&quot;:&quot;Kilty&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;04&quot;,&quot;issue&quot;:&quot;2&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;767-786&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b01634&quot;},&quot;abstract&quot;:&quot;By use of a structure-based computational method for identification of structurally novel Janus kinase (JAK) inhibitors predicted to bind beyond the ATP binding site, a potent series of indazoles was identified as selective pan-JAK inhibitors with a type 1.5 binding mode. Optimization of the series for potency and increased duration of action commensurate with inhaled or topical delivery resulted in potent pan-JAK inhibitor 2 (PF-06263276), which was advanced into clinical studies.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01634&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01634" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01634&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01634" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01634&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01634" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01634&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01634&amp;href=/doi/10.1021/acs.jmedchem.6b01634" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b01634" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b01634" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b01634%26sid%3Dliteratum%253Aachs%26pmid%3D27983835%26genre%3Darticle%26aulast%3DJones%26date%3D2017%26atitle%3DDesign%2Band%2BSynthesis%2Bof%2Ba%2BPan-Janus%2BKinase%2BInhibitor%2BClinical%2BCandidate%2B%2528PF-06263276%2529%2BSuitable%2Bfor%2BInhaled%2Band%2BTopical%2BDelivery%2Bfor%2Bthe%2BTreatment%2Bof%2BInflammatory%2BDiseases%2Bof%2Bthe%2BLungs%2Band%2BSkin%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D2%26spage%3D767%26epage%3D786%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291456" title="Hydrocarbons">Hydrocarbons</a>,</li><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/2" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/jmcmar.2017.60.issue-2/20170126/jmcmar.2017.60.issue-2.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0031.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">By use of a structure-based computational method for identification of structurally novel Janus kinase (JAK) inhibitors predicted to bind beyond the ATP binding site, a potent series of indazoles was identified as selective pan-JAK inhibitors with a type 1.5 binding mode. Optimization of the series for potency and increased duration of action commensurate with inhaled or topical delivery resulted in potent pan-JAK inhibitor <b>2</b> (PF-06263276), which was advanced into clinical studies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50163" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50163" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Janus kinases, JAKs, are a family of tyrosine kinases comprising four members (JAK1, -2, -3, and Tyk2). They play a critical role in both innate and adaptive immunity, since they function as key transducers in the signaling processes of many cytokine receptors.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> As such, they have emerged as attractive targets for a number of inflammatory diseases, and numerous inhibitors are under active clinical development.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Among these, tofacitinib, <b>1</b> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) was first approved in 2012 by the FDA for the treatment of rheumatoid arthritis (RA).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The efficacy and safety of tofacitinib has been studied in several immune-mediated inflammatory diseases, including rheumatoid arthritis,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> psoriasis,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> ulcerative colitis,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Crohnâs disease,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> psoriatic arthritis,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and ankylosing spondylitis.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0001.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of tofacitinib (<b>1</b>) and novel pan-JAK inhibitor (<b>2</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">By use of JAK enzymatic assays run at physiologically relevant 1 mM ATP concentration, tofacitinib displays selectivity for JAK1 inhibition, although it also inhibits JAK3 (3-fold weaker) and JAK2 (5-fold weaker). In a cellular settting, tofacitinib preferentially inhibits signaling by heterodimeric cytokine receptors that associate with JAK3 and/or JAK1 with functional selectivity over cytokine receptors that signal via pairs of JAK2. For example in human whole blood assays, tofacitinib inhibits IL-15, IFNÎ±, and IL-6 signaling with IC<sub>50</sub> values between 35 and 80 nM, whereas the IC<sub>50</sub> for JAK2 dependent EPO signaling was â¼300 nM. Given the role of JAK2 dependent EPO signaling in red blood cell production, reduction in hemoglobin levels was observed at higher doses with tofacitinib in clinical trials.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Despite this, the functional selectivity for cytokine inhibition for EPO signaling has proven to be manageable at clinical doses that provide benefit to rheumatoid arthritis and psoriasis patients without reducing hemoglobin.<a onclick="showRef(event, 'cit4a ref10'); return false;" href="javascript:void(0);" class="ref cit4a ref10">(4a, 10)</a></div><div class="NLM_p last">There are a number of JAK inhibitors in clinical development that have varying selectivities within the JAK family. In a cellular setting the advanced candidates preferentially inhibit JAK1 dependent cytokines, including the Î³-common chain cytokines, interferons, and IL-6.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Since tofacitinib and other JAK inhibitor advanced clinical candidates preferentially inhibit JAK1-dependent cytokines, little clinical differentiation is expected. To further improve upon the therapeutic potential of JAK inhibition in general, a greater degree of selectivity over systemic JAK2 inhibition and EPO signaling in particular would be desirable. Besides attempting to produce an inhibitor with higher selectivity among the JAK family, an alternative approach for certain diseases would be to target JAK inhibition directly at the site of action in the relevant organ of interest while avoiding widespread systemic JAK inhibition. Herein we describe the design and development of a novel and potent pan-JAK inhibitor <b>2</b> (PF-06263276, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>),<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> suitable for inhaled or topical administration as an organ targeted therapy. Compound <b>2</b> has the potential to treat inflammatory diseases of the lungs (such as COPD)<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and skin (such as mild-to-moderate psoriasis)<a onclick="showRef(event, 'cit5a'); return false;" href="javascript:void(0);" class="ref cit5a">(5a)</a> with negligible systemic JAK inhibition.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27823" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27823" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Following our previously described concept of âinhalation by designâ,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> we sought to design a JAK inhibitor that fulfilled the following criteria: (1) high potency to minimize dose size, given the limits of dose sizes of typical dry powder inhalation (DPI) devices (<1 mg drug product) and to minimize the percentage of active ingredient required in topical formulations, (2) high selectivity for the JAK family of kinases versus the rest of the kinome, (3) low systemic exposure and high metabolic clearance to maximize the therapeutic index by targeting drug only to the site of action (with no potent active metabolites formed), (4) multiple routes and mechanisms of metabolism to minimize the potential for any drugâdrug interactions, (5) suitable solid form characteristics to allow for blending with lactose for use in a DPI device and formulation as a topical ointment or cream, (6) evidence of long duration of action (DoA) of JAK inhibition in enzymatic assays (through kinetic experiments) or cell based assays (through cell wash-out experiments), to allow for sustained target modulation in vivo.</div><div class="NLM_p">Given the successful clinical precedent of tofacitinib to modulate JAK driven disease, our initial tactic was to increase the lipophilicity in this template to introduce metabolic instability, with the aim to maintain or improve the significant JAK potency and selectivity typically observed with this chemotype, while also assaying for evidence of DoA. We quickly found that a urea linkage could be used in place of the amide bond in tofacitinib, and this allowed for facile introduction of lipophilic groups that maintained excellent JAK potency and selectivity while introducing metabolic instability. For example <b>3</b> (PF-00956980), a useful commercially available JAK inhibitor tool, (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) maintains excellent JAK potency and has high turnover in human liver microsomes (HLM).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The pyrrolidine ring of <b>3</b> could be further substituted with no loss in potency by larger groups containing phenols, which were introduced to allow for rapid phase II metabolism of compounds, thus providing a second route of metabolism. For example <b>4</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) has high turnover in both HLM and HLM UGT assays and increased JAK enzyme potency relative to compound <b>3</b>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Potency and in Vitro Metabolic Stability Data for Tofacitinib Analogues <b>3</b> and <b>4</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0023.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="4" align="center">IC<sub>50</sub>â¯<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> (nM)</th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">JAK1</th><th class="colsep0 rowsep0" align="center">JAK2</th><th class="colsep0 rowsep0" align="center">JAK3</th><th class="colsep0 rowsep0" align="center">Tyk2</th><th class="colsep0 rowsep0" align="center">HLM<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a> ((Î¼L/min)/mgÂ protein)</th><th class="colsep0 rowsep0" align="center">HLM UGT<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a> ((Î¼L/min)/mgÂ protein)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">37.5</td><td class="colsep0 rowsep0" align="left">123.6</td><td class="colsep0 rowsep0" align="left">139.3</td><td class="colsep0 rowsep0" align="left">1632.2</td><td class="colsep0 rowsep0" align="left">82</td><td class="colsep0 rowsep0" align="left"><3.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">21.2</td><td class="colsep0 rowsep0" align="left">34.1</td><td class="colsep0 rowsep0" align="left">958.6</td><td class="colsep0 rowsep0" align="left">131</td><td class="colsep0 rowsep0" align="left">>200</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Compounds were routinely assayed using Caliper microfluidic assays for their potency of inhibition of phosphorylation of a peptide substrate by the appropriate JAK enzyme at 1 mM ATP concentration. All IC<sub>50</sub> values reported represent geometric mean values of a minimum of three determinations.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Compounds were routinely assessed for metabolic stability in human liver microsomes (HLMs).</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Compounds were assessed for phase II glucuronidation in HLM by including the microsomal activator Brij58 and cofactor uridine diphosphate glucuronic acid (UDPGA) and excluding the cytochrome P450 dependent cofactor NADPH.</p></div></div></div><div class="NLM_p">Urea <b>4</b> was shown to have a suitable crystalline solid form and acceptable thermodynamic solubility (20 Î¼g/mL) to meet our initial compound criteria; however in a number of different assay formats we could not demonstrate evidence for significant DoA with this compound nor with any others within this chemotype. To investigate enzyme inhibition kinetics, we used a continuous JAK3 dilution recovery assay using microfluidic mobility shift assay technology.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Both tofacitinib <b>1</b> and urea <b>3</b> showed no evidence of slow-offset from JAK3 in this assay, while <b>4</b> showed an offset rate of 0.024 min<sup>â1</sup> that translated to a <i>T</i><sub>1/2</sub> of approximately 28 min. In a PBMC cell-based assay we could measure inhibition of the cellular pSTAT5 response to IL-2 stimulation with <b>3</b> and <b>4</b> giving IC<sub>50</sub> values of 27 nM and 343 nM, respectively. Using this assay, we investigated cellular DoA by incubating compounds for 1 h at 10-fold the IC<sub>50</sub>, washing cells extensively, and then monitoring recovery of the cellular pSTAT5 response to IL-2 stimulation over time. Both <b>3</b> and <b>4</b> showed no sign of pSTAT5 inhibition in this assay immediately following cell washing. Assessing these data together, we did not view these compounds as having significant potential to show clinical duration of action as inhaled or topical agents in vivo, and thus we sought an alternative chemical series.</div><div class="NLM_p">Examination of overlaid X-ray crystal structures of tofacitinib <b>1</b> and <b>4</b> bound to JAK2 (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>) shows that they both adopt the same âtype-1â inhibitor binding mode with the methionine gatekeeper residue flanking the back of the pocket in both cases.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The larger molecule <b>4</b> shows some displacement of the glycine rich P-loop of the kinase relative to tofacitinib, although as demonstrated by our data, this binding mode does not appear to result in any significant kinetic advantage, likely due to high flexibility of the protein in this region.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0002.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Overlaid X-ray cocrystal structures illustrating binding mode of tofacitinib (<b>1</b>) (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LXK">3LXK</a>) and <b>4</b> (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ7">5TQ7</a>) bound to JAK2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It has been well documented by us and others that certain kinase inhibitor binding modes appear to be correlated to slow-offset binding kinetics, in particular the âtype 2â inhibitor binding mode.<a onclick="showRef(event, 'cit13c ref16'); return false;" href="javascript:void(0);" class="ref cit13c ref16">(13c, 16)</a> This binding mode results in a portion of the inhibitor binding at a remote distance from the hinge binding motif, behind the gatekeeper amino acid, into an induced âback pocketâ of the kinase, resulting in significant movement of the DFG portion of the activation loop and stabilization of an inactive form of the kinase. In order to find a JAK inhibitor series with evidence of DoA in enzyme kinetics and cell based experiments, we sought to leverage our internal database of kinase X-ray cocrystal structures, along with kinase cocrystal structures available from the PDB,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> to identify a subset of kinase inhibitors with the potential to bind behind the gatekeeper residue and to screen this subset for potency against the JAK kinases.</div><div class="NLM_p">Using approximately 2500 in-house kinase inhibitor crystal structures, together with approximately 1500 additional structures available from the PDB, we computationally collected and aligned all structures into a common orientation. A computational triage was then performed to identify any inhibitor templates that were predicted to bind to the hinge region of the kinase and within 2 Ã of the methionine gatekeeper residue in JAK3. We reasoned that any compounds found to be potent JAK inhibitors from this selection would likely bind in a manner necessitating a conformational change in the kinase, placing binding elements in the back pocket of the kinase, potentially leading to slower offset kinetics. This screening effort resulted in the discovery that the indazole-phenol <b>5</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>), a compound in our corporate collection from a previous research program,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> is a potent pan-JAK inhibitor with IC<sub>50</sub> values of <1 nM to 10 nM against the JAK kinase family at 1 mM ATP concentration. <b>5</b> displayed an enzymatic kinetic offset rate of 0.006 min<sup>â1</sup> that translated to a <i>T</i><sub>1/2</sub> of approximately 114 min for JAK3. It also showed a significant time dependent inhibition of the cellular pSTAT5 response to IL-2 stimulation following compound incubation and cell washing, with a <i>T</i><sub>1/2</sub> of 6.5 h.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Profile of Indazole-phenol <b>5</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0024.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="4" align="center">IC<sub>50</sub>â¯<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (nM)</th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">JAK1</th><th class="colsep0 rowsep0" align="center">JAK2</th><th class="colsep0 rowsep0" align="center">JAK3</th><th class="colsep0 rowsep0" align="center">Tyk2</th><th class="colsep0 rowsep0" align="center">HLM<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> ((Î¼L/min)/mgÂ protein)</th><th class="colsep0 rowsep0" align="center">HLM UGT<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a> ((Î¼L/min)/mgÂ protein)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left">8.3</td><td class="colsep0 rowsep0" align="left">9.1</td><td class="colsep0 rowsep0" align="left">35</td><td class="colsep0 rowsep0" align="left">49</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Compounds were routinely assayed using Caliper microfluidic assays for their potency of inhibition of phosphorylation of a peptide substrate by the appropriate JAK enzyme at 1 mM ATP concentration. All IC<sub>50</sub> values reported represent geometric mean values of a minimum of three determinations.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Compounds were routinely assessed for metabolic stability in human liver microsomes (HLMs).</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">Compounds were assessed for phase II glucuronidation in HLM by including the microsomal activator Brij58 and cofactor uridine diphosphate glucuronic acid (UDPGA) and excluding the cytochrome P450 dependent cofactor NADPH.</p></div></div></div><div class="NLM_p">We were pleased to find that an X-ray crystal structure of <b>5</b> bound to JAK2 (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>) showed a novel binding mode for the JAK kinases, compared to the previously observed type-1 binding mode observed with tofacitinib. The methionine gatekeeper residue moved approximately 4.3 Ã from the known type-1 binding mode orientation, allowing the phenolic portion of the molecule to bind behind the gatekeeper in an induced back pocket. The indazole-benzimidazole portion of the molecule forms three hydrogen bonding interactions with the hinge region of the kinase, while the phenol group makes two hydrogen bonding interactions in the back-pocket, with the Î±-Glu (E898) of the C-helix and the backbone NH of the Phe (F995) of the DFG motif. The ethyl group of the phenol ring occupies the lipophilic space left by movement of the methionine side chain and helps induce a twist across the biaryl bond to the indazole ring. It is interesting to note that despite significant binding in the backpocket and the movement of the gatekeeper methionine, the DFG motif has not moved significantly and that this structure does not represent a type-2 binding mode. Similar binding modes have been described previously for other kinases as type 1.5.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> On the basis of this binding mode, combined with evidence of slower offset kinetics and more significant cellular DoA, we chose to pursue <b>5</b> as an alternative lead for the program.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0003.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray cocrystal structure of <b>5</b> bound to JAK2 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ3">5TQ3</a>) overlaid on protein from cocrystal with <b>4</b> to illustrate movement of the methionine gatekeeper residue. Numbers correspond to hydrogen bonding distances in angstroms.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Considering <b>5</b> as a lead, it already fulfilled our JAK enzyme potency requirements and displayed significant DoA in both enzyme and cellular assays. However, the aqueous solubility of <b>5</b> was very poor, to the extent that an accurate measurement could not be determined. In addition, despite a significant increase in lipophilicity compared to the tofacitinib series, turnover in HLM was only modest, where high metabolism was desired. It was however of significant promise that the molecule already contained a phenol group which brought modest turnover in an in vitro assay (HLM UGT) which contained cofactors for phase 2 glucuronidation. Given the apparent importance of the hydrogen bonding interactions of the phenol group in binding to JAK, we postulated that any phase 2 metabolites of the phenol group (for example the glucuronide or sulfate) would be largely inactive as JAK inhibitors, thus greatly reducing any liability from systemic JAK inhibition of potential circulating metabolites. The cross-kinase promiscuity (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>) appeared less optimal for <b>5</b>, compared to the tofacitinib chemotype, as it inhibited 9 of 35 additional kinases at the ATP <i>K</i><sub>m</sub> concentration in a screening panel with >50% inhibition at 1 Î¼M compound concentration, although only one of these (ZC1/HGK, also known as MAP4K4) was inhibited at >85%.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0004.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Heat map showing kinase inhibition profile of <b>5</b> dosed at 1 Î¼M against a panel of 36 kinases at the ATP <i>K</i><sub>m</sub> concentration. Colors correspond to % inhibition of a given kinase as per the color legend shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Initial structureâactivity relationships (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>) were investigated around the phenol ring in order to probe for improvements in JAK kinase potency and selectivity, as well as to increase the overall metabolic rate. We employed enzymatic assays for each JAK kinase at 1 mM ATP concentration rather than at the <i>K</i><sub>m</sub> concentrations to gain a better understanding of compound potency and selectivity under more physiologically relevant conditions.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In addition assays in primary PBMC cells were used to measure inhibition of the pSTAT5 response to IL-15 for cellular DoA, as well as inhibition of the IFNÎ³ response to IL-2 for potency assessment.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR around Phenol Ring: JAK Kinase Potency and Selected Cellular Potency Data</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0025.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0026.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Compounds were routinely assayed using Caliper microfluidic assays for their potency of inhibition of phosphorylation of a peptide substrate by the appropriate JAK enzyme at 1 mM ATP concentration. All IC<sub>50</sub> values reported represent geometric mean values of a minimum of three determinations. nt denotes ânot testedâ.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Cellular potency was routinely assayed in peripheral blood mononuclear cells (PBMCs) measuring inhibition of interferon Î³ (IFNÎ³) release following stimulation with interleukin 2 (IL2). All IC<sub>50</sub> values reported represent geometric mean values of a minimum of three determinations.</p></div></div><div></div></div><div class="NLM_p">The location of the phenol OH group was shown to be preferred in the para position to the biaryl linkage, as the equivalent meta phenol <b>6</b> was a significantly weaker inhibitor against JAK enzymes and in the PBMC cellular assay. This is consistent with the observed X-ray cocrystal structure of <b>5</b> where the two hydrogen bonds to the para phenolic OH group appear to be close to optimal distances. Not surprisingly, removal of the OH group or methylation to provide a para methoxyl group resulted in significant loss in potency (data not shown). Increasing the size of the substituent on the phenol ring to either an isopropyl or <i>n</i>-propyl group (<b>7</b> and <b>8</b>) resulted in a drop in both enzyme and cellular potency, while increasing the size of this group still further led to even more significant loss in potency (data now shown). The presence of the ethyl group was found not to be an essential feature for good potency against JAK kinases, as a number of compounds without the ethyl group showed good enzyme and cellular potency. However, these compounds all had far poorer kinase selectivity (data now shown). This suggests that an ethyl substituent is close to the optimal size for a group at this position to maintain good potency while also providing the benefit of improved kinase selectivity. Consistent with this observation, a methoxyl group was also well tolerated at this position, as in <b>9</b>, albeit with some loss in potency compared to <b>5</b>.</div><div class="NLM_p">At this point we also explored adding groups such as chloro, cyano, and fluoro adjacent to the phenolic OH group in an attempt to modulate its glucuronidation rate by acidification.<a onclick="showRef(event, 'cit13b'); return false;" href="javascript:void(0);" class="ref cit13b">(13b)</a> However, to maintain good JAK potency, only fluoro groups were found to be well tolerated in these positions (<b>10</b> and <b>11</b>), with only a small loss in potency compared to <b>5</b>. This is again consistent with the observed binding mode as these positions lie in very close proximity to the protein surface, allowing only for a small atom to be substituted. It appears as though the position para to the ethyl group has slightly more space in the X-ray structure, which is reflected in the better cell potency observed for <b>11</b> over <b>10</b>. Interestingly, the fluoro substitution para to the ethyl group also resulted in improved kinase selectivity, as <b>11</b> inhibited only 3 kinases of a panel of 36 at >50% at 1 Î¼M concentration, with only JAK3 (other JAK family members were not present in the screening subset) in the panel being significantly inhibited at >85% as expected (kinase heat maps for a number of key analogues can be found in the <a href="/doi/suppl/10.1021/acs.jmedchem.6b01634/suppl_file/jm6b01634_si_002.pdf" class="ext-link">Supporting Information</a>). Gratifyingly, this change also dramatically increased the glucuronidation rate for <b>11</b>, which showed a turnover rate in the HLM UGT assay of >360 (Î¼L/min)/mg protein. This was not the case for <b>10</b>, which showed no increase in glucuronidation rate (46 (Î¼L/min)/mg protein) versus <b>5</b>, despite the two phenols <b>10</b> and <b>11</b> having very similar calculated p<i>K</i><sub>a</sub> values. Clearly structural effects around the phenol as well as acidification are important contributing factors for overall glucuronidation rates. Fluorophenol <b>11</b> also showed good DoA in our cellular wash-out assay, inhibiting the pSTAT5 response with a <i>T</i><sub>1/2</sub> of 3.5 h, consistent with the earlier observation for compounds in this series. However, aqueous solubility was again shown to be low and an accurate value could not be measured in a thermodynamic solubility assay. In addition, we could not formulate these molecules successfully for in vivo efficacy evaluation when attempting to use solution dosing via the inhaled route. While indazole-benzimidazoles such as <b>11</b> showed some promise to meet our criteria, they were clearly not soluble enough to be considered for dosing via the inhaled route, although useful SAR information had been gained. Moving forward, we needed to address the poor solubility while maintaining the excellent potency and encouraging DoA of this series.</div><div class="NLM_p">In an attempt to improve compound solubility while maintaining an otherwise favorable profile, we sought to reduce the overall aromatic ring count in our series.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> SAR investigations in this series were carried out using the nonfluorinated phenol template. Truncating the benzimidazole back to imidazole <b>12</b> (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>) resulted in no loss of potency in both kinase enzymes and cell based assays. Encouragingly, in addition to excellent potency, we could also see an improvement in thermodynamic solubility (4.1 Î¼M) measured from a crystalline solid sample of <b>12</b> in water buffered at pH 7.4. Not surprisingly, truncating further to remove the imidazole completely (R = H) resulted in significant loss of potency given that a key H-bonding interaction with the hinge motif of the kinase had been removed (data not shown). Alternative heterocycles that maintained an H-bonding interaction with the hinge motif, through either an NâH group or aromatic CâH group, in general showed good enzyme inhibition potency but a reduced cellular potency relative to imidazole <b>12</b>. Further truncation of the imidazole to the amide functionality, as in primary amide <b>13</b> and methylamide <b>14</b>, maintained the excellent potency profile while providing a further improvement in solubility (15 Î¼M and 14 Î¼M, respectively, measured from crystalline solid samples in water buffered at pH 7.4). Methylamide <b>14</b> in particular showed an excellent kinase selectivity profile with only JAK3 out of a panel of 36 kinases inhibited at >50% at 1 Î¼M concentration. An X-ray cocrystal structure of primary amide <b>13</b> binding to JAK2 (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>) showed the expected binding mode for the series, with three key hydrogen bonds in a donorâacceptorâdonor motif from the indazole NâH and lone pair and NâH of the amide to the hinge region of the kinase, as well as the two hydrogen bonds from the phenol group to the back pocket residues as noted previously. Not surprisingly, the dimethylamide <b>15</b> showed significant loss of potency, consistent with the requirement for the amide NâH hydrogen bonding interaction with the kinase. However, despite adopting the same binding mode as the indazole-benzimidazole <b>5</b>, none of these potent and more soluble truncated compounds showed a significant DoA in our cellular assay nor significant slow offset in the kinase kinetic assay. Subsequent compounds that maintained good DoA (vide infra) suggested that additional interactions between the ligand and kinase protein have been lost with this series of smaller amide compounds, leading to the loss of DoA.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Replacements for Benzimidazole: JAK Kinase Potency, Cellular Potency and Solubility Data</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0027.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0028.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Compounds were routinely assayed using Caliper microfluidic assays for their potency of inhibition of phosphorylation of a peptide substrate by the appropriate JAK enzyme at 1 mM ATP concentration. All IC<sub>50</sub> values reported represent geometric mean values of a minimum of three determinations.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">Cellular potency was routinely assayed in peripheral blood mononuclear cells (PBMCs) measuring inhibition of interferon Î³ (IFNÎ³) release following stimulation with interleukin 2 (IL2). All IC<sub>50</sub> values reported represent geometric mean values of a minimum of three determinations.</p></div></div><div></div></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0005.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Crystal structures of amides <b>13</b> (upper picture, PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ4">5TQ4</a>) and <b>16</b> (lower picture, PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ5">5TQ5</a>) bound to JAK2. The triad of amino acids restricting exit of more sterically demanding amides from the binding pocket is illustrated in cyan. Numbers correspond to hydrogen bonding distances in angstroms.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We reasoned that further binding potency and improved DoA could be achieved by expanding the amide series into the pocket occupied by the benzimidazole group in our initial lead <b>5</b> while maintaining improved solubility. Of a number of larger amide analogues prepared, we found that only those made from aromatic amines, for example <b>16</b> (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>), maintained any reasonable kinase inhibition potency. Upon inspection of the X-ray crystal structure of <b>16</b> bound to JAK2 (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>), it is clear that the region of the kinase where the amide heterocyclic group is bound is restricted in size by a triad of surrounding amino acids, Leu-855, Tyr-931, and Gly-935. We found that amides substituted with a methyl group (as in <b>14</b>) or a planar group (as in <b>16</b>) were tolerated in this position, allowing access through the Leu-Tyr-Gly triad of amino acids to the more open space beyond the hinge region. Heterocyclic amide <b>16</b> showed reasonable JAK inhibition potency in both enzymatic and cellular assays, as well as significant DoA in our cellular wash-out assay, with a <i>T</i><sub>1/2</sub> of approximately 4.5 h. In addition, kinase selectivity for this compound was good, with only 2 kinases (besides JAK3) in a panel of 36 kinases showing >50% inhibition at 1 Î¼M concentration. Solubility for amide <b>16</b>, along with most other larger heterocyclic amides prepared, although improved over <b>5</b>, was however found to be poor (0.5 Î¼M). Even though we had reduced the aromatic ring count relative to <b>5</b>, amide <b>16</b> is still a rather planar molecule where crystal packing forces in the solid state are likely to be significant.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In addition, chemical stability toward hydrolysis was found to be less than optimal for the majority of these heterocyclic amides over a relatively short time (>10% degradation seen after 1â2 days at pH 8.0 at 40 Â°C), raising concerns for potential solid form stability and formulation problems in this series. Taken together, these data prompted us to pursue a related but ultimately more successful subseries as described below.</div><div class="NLM_p">We pursued an alternative tactic to improving solubility while maintaining the overall molecular size and similar shape of the indazole benzimidazole lead, by increasing the sp<sup>3</sup> carbon count in our molecule through saturation of the second aromatic ring of the benzimidazole system.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The imidazopiperidine motif <b>17</b> (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>) serves this purpose, maintaining the donorâacceptorâdonor motif required for hinge binding, as well as the planarity required to maintain binding through the Leu-Tyr-Gly triad of the kinase. In addition, the amine functionality of the piperidine allowed us to further build out from this portion of the molecule to increase binding affinity and DoA.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0006.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Benzimidazole to imidazopiperidine transformation, showing increasing saturation and sp<sup>3</sup> count in our lead series.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Our SAR exploration was carried out using both the nonfluorinated and fluorinated (at R2) phenol templates (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). The imidazopiperidine was shown to be an effective replacement for the benzimidazole group in original lead <b>5</b>, with amine <b>18</b> showing good enzyme and cell potency. Both amide <b>19</b> and sulfonamide <b>20</b> groups could be prepared with no loss in potency, although the amides typically showed greater cellular potency. This synthetic strategy allowed for a wide range of substituents to be explored, enabling modulation of various properties that could increase HLM and to explore effects on potency, kinase selectivity, and DoA. The methyl and acetamide analogues (<b>18</b> and <b>19</b>) showed improved solubility over the earlier benzimidazoles as expected (10â20 Î¼M). However, their kinase selectivity profiles were generally much poorer, with at least 10 of a panel of 36 kinases showing >85% inhibition for each of these compounds. Larger substituents, such as benzyl <b>21</b> and benzamides <b>22</b> and <b>2</b>, maintained excellent enzymatic and cellular JAK potency while also introducing significantly higher HLM turnover, in keeping with their increased lipophilicity. We were pleased to find that, as previously discovered, introduction of a fluorine atom para to the ethyl group greatly increased the glucuronidation rate for these compounds. As shown for the fluorinated piperidinyl-pyrazine <b>2</b>, the turnover rate in the HLM UGT assay is 129 (Î¼L/min)/mg protein, compared with 17 (Î¼L/min)/mg protein for the nonfluorinated equivalent (compound not shown). These compounds with larger substituents on the piperidine ring also showed significant cellular DoA, typically with <i>T</i><sub>1/2</sub> of >6 h.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Imidazopiperidine Replacement for Benzimidazole: JAK Kinase Potency and Selected Cellular Potency Data</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0029.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0030.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>Table a</sup><p class="last">Compounds were routinely assayed using Caliper microfluidic assays for their potency of inhibition of phosphorylation of a peptide substrate by the appropriate JAK enzyme at 1 mM ATP concentration. All IC<sub>50</sub> values reported represent geometric mean values of a minimum of three determinations.</p></div><div class="footnote" id="t5fn2"><sup>Table b</sup><p class="last">Cellular potency was routinely assayed in peripheral blood mononuclear cells (PBMCs) measuring inhibition of interferon Î³ (IFNÎ³) release following stimulation with interleukin 2 (IL2). All IC<sub>50</sub> values reported represent geometric mean values of a minimum of three determinations</p></div><div class="footnote" id="t5fn3"><sup>Table c</sup><p class="last">Compounds were routinely assessed for metabolic stability in human liver microsomes (HLMs).</p></div><div class="footnote" id="t5fn4"><sup>Table d</sup><p class="last">Compounds were assessed for phase II glucuronidation in HLM by including the microsomal activator Brij58 and cofactor uridine diphosphate glucuronic acid (UDPGA) and excluding the cytochrome P450 dependent cofactor NADPH.</p></div></div><div></div></div><div class="NLM_p">Fluorinated piperidinyl-pyrazine <b>2</b> met all of our in vitro assay criteria and was selected for more advanced studies. Overall it demonstrated good JAK potency, kinase selectivity, metabolic turnover through two different routes of metabolism, as well as sufficient solubility in various formulations for in vivo testing, even though thermodynamic solubility in aqueous solution was low (â¼0.5 Î¼M). In addition, a crystalline solid form for <b>2</b> was found with excellent chemical and physical stability. Most noteworthy, <b>2</b> displayed a very long cellular DoA with a <i>T</i><sub>1/2</sub> of 9 h in the PBMC cellular wash-out assay. Profiling <b>2</b> against a panel of 36 kinases at 1 Î¼M, a concentration that significantly exceeds the JAK cellular and enzymatic IC<sub>50</sub> values at 1 mM ATP, demonstrated that it has suitable selectivity over non-JAK kinases as only JAK3 was inhibited more than 85% at this concentration (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0007.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Heat map showing kinase inhibition profile of <b>2</b> dosed at 1 Î¼M against a panel of 36 kinases. Colors correspond to % inhibition of a given kinase as per the color legend shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">An X-ray crystal structure of <b>2</b> bound to JAK2 (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>) showed the expected binding mode as described previously, with some additional interactions observed with two of the residues flanking the front pocket. First, the piperidinyl-pyrazine heterocyclic moiety is wrapped alongside and engaged in a Ï-stacking interaction with the amide carbonyl groups of Leu-855 in the glycine rich P-loop, which also bridges through water to interact with the imidazole ring. Second, the amide carbonyl in <b>2</b> bridges via another conserved water to interact with Tyr-931. This additional network of binding interactions might explain the longer DoA observed with this larger class of compound within this series.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0008.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. X-ray cocrystal structure of <b>2</b> bound to JAK2 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ8">5TQ8</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> JAK Inhibitory Profile of <b>2</b> in Human Whole Blood (HWB)</h3><div class="NLM_p">In order to test functional potency and to provide insight into the JAK inhibitory profile of <b>2</b>, studies in human whole blood investigated inhibition of STAT phosphorylation induced by a selection of cytokines known to signal through various combinations of JAK enzymes (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). In each assay the inhibition by <b>2</b> of STAT phosphorylation was measured in a specific subpopulation of white blood cells and IC<sub>50</sub> values were determined. Free IC<sub>50</sub> values were calculated by taking into account plasma protein binding, where the fraction unbound in plasma is 0.001. These data confirmed that <b>2</b> is a functional pan-JAK inhibitor in human whole blood.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Inhibitory Potency of <b>2</b> in Human Whole Blood versus Various Stimulatory Cytokines</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cytokine</th><th class="colsep0 rowsep0" align="center">JAK dimer</th><th class="colsep0 rowsep0" align="center">white blood cells</th><th class="colsep0 rowsep0" align="center">pSTAT</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">free IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IFNÎ±</td><td class="colsep0 rowsep0" align="left">JAK1/TYK2</td><td class="colsep0 rowsep0" align="left">lymphocytes</td><td class="colsep0 rowsep0" align="left">pSTAT3</td><td class="colsep0 rowsep0" align="left">0.62</td><td class="colsep0 rowsep0" align="left">0.62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-23</td><td class="colsep0 rowsep0" align="left">JAK2/TYK2</td><td class="colsep0 rowsep0" align="left">lymphocytes</td><td class="colsep0 rowsep0" align="left">pSTAT3</td><td class="colsep0 rowsep0" align="left">4.2</td><td class="colsep0 rowsep0" align="left">4.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-4</td><td class="colsep0 rowsep0" align="left">JAK1/JAK3</td><td class="colsep0 rowsep0" align="left">monocytes</td><td class="colsep0 rowsep0" align="left">pSTAT6</td><td class="colsep0 rowsep0" align="left">1.8</td><td class="colsep0 rowsep0" align="left">1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-6</td><td class="colsep0 rowsep0" align="left">JAK1/JAK2</td><td class="colsep0 rowsep0" align="left">monocytes</td><td class="colsep0 rowsep0" align="left">pSTAT3</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GM-CSF</td><td class="colsep0 rowsep0" align="left">JAK2/JAK2</td><td class="colsep0 rowsep0" align="left">monocytes</td><td class="colsep0 rowsep0" align="left">pSTAT5</td><td class="colsep0 rowsep0" align="left">5.2</td><td class="colsep0 rowsep0" align="left">5.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">All IC<sub>50</sub> values reported represent geometric mean values of a minimum of three determinations.</p></div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Pharmaceutical Properties of <b>2</b></h3><div class="NLM_p">Fluorinated piperidinyl-pyrazine <b>2</b> is a lipophilic compound with a cLogP of 4.4 and logÂ <i>D</i> of 3.9 (measured by a shake flask method). The molecular weight of the compound is 566 Da, and the topological polar surface area (TPSA) is calculated to be 126 Ã<sup>2</sup>. The compound contains both a weakly basic imidazole group with a measured p<i>K</i><sub>a</sub> of 4.5 and a weakly acidic fluorophenol group with a measured p<i>K</i><sub>a</sub> of 8.7. Following extensive screening efforts, including efforts to generate various salt forms of the compound, a stable neutral nonsolvated crystalline form was found that could be crystallized directly from the final reaction step to provide a means of isolating the compound with excellent purity (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>, left-hand panel). This form has very low hygroscopicity and is chemically stable both at room temperature and at 40 Â°C with 75% relative humidity for up to 6 weeks, underwriting its long-term stability. The material is also stable to jet milling to provide solid material with regular and consistent particle size in the respirable range (â¼2 Î¼m).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The resulting micronized material (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>, right-hand panel) has been found to be chemically and physically stable when blended with lactose for up to 4 weeks, demonstrating its suitability for use in a dry powder inhalation device.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0009.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. SEM images of solid <b>2</b> following crystallization (left-hand panel) and subsequent micronization (right-hand panel).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition this crystalline material was also amenable to preparation as a 4% solution in a base formulation typically used in topical applications to the skin as shown in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Components of 4% Dermal Formulation of <b>2</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">component</th><th class="colsep0 rowsep0" align="center">%Â wt/wt</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">propylene glycol</td><td class="colsep0 rowsep0" align="left">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">polyethylene glycol 400</td><td class="colsep0 rowsep0" align="left">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dimethyl isosorbide</td><td class="colsep0 rowsep0" align="left">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">glycerin</td><td class="colsep0 rowsep0" align="left">25.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BHA</td><td class="colsep0 rowsep0" align="left">0.1</td></tr></tbody></table></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> In Vitro Metabolism and Pharmacokinetic Properties of <b>2</b></h3><div class="NLM_p">Following in vitro incubation of <b>2</b> in human hepatocytes, the major metabolites observed were produced by direct glucuronidation and P450 metabolism, consistent with the presence of the fluorinated phenol group functioning as an effective handle for phase II conjugation. As discussed previously in relation to the binding mode of <b>2</b>, these phenol conjugated metabolites are expected to show no inhibition of JAK kinases once formed. This metabolic profile was consistent across rat and dog in in vitro hepatocyte and microsomal metabolism studies.</div><div class="NLM_p">The pharmacokinetic properties of <b>2</b> were assessed in vivo and were found to be consistent with its high lipophilicity and neutral physicochemistry (<a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>). Consistent with the high in vitro intrinsic clearance values previously described, <b>2</b> exhibits very high unbound clearance in the rat and dog and has an oral bioavailability of <5% following oral solution administration to the rat.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. In Vivo Rat and Dog Plasma Pharmacokinetic Data of <b>2</b> after Intravenous (iv) and Oral (po Dosing</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">Cl (mLÂ min<sup>â1</sup>Â kg<sup>â1</sup>)</th><th class="colsep0 rowsep0" align="center">Cl<sub>unbound</sub>â¯<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a> (mLÂ min<sup>â1</sup>Â kg<sup>â1</sup>)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub>â¯<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a> (L/kg)</th><th class="colsep0 rowsep0" align="center">terminal <i>T</i><sub>1/2</sub>â¯<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a> (h)</th><th class="colsep0 rowsep0" align="center">oral bioavailability (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ratÂ iv</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">>48000</td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ratÂ po</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dogÂ iv</td><td class="colsep0 rowsep0" align="left">0.1<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">>18000</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="left">Â </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">30 min infusion.</p></div><div class="footnote" id="t8fn2"><sup>b</sup><p class="last">Parameters from iv PK profile.</p></div><div class="footnote" id="t8fn3"><sup>c</sup><p class="last">Plasma protein binding, â¥99.9%.</p></div></div></div><div class="NLM_p last">On the basis of these human in vitro data and the in vivo rat and dog pharmacokinetic data, <b>2</b> was predicted to be cleared in humans by glucuronidation and CYP3A4 metabolism, exhibiting low levels of unbound circulating parent following inhaled or dermal delivery due to high unbound clearance. Due to the predicted negligible oral absorption and lack of observed circulating metabolites in animal Pk studies, the potential for significant levels of circulating active metabolites in human was deemed to be low risk. Therefore, following topical dosing to either the lung or skin, <b>2</b> demonstrated suitable pharmacokinetic properties to provide high confidence that it would demonstrate an organ targeted effect, with negligible systemic exposure of parent compound and no active circulating metabolites. On the basis of the multiple routes of metabolism (P450 and glucironidation) and projected low levels of unbound exposure in human, the potential for <b>2</b> to be either a victim or perpetrator of a drugâdrug interaction was also deemed to be low.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Biological in Vivo Activity of <b>2</b></h3><div class="NLM_p">The in vivo activity of <b>2</b> dosed as a solution via the intratracheal (i.t.) route was demonstrated in a mouse pharmacodynamic model of IL-6 induced pSTAT3 response in the lungs, mediated via the JAK1/JAK2 mechanism (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>). <b>2</b> caused a dose-related inhibition of the IL-6-elicited increase in lung pSTAT3, giving an ED<sub>50</sub> of approximately 3 Î¼g/animal. For comparison, the inhaled corticosteroid, fluticasone propionate, demonstrates an ED<sub>50</sub> of between 3 Î¼g/animal and 30 Î¼g/animal across a variety of mouse models when dosed i.t.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0010.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Effects of intratracheal administration of <b>2</b> on IL-6 (i.t.) induced increases in lung phosphorylated STAT3 in the mouse. Left hand panel represents absolute quantity of phosphorylated pSTAT in mouse lung. Right hand panel represents the percentage inhibition Â± 95% CI calculated from the difference in geometric mean values between vehicle/IL-6-treated and vehicle/saline-treated groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In vivo activity was also assessed via topical application of <b>2</b> to the skin of a mouse ear in a dermal model of IL-23 induced inflammation (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>). IL-23 is known to be a major driver of psoriasis pathology mediated via the JAK-STAT pathway.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> For mice ears treated topically with <b>2</b> as a 4% solution, a significant reduction of ear swelling (48%) was observed over a period of 11 days following multiple IL-23 injections in the ear, consistent with inhibition of the JAK2/TYK2 pathway. For compound treated mice, swelling typically occurred to less than 50 Î¼m, while ears of control mice receiving IL-23 injections with no compound treatment typically swelled to over 100 Î¼m.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0011.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Effects on mouse ear swelling following IL-23 injection and treatment with a topical formulation of <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Proof of organ targeted JAK inhibition in the lung versus systemic JAK inhibition was shown by comparison of lung pSTAT3 inhibition to systemic pSTAT5 inhibition following i.t. dosing of <b>2</b> (<a class="ref internalNav" href="#fig12" aria-label="Figure 12">Figure 12</a>). <b>2</b> inhibited phosphorylation of STAT3 in the lung following IL-6 stimulation by 100% at doses of 10 Î¼g and above. In contrast, a 10 Î¼g dose resulted in no inhibition of STAT5 phosphorylation in the blood following ex vivo GM-CSF stimulation, while a 100 Î¼g resulted in less than 50% inhibition. These data provide evidence that <b>2</b> exerts significantly greater efficacy in the lung compared to within the blood following i.t. administration, and this is consistent with very low systemic exposures expected when considering the pharmacokinetic properties of <b>2</b>.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0012.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Effects of i.t. administration of <b>2</b> on inhibition of STAT phosphorylation in the lungs and blood. Data show the effect on IL-6-induced lung phosphorylated STAT3 or GM-CSF-induced blood phosphorylated STAT5 with values representing the percentage inhibition Â± 95% CI calculated from the difference in geometric mean values between vehicle/IL-6-treated and vehicle/saline-treated groups: <i>N</i> = 6 (lung) and <i>N</i> = 3 (blood).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Sustained occupancy of JAK1 after i.t. dosing was also demonstrated in this model, supporting the potential for an extended DoA in human lung. The JAK1 occupancy of <b>2</b> in mouse lung was measured by ActivX Biosciences, Inc. (San Diego, CA, U.S.) following i.t. administration of either 10 Î¼g (ED<sub>80</sub> dose) or 100 Î¼g (maximum inhibitory dose tested) of <b>2</b>.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> These data suggest that <b>2</b> maintains significant target occupancy 4 h postdose for JAK1 (<a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>), which is consistent with the long duration of action demonstrated in human in vitro cell systems. Given that the half-lives of JAK enzymes in cellular systems have previously been determined to be 2â3 h,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> the long duration of action that we observe could be by virtue of tissue retention of the compound in the mouse lung in the in vivo assays, as well as cellular retention of compounds in the in vitro assays, in addition to compound kinetic slow-off effects on the kinase.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0013.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Effects of i.t. administration of <b>2</b> on JAK1 target occupancy. Values represent the % occupancy over time with a dose of 10 Î¼g (left-hand graph) or 100 Î¼g (right-hand graph).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> In Vitro and in Vivo Safety Profile of <b>2</b></h3><div class="NLM_p last"><b>2</b> was screened at 10 Î¼M in a panel of receptors, transporters, enzymes, and ion channels (CEREP radioligand binding and enzyme inhibition profile), which demonstrated greater than 50% inhibition of binding or activity against a small number of targets, namely, 5-HT<sub>7</sub>, Abl kinase, acetylcholinesterase, Î±<sub>2B</sub> adrenergic receptor, AurA/Aur2 kinase, KDR kinase, Lck kinase, and Na<sup>+</sup> channel (site 2). However, these activities were observed at multiples of greater than 100-fold above the projected free systemic plasma exposures at the maximum clinical lung dose (200 Î¼g), so <b>2</b> was not anticipated to have any consequences at these receptors, transporters, enzymes, and ion channels if evaluated at clinically relevant exposures. Furthermore, <b>2</b> had no effects on the hERG potassium current at 1 Î¼M (<1% inhibition). Cough has historically been a major cause of attrition of inhaled therapies, so <b>2</b> was dosed up to 2 mg in 400 Î¼L of micelle vehicle to the mouse A delta fiber sensory nerve preparation. No nerve activation was detected with <b>2</b>, providing evidence that <b>2</b> presents a low risk for cough effects. Exploratory 7-day intravenous toxicology studies were conducted in rats and dogs to assess risk associated with systemic exposure. There were no adverse test article-related findings in any of the parameters evaluated, with a 36-fold margin achieved in rat over total plasma AUC based on a projected exposure following a human clinical lung dose of 200 Î¼g, and a 55-fold margin achieved in dog plasma AUC. The BioLum Ames bacterial mutagenicity assay showed no evidence of genetic toxicity with and without metabolic activation, which was also the case for the CHO in vitro micronucleus test. Peripheral blood micronucleus assessment was also made from the rat 7-day intravenous exploratory toxicology study, and no evidence of genetic toxicity was observed.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Chemistry: Synthesis of Compounds</h3><div class="NLM_p">The tofacitinib analogue with phenolic sulfone <b>4</b> was prepared as detailed in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, beginning with alcohol <b>23</b>, whose preparation has been detailed previously.<a onclick="showRef(event, 'cit3a'); return false;" href="javascript:void(0);" class="ref cit3a">(3a)</a> Reaction of the secondary alcohol with disulfanediyldiphenol proceeded with inversion of stereochemistry, providing the sulfide <b>24</b>, which was oxidized with potassium peroxymonosulfate to sulfone <b>4</b>.</div><figure id="sch1" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0014.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Tofacitinib Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 3,3â²-disulfanediyldiphenol, Bu<sub>3</sub>P, toluene, 100 Â°C, 3 h, 69%; (b) potassium peroxymonosulfate, H<sub>2</sub>O, THF, IPA, rt, 1 h, 95%.</p></p></figure><div class="NLM_p">Our lead indazole <b>5</b> and initial indazole analogues <b>6</b> and <b>9</b> were available in the Pfizer compound collection having been prepared earlier according to procedures outlined in the patent literature.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">The synthetic strategy for preparation of the majority of the indazoles is outlined in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The key reaction involved formation of a biaryl bond through palladium-catalyzed cross coupling of indazoles <b>h</b> with protected phenols <b>g</b> to provide key intermediate biaryl indazolo-aldehydes <b>f</b>, through which the majority of targets were prepared. The aldehyde functionality in <b>f</b> could be directly reacted with diamines to provide imidazole analogues <b>b</b> or converted to either imidates <b>d</b> or carboxylic acids <b>e</b>. Imidazopiperidine targets <b>a</b> could be accessed from the imidate intermediate <b>d</b>, while amide targets <b>c</b> could be accessed from the carboxylic acid <b>e</b>. For certain targets <b>j</b>, the aldehyde functionality in <b>h</b> was first converted to a benzimidazole providing <b>i</b>, before palladium catalyzed cross coupling with phenols <b>g</b>.</div><figure id="sch2" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0015.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Retrosynthesis for Preparation of Target Indazoles</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The propyl substituted indazolophenols <b>7</b> and <b>8</b> were prepared as detailed in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. The aldehyde group of bromoindazole <b>25</b> was first converted to a benzimidazole group through reaction with 1,2 diaminobenzene and ammonium bromide providing <b>26</b>. Following SEM protection of the NâH groups, the bromide was converted to a boronic ester affording <b>27</b> in good yield. Following bromination of the phenol <b>28</b>, the resulting bromide <b>29</b>, or the commercially available bromide <b>30</b>, was reacted with <b>27</b> in a palladium catalyzed cross-coupling reaction to provide the final targets <b>7</b> and <b>8</b> in reasonable yield.</div><figure id="sch3" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0016.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Indazoles<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) benzene-1,2-diamine, NH<sub>4</sub>Br, MeOH, 0 Â°C to rt, 18 h, 52%; (b) NaH, THF, 0 Â°C, 30 min, then (2-trimethylsilyl)ethoxymethyl chloride, 2 h, 58%; (c) bis(pinacolato)diboron, (dppf)PdCl<sub>2</sub>, KOAc, 1,4-dioxane, 100 Â°C, 15 h, 97%; (d) 4-bromo-3-(propan-2-yl)phenol <b>30</b> or 4-bromo-3-propylphenol <b>29</b>, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, DME, 150 Â°C, 1 h, 22â30%; (e) conc HCl, MeOH, 60 Â°C, 18 h, 56â88%; (f) NBS, MeCN, 0 Â°C to rt, 18 h, 84%.</p></p></figure><div class="NLM_p">The fluorophenol containing targets <b>10</b> and <b>11</b> were prepared in a similar manner as detailed in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. We found it preferable to reverse the polarity of the Pd-coupling to install the boronic ester on the protected phenol portion of the molecule first while maintaining the bromide on the indazole ring. This arrangement of required reaction partners generally provided improved yields in the subsequent palladium catalyzed cross-coupling reaction over the earlier route described in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Bromination of commercially available fluoromethoxybenzenes <b>31</b> and <b>32</b> followed by boronic ester formation provided the boronic esters <b>33</b> and <b>34</b>. Cross-coupling with bromoindazole <b>25</b> then provided aldehydes <b>35</b> and <b>36</b>. Reaction of the aldehyde group with 1,2 diaminobenzene and sodium sulfite provided the corresponding benzimidazoles which were processed to the final targets <b>10</b> and <b>11</b> by removal of the SEM group and deprotection of the methyl ether.</div><figure id="sch4" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0017.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) NaH, THF, 0 Â°C 1 h, then (2-trimethylsilyl)ethoxymethyl chloride, 0 Â°C to rt, 16 h, 99%; (b) <b>33</b> or <b>34</b>, (Ph<sub>3</sub>P)<sub>4</sub>Pd, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, H<sub>2</sub>O, 100 Â°C, 15 h, 68â71%; (c) benzene-1,2-diamine, Na<sub>2</sub>SO<sub>3</sub>, DMA, 100 Â°C 16 h, 65â70%; (d) conc HCl, MeOH, 60 Â°C, 16 h, 80â82%; (e) BBr<sub>3</sub>, DCM, rt, 72 h, 20â54%; (f) NBS, MeCN, 0 Â°C to rt, 18 h; (g) bis(pinacolato)diboron, (Ph<sub>3</sub>P)<sub>4</sub>Pd, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 100 Â°C, 15 h, 33â38% over 2 steps.</p></p></figure><div class="NLM_p">The imidazole <b>12</b> was prepared as shown in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. We found in general a SEM to be a convenient protecting group for the phenol, allowing for a more straightforward and unified final deprotection step as compared to a methyl ether. Thus, the phenol in commercially available aryl bromide <b>38</b> was protected with a SEM group before conversion of the bromide to a boronic ester, providing <b>39</b>. Cross-coupling with bromoindazole <b>25</b> proceeded in excellent yield to give aldehyde <b>37</b>. Conversion of the aldehyde to an imidazole group with glyoxal and ammonium hydroxide followed by removal of the SEM groups provided the final target imidazole <b>12</b>.</div><figure id="sch5" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0018.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) NaH, THF, 0 Â°C 1 h, then (2-trimethylsilyl)ethoxymethyl chloride, 0 Â°C to rt, 16 h, 99%; (b) <b>39</b>, (Ph<sub>3</sub>P)<sub>4</sub>Pd, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, H<sub>2</sub>O, 100 Â°C, 16 h, 94%; (c) glyoxal, NH<sub>4</sub>OH, MeOH, THF, rt, 16 h, 18%; (d) TBAF, THF, 1,2-diaminoethane, 80 Â°C, 16 h, 35%; (e) (2-trimethylsilyl)ethoxymethyl chloride, DIEA, DCM, rt, 18 h, 83%; (f) bis(pinacolato)diboron, (Ph<sub>3</sub>P)<sub>4</sub>Pd, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 100 Â°C, 16 h, 21%.</p></p></figure><div class="NLM_p">Amides <b>13</b>â<b>16</b> were prepared as detailed in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>. Aldehyde <b>37</b> was either oxidized, providing the corresponding carboxylic acid <b>40</b> following removal of the SEM groups, or converted to the nitrile <b>41</b> via dehydration of the corresponding oxime. Standard amide bond forming reactions with the acid <b>40</b> provided secondary and tertiary amides <b>14</b>â<b>16</b>, while the nitrile <b>41</b> was treated with basic hydrogen peroxide to provide the primary amide <b>13</b> following SEM group removal.</div><figure id="sch6" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0019.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaClO<sub>2</sub>, 2-methylbut-2-ene, NaH<sub>2</sub>PO<sub>4</sub>, <sup><i>t</i></sup>BuOH, H<sub>2</sub>O, rt, 1 h, 72%; (b) TBAF, THF, 1,2-diaminoethane, rt, 16 h, 41%; (c) methylamine or dimethylamine hydrochloride, EDC, HOBT, 4-methylmorpholine, DMF, rt, 16 h, 60â63%; (d) 2-methyl-5-aminopyridine, HATU, TEA, DMAP, DMA, 30 Â°C, 16 h; (e) (i) hydroxylamine hydrochloride, Et<sub>3</sub>N, MeCN, 60 Â°C, 1.5 h; (ii) trichloroacetyl chloride, Et<sub>3</sub>N, MeCN, 60 Â°C, 16 h, 82%; (f) 30% H<sub>2</sub>O<sub>2</sub>, KOH, EtOH, rt, 4 h, 82%; (g) TBAF, THF, 1,2-diaminoethane, 60 Â°C, 3 h, 63%.</p></p></figure><div class="NLM_p">Our initial synthesis of imidazopiperidine analogues such as <b>18</b>â<b>20</b> involved a key palladium catalyzed Stille cross-coupling reaction between the protected iodoimidazopiperidine <b>46</b>, prepared from commercially available imidazopiperidine <b>45</b>, and the trimethylstannate derived from iodide <b>43</b>, which itself derived from iodoindazole <b>42</b> through cross coupling with boronate ester <b>39</b> followed by iodination and SEM protection (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>). The Stille cross coupling reaction proceeded in low to moderate yield to provide the indazole-imidazopiperidine <b>44</b> following global deprotection. The free amine group of the unprotected piperidine could then be used successfully in reductive amination chemistry, amide and sulfonamide bond formation, providing analogues <b>18</b>â<b>20</b>.</div><figure id="sch7" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0020.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 7. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) <b>39</b>, (dppf)PdCl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, DME, H<sub>2</sub>O, 140 Â°C, 1 h, 79%; (b) KOH, DMF, rt, 5 min, then I<sub>2</sub>, rt, 30 min, 84%; (c) NaH, THF, 0 Â°C 15 min, then (2-trimethylsilyl)ethoxymethyl chloride, 0 Â°C to rt, 16 h, 40%; (d) (Me<sub>3</sub>Sn)<sub>2</sub>, (Ph<sub>3</sub>P)<sub>4</sub>Pd, toluene, 80 Â°C, 16 h, 69%; (e) <b>46</b>, CuI, (Ph<sub>3</sub>P)<sub>4</sub>Pd, THF, 65 Â°C, 90 h, 26%; (f) Pd(OH)<sub>2</sub>/C, H<sub>2</sub> 200 psi, EtOH, 60 Â°C, 24 h, 86%; (g) conc HCl, MeOH, 64 Â°C, 18 h, 100%; (h) CH<sub>2</sub>O 37% in H<sub>2</sub>O, NaBH(OAc)<sub>3</sub>, DIEA, DMF, AcOH, rt, 16 h, 50%; (i) Ac<sub>2</sub>O or (MeSO<sub>2</sub>)<sub>2</sub>O, Et<sub>3</sub>N, DMF, rt, 16 h, 13â30%; (j) Boc<sub>2</sub>O, Et<sub>3</sub>N, DCM, 0 Â°C to rt, 16 h, 85%; (k) <i>n</i>-BuLi, THF, â78 Â°C, then I<sub>2</sub>, 1.25 h, 33%.</p></p></figure><div class="NLM_p">An alternative synthetic route (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>) was used to prepare additional imidazopiperidine analogues such as <b>21</b>, which involved a condensation reaction between imidate <b>48</b> and amino acetal <b>53</b>, followed by cyclocondensation of amidine intermediate <b>49</b>. This route provided a facile and more reliable route to key targets, providing significantly higher yields on scale up and avoiding the use of tin reagents on larger scale. Imidate <b>48</b> was prepared from the commercially available bromoindazole <b>25</b> through initial THP protection and conversion of the aldehyde to a nitrile group, providing <b>47</b>. Palladium catalyzed cross-coupling with the boronate ester <b>51</b> and conversion of the nitrile to an imidate using sodium methoxide furnished <b>48</b>. The boronate ester itself was prepared from commercially available fluorophenol <b>50</b>, which was first brominated in the position para to the phenol, followed by SEM protection of the phenol and palladium catalyzed boronate ester formation, providing <b>51</b>. The requisite amino acetal <b>53</b> was prepared according to a known sequence from commercially available 4-ketopiperidine <b>52</b>, a key step in the sequence being a Neber rearrangement.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Following condensation of imidate <b>48</b> and amino acetal <b>53</b>, cyclocondensation of the amidine <b>49</b> was carried out under acidic conditions which also led to successful deprotection of the SEM and THP groups, providing target amine <b>21</b> in excellent yield.</div><figure id="sch8" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0021.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 8. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 3,4-dihydro-2<i>H</i>-pyran, pTSA, DCM, 0 Â°C to rt, 16 h, 73%; (b) hydroxylamine hydrochloride, Et<sub>3</sub>N, MeCN, 60 Â°C, 3 h, then TFAA, Et<sub>3</sub>N, MeCN, 0 Â°C to rt, 2 h, 99%; (c) <b>51</b>, (Ph<sub>3</sub>P)<sub>4</sub>Pd, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, H<sub>2</sub>O, 110 Â°C, 18 h, 81%; (d) NaOMe, MeOH, rt, 18 h, 100%; (e) <b>53</b>, AcOH, EtOH, 50 Â°C, 18 h, 45%; (f) conc HCl, EtOH, rt, 18 h, 100%; (g) conc HCl, EtOH, 65 Â°C, 18 h, 80%; (h) CuBr<sub>2</sub>, MeCN, rt, 16 h, 100%; (i) (2-trimethylsilyl)ethoxymethyl chloride, DIEA, DCM, rt, 18 h, 86%; (j) bis(pinacolato)diboron, Pd(dppf)Cl<sub>2</sub>, KOAc, 1,4-dioxane, 100 Â°C, 18 h, 100%.</p></p></figure><div class="NLM_p">In order to prepare further amide derivatives of the imidazopiperidine group, as well as to provide a more unified and efficient protecting group strategy, we employed the Boc protected amino acetal <b>57</b> in the condensation reaction with imidate <b>48</b> (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>). Treatment of the resulting amidine <b>54</b> with acid led to cyclocondensation and global deprotection of all acid labile protecting groups, providing imidazopiperidine <b>55</b> in excellent overall yield. The amino acetal <b>57</b> was prepared according to a known sequence involving a Neber rearrangement from commercially available 4-ketopiperidine <b>56</b>.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Intermediate <b>55</b> was a highly versatile intermediate that could be prepared on multigram scale following the synthetic procedures described herein. The piperidine amino group could be reacted selectively to prepare a range of amides, sulfonamides, carbamates, ureas, and tertiary amines. Synthesis of two key amide analogues is illustrated in <a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>. Standard amide bond coupling conditions using HATU were employed to couple <b>55</b> with commercially available parafluorobenzoic acid or pyrazine carboxylic acid <b>58</b>, providing amides <b>22</b> and <b>2</b> in excellent yields.</div><figure id="sch9" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0022.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 9. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>57</b>, AcOH, EtOH, 50 Â°C, 18 h, 100%; (b) conc HCl, EtOH, rt, 18 h, 88%; (c) 4-fluorobenzoic acid or <b>58</b>, HATU, DIEA, DMF, rt, 18 h, 89%;</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63242" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63242" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We have described our approach to the discovery of a novel JAK inhibitor <b>2</b> that is well suited for inhaled delivery to the lungs and/or topical delivery to the skin. Our initial effort to work within our clinically precedented tofacitinib chemical series produced compounds that met most of the requirements for our program, but these did not have the key fundamental property of DoA. This led us to adopt a new approach and use X-ray crystal structures to guide a targeted screening effort to find JAK inhibitors with novel binding modes. This led to the discovery of the indazole series of compounds that bound in a type 1.5 binding mode to JAK and that showed good evidence of duration of action. We then followed a number of approaches to improve upon the solubility, kinase selectivity, and cellular duration of action of this series as described, leading to the preparation of <b>2</b>. The in vitro and in vivo potency, pharmacokinetic and safety profile of <b>2</b> demonstrate that it is potentially well suited for use as an inhaled or topical therapy to treat inflammatory diseases, such as COPD or psoriasis, through direct administration to the lungs or skin, while avoiding any systemic-based JAK inhibition. We believe that this profile may offer an improved safety profile for use in these disease indications over oral JAK kinase inhibitors, given the challenges associated with systemic JAK2 inhibition in particular. The pharmaceutical properties of <b>2</b> are suitable for combination with lactose in a dry powder inhaler, as well as for use in typical topical formulations. Taken together, this promising overall profile has led to the nomination of <b>2</b> as a development candidate, an inhaled therapy for COPD, and a topical therapy for psoriasis. Further information relating to the research and development of <b>2</b> will be reported in due course.</div><div class="NLM_p last">A similar approach to JAK inhibition via the inhaled route has recently been described,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> as well as a similar approach to provide soft drug JAK inhibitors for topical use to treat psoriasis.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47703" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47703" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> General Experimental</h3><div class="NLM_p">Unless otherwise indicated, all reactions were carried out under a nitrogen atmosphere, using commercially available anhydrous solvents. Thin-layer chromatography was performed on glass-backed precoated Merck silica gel (60 F254) plates, and compounds were visualized using UV light, 5% aqueous potassium permanganate, or chloroplatinic acid/potassium iodide solution. Silica gel column chromatography was carried out using 40â63 Î¼m silica gel (Merck silica gel 60). Proton NMR spectra were measured on a Varian Inova 400 or Varian Mercury 400 spectrometer in the solvents specified. Low resolution mass spectra were recorded on either a Fisons Trio 1000, using thermospray positive ionization, or a Finnigan Navigator, using electrospray positive or negative ionization. High resolution mass spectra were recorded on a Bruker Apex II FT-MS using electrospray positive ionization. All target compounds were purified until at least >95% purity as judged by HPLC utilizing an ELSD detection system.</div><div class="NLM_p last"><sup>1</sup>H nuclear magnetic resonance (NMR) spectra were in all cases consistent with the proposed structures. Characteristic chemical shifts (Î´) are given in parts-per-million downfield from tetramethylsilane using conventional abbreviations for designation of major peaks: e.g., s, singlet; d, doublet; t, triplet; m, multiplet; br, broad. The mass spectra (<i>m</i>/<i>z</i>) were recorded with electrospray ionization (ESI). The following abbreviations have been used for common solvents: CDCl<sub>3</sub>, deuterochloroform; DMSO-<i>d</i><sub>6</sub>, deuterodimethyl sulfoxide; methanol-<i>d</i><sub>4</sub>, deuteromethanol. Concentration of solutions after reactions and extractions involved the use of a rotary evaporator operating at a reduced pressure of â¼20 Torr. LCMS analysis was carried out using the following conditions. Solvent A: 0.1% formic acid in water. Solvent B: 0.1% formic acid in acetonitrile. Column: C18 phase Phenomenex 20 mm Ã 4.0 mm with 3 Î¼m particle size. Gradient: 98â10% A over 1.5 min, 0.3 min hold, 0.2 re-equilibration, 1.8 mL/min flow rate. UV: 210â450 nm DAD. Temperature: 75 Â°C.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> PAINS Analysis</h3><div class="NLM_p last">Compounds were examined for known classes of pan assay interference compounds using an in-house computational structure filter based on literature precedent.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> None of the final compounds that were assayed for bioactivity were flagged as being potential PAINS.</div></div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Chemistry. Synthetic Procedures to <b>2</b></h3><div class="NLM_p last">Additional experimental procedures for all novel compounds prepared during the course of this work can be found in the <a href="/doi/suppl/10.1021/acs.jmedchem.6b01634/suppl_file/jm6b01634_si_002.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 2-[6-(2-Ethyl-5-fluoro-4-hydroxyphenyl)-1<i>H</i>-indazol-3-yl]-1,4,6,7-tetrahydroimidazo[4,5-<i>c</i>]pyridin-5-yl-(5-piperidin-1-yl-pyrazin-2-yl)methanone (<b>2</b>)</h3><div class="NLM_p last">To a solution of 5-piperidin-1-ylpyrazine-2-carboxylic acid <b>58</b> (10.7 g, 51.8 mmol) in dimethylformamide (200 mL) were added <i>N</i>,<i>N</i>-diisopropylethylamine (24.6 mL, 141 mmol) and HATU (21.5 g, 56.5 mmol, and the resulting mixture was stirred at ambient temperature for 10 min before being added dropwise to a suspension of compound <b>55</b> (19.5 g, 47.1 mmol) in dimethylformamide (200 mL) over 30 min, using a further 75 mL dimethylformamide to wash the vessel. The reaction mixture was then stirred at ambient temperature for 18 h. A further portion of 5-piperidin-1-ylpyrazine-2-carboxylic acid <b>58</b> (1.07 g, 5.18 mmol) in dimethylformamide (40 mL) was treated with <i>N</i>,<i>N</i>-diisopropylethylamine (2.46 mL, 14.1 mmol) and activated with HATU (2.15 g, 5.65 mmol), and the resulting mixture was stirred at ambient temperature for 10 min before being added to the original reaction mixture which was then stirred for a further 4 h. The reaction mixture was poured onto water (1.2 L), and the pH was adjusted to 7 with sodium hydroxide solution. The resulting suspension was stirred at ambient temperature for 30 min. The precipitate was collected by filtration, washed with water (400 mL), and then dried in vacuo. The crude material was dissolved in ethanol (113 mL) and treated with a 1 M aqueous solution of sodium hydroxide. The reaction mixture was stirred at ambient temperature for 18 h. The precipitate was collected by filtration, washed with a cold solution of 1:3 1 M sodium hydroxide/ethanol (100 mL), and dried in vacuo. The residue was dissolved in water (100 mL) and treated with a 10% aqueous solution of citric acid (10 mL) to adjust the pH to 4. A few drops of 1 M sodium hydroxide solution were added to bring the pH to 7. The resulting suspension was stirred at ambient temperature for 1 h and the solid collected by filtration, washed with water, and then dried in vacuo to give the title compound <b>2</b> (13.86 g, 89%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.90 (br s, 1H), 8.44 (s, 1H), 8.31 (d, <i>J</i> = 1.17 Hz, 1H), 8.27 (br s, 1H), 7.58 (s, 1H), 7.32 (d, <i>J</i> = 7.42 Hz, 1H), 7.05 (d, <i>J</i> = 11.72 Hz, 1H), 6.94 (d, <i>J</i> = 9.18 Hz, 1H), 4.96 (br s, 1H), 4.82 (br s, 1H), 4.02 (t, <i>J</i> = 5.37 Hz, 2H), 3.66â3.75 (m, 4H), 2.92 (br s, 2H), 2.42â2.49 (m, 2H), 1.66 (d, <i>J</i> = 4.69 Hz, 2H), 1.58 (d, <i>J</i> = 3.90 Hz, 4H), 1.02 (t, <i>J</i> = 7.52 Hz, 3H). LCMS found 567 [M + H]<sup>+</sup>. HRMS calcd for C<sub>31</sub>H<sub>32</sub>FN<sub>8</sub>O<sub>2</sub>: 567.2627. Found [M + H]<sup>+</sup>: 567.2621.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 6-Bromo-1-(tetrahydropyran-2-yl)-1<i>H</i>-indazole-3-carbonitrile (<b>47</b>)</h3><div class="NLM_p last">To a solution of 6-bromo-1<i>H</i>-indazole-3-carbaldehyde <b>25</b> (13.97 g, 61.9 mmol) in dichloromethane (150 mL) was added <i>p</i>-toluenesulfonic acid (2.36 g, 12.4 mmol), and the mixture was cooled to 0 Â°C. 3,4-Dihydro-2<i>H</i>-pyran (8.47 mL, 92.8 mmol) was added dropwise to the solution, and the reaction was stirred at ambient temperature overnight. The reaction mixture was diluted with dichloromethane (200 mL) and washed with a solution of saturated aqueous sodium hydrogen carbonate (500 mL). The aqueous layer was re-extracted with dichloromethane (500 mL), and the combined organic layers were washed with brine (2 Ã 1 L), dried over anhydrous magnesium sulfate, and concentrated in vacuo. The crude material was refluxed in cyclohexane (20 mL) and filtered while hot. The filtrate was concentrated in vacuo, and the residue was stirred in heptane for 48 h. The resulting solid was collected by filtration to give 6-bromo-1-(tetrahydropyran-2-yl)-1<i>H</i>-indazole-3-carbaldehyde (13.87 g, 73%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 10.19â10.25 (m, 1H), 8.16 (d, <i>J</i> = 8.59 Hz, 1H), 7.88 (d, <i>J</i> = 0.98 Hz, 1H), 7.46 (dd, <i>J</i> = 1.56, 8.59 Hz, 1H), 5.78 (dd, <i>J</i> = 2.83, 8.69 Hz, 1H), 4.95 (dd, <i>J</i> = 2.64, 4.78 Hz, 2H), 3.96â4.04 (m, 2H), 3.88 (ddd, <i>J</i> = 3.42, 7.32, 11.13 Hz, 3H), 3.74â3.82 (m, 1H), 3.46â3.57 (m, 3H), 2.48â2.61 (m, 2H), 2.08â2.28 (m, 3H), 1.81â1.95 (m, 4H), 1.71â1.80 (m, 6H), 1.48â1.66 (m, 16H). LCMS found 309 [M + H]<sup>+</sup>. To a solution of 6-bromo-1-(tetrahydropyran-2-yl)-1<i>H</i>-indazole-3-carbaldehyde (60 g, 194 mmol) in acetonitrile (1.5 L) were added triethylamine (68.5 mL, 485 mmol) and hydroxylamine hydrochloride (20 g, 291 mmol). The reaction was heated at 60 Â°C for 3 h. The reaction was cooled to 0 Â°C, further triethylamine (220 mL, 1.55 mol) was added, and TFAA (109 mL, 776 mmol) was added dropwise. The reaction was allowed to warm to ambient temperature and stirred for 2 h. Water (2 L) was added to the reaction mixture, and the resulting solid was collected by filtration. The solid was dissolved in dichloromethane (1 L), and the resulting solution was washed with water (2 Ã 500 mL). The organic layer was dried over anhydrous magnesium sulfate and concentrated in vacuo to give the title compound <b>47</b> (58.59 g, 99%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.93 (d, <i>J</i> = 0.98 Hz, 1H), 7.69 (d, <i>J</i> = 8.79 Hz, 1H), 7.46 (dd, <i>J</i> = 1.56, 8.79 Hz, 1H), 5.76 (dd, <i>J</i> = 2.93, 8.20 Hz, 1H), 3.88â3.96 (m, 1H), 3.71â3.81 (m, 1H), 2.40â2.54 (m, 1H), 2.05â2.23 (m, 2H), 1.68â1.85 (m, 3H). LCMS found 306 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 6-[2-Ethyl-5-fluoro-4-(2-trimethylsilanylethoxymethoxy)phenyl]-1-(tetrahydropyran-2-yl)-1<i>H</i>-indazole-3-carboximidic Acid Methyl Ester (<b>48</b>)</h3><div class="NLM_p last">To a solution of <b>47</b> (28.5 g, 93 mmol) and <b>51</b> (73.8 g, 112 mmol) in 1,4-dioxane (500 mL) was added a solution of potassium phosphate (59.2 g, 279 mmol) in water (120 mL). The mixture was degassed with nitrogen, and then tetrakis(triphenylphosphine)palladium (0) (10.8 g, 9.3 mmol) was added. The reaction mixture was heated at 110 Â°C for 18 h. The reaction mixture was concentrated in vacuo, and the residue was redissolved in ethyl acetate (1 L) and filtered through Arbocel, washing with ethyl acetate (2 Ã 500 mL). The combined organic phases were concentrated in vacuo. The residue was purified by column chromatography on silica gel, eluting with 10% ethyl acetate in heptane to give 6-[2-ethyl-5-fluoro-4-(2-trimethylsilanylethoxymethoxy)phenyl]-1-(tetrahydropyran-2-yl)-1<i>H</i>-indazole-3-carbonitrile (37.4 g, 81%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.85 (dd, <i>J</i> = 0.78, 8.40 Hz, 1H), 7.62 (d, <i>J</i> = 0.98 Hz, 1H), 7.30 (dd, <i>J</i> = 1.27, 8.30 Hz, 1H), 7.18 (d, <i>J</i> = 8.40 Hz, 1H), 7.15â7.23 (m, 1H), 7.00 (d, <i>J</i> = 11.52 Hz, 1H), 5.82 (dd, <i>J</i> = 2.73, 8.59 Hz, 1H), 5.30â5.35 (m, 2H), 3.94â4.01 (m, 1H), 3.83â3.91 (m, 2H), 3.75 (ddd, <i>J</i> = 3.71, 8.64, 11.86 Hz, 1H), 2.53 (q, <i>J</i> = 7.35 Hz, 2H), 2.12â2.25 (m, 2H), 1.66â1.89 (m, 3H), 1.11 (t, <i>J</i> = 7.52 Hz, 3H), 1.02 (dd, <i>J</i> = 7.71, 8.88 Hz, 2H), 0.01â0.09 (m, 9H). To a solution of 6-[2-ethyl-5-fluoro-4-(2-trimethylsilanylethoxymethoxy)phenyl]-1-(tetrahydropyran-2-yl)-1<i>H</i>-indazole-3-carbonitrile (37.42 g, 75.6 mmol) in methanol (700 mL) was added sodium methoxide (12.21 g, 226.8 mmol), and the reaction mixture was then stirred at ambient temperature for 18 h. The solvent was removed in vacuo, and the residue was partitioned between ethyl acetate (1 L) and water (500 mL). The organic layer was washed with water (500 mL), dried over anhydrous magnesium sulfate, and concentrated in vacuo to give the title compound <b>48</b> (37.26g, 94%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.41â8.61 (m, 1H), 8.05â8.12 (m, 1H), 7.50 (s, 1H), 7.14â7.23 (m, 2H), 7.03 (d, <i>J</i> = 11.52 Hz, 1H), 5.76 (dd, <i>J</i> = 2.73, 9.18 Hz, 1H), 4.06â4.12 (m, 3H), 4.00â4.06 (m, 1H), 3.82â3.91 (m, 2H), 3.70â3.79 (m, 1H), 3.50 (s, 2H), 2.49â2.66 (m, 2H), 2.06â2.25 (m, 2H), 1.63â1.88 (m, 4H), 1.10 (t, <i>J</i> = 7.52 Hz, 3H), 0.97â1.06 (m, 2H), â0.02 to 0.13 (m, 9H). LCMS found 528 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 2-[2-Ethyl-5-fluoro-4-(2-trimethylsilanylethoxymethoxy)phenyl]-4,4,5,5-tetramethyl[1,3,2]dioxaborolane (<b>51</b>)</h3><div class="NLM_p last">To a solution of 5-ethyl-2-fluorophenol <b>50</b> (76.36g, 545 mmol) in acetonitrile (2.5 L) was added copper(II) bromide (361.5 g, 1.62 mol). The resulting suspension was stirred at ambient temperature overnight. The solvent was removed in vacuo, and the residue was suspended in ethyl acetate (3 L) and filtered through a pad of Arbocel. The filtrate was washed with water (2 L) and brine (2 L), dried over anhydrous magnesium sulfate, and concentrated in vacuo to give 4-bromo-5-ethyl-2-fluorophenol (119 g, 100%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.29 (d, <i>J</i> = 2.34 Hz, 1H), 6.92 (d, <i>J</i> = 9.37 Hz, 1H), 5.21 (br s, 1H), 2.69 (q, <i>J</i> = 7.41 Hz, 2H), 1.22 (t, <i>J</i> = 7.61 Hz, 3H). To a solution of 4-bromo-5-ethyl-2-fluorophenol (80 g, 365 mmol) in DCM (1 L) was added <i>N</i>,<i>N</i>-diisopropylethylamine (70 mL, 401 mmol) and (2-trimethylsilyl)ethoxymethyl chloride (71 mL, 401 mmol). The resulting solution was stirred at ambient temperature for 18 h. The reaction mixture was washed with water (1 L), dried over anhydrous magnesium sulfate, and concentrated in vacuo to yield the crude product. This material was purified by silica gel chromatography, eluting with 30% DCM in heptane to give [2-(4-bromo-5-ethyl-2-fluorophenoxymethoxy)ethyl]trimethylsilane. (109.8 g, 86%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.25â7.30 (m, 1H), 7.07â7.12 (m, 1H), 5.24 (s, 2H), 3.77â3.85 (m, 2H), 2.69 (q, <i>J</i> = 7.48 Hz, 2H), 1.21 (t, <i>J</i> = 7.52 Hz, 3H), 0.94â1.01 (m, 2H), 0.01â0.05 (m, 9H). To a solution of [2-(4-bromo-5-ethyl-2-fluorophenoxymethoxy)ethyl]trimethylsilane (105g, 300.6 mmol) in dioxane (1 L) were added bis(pinacolato)diboron (76.4 g, 300.6 mmol) and potassium acetate (88.5 g, 902 mmol). The resulting suspension was degassed with nitrogen, Pd(dppf)Cl<sub>2</sub> (24.54 g, 30.1 mmol) was added, and the reaction was heated at reflux for 18 h. The reaction was cooled to ambient temperature, and the solvent was removed in vacuo. The resulting black solid was suspended in ethyl acetate (2 L) and filtered through Arbocel, washing with further ethyl acetate. The filtrate was washed with water (1.5 L) and brine (1.5 L), dried over anhydrous magnesium sulfate, and concentrated in vacuo to give the title compound <b>51</b> (155.5 g, 130%) that was used crude in the next step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.47 (d, <i>J</i> = 12.10 Hz, 1H), 6.98â7.04 (m, 1H), 5.27 (s, 2H), 3.77â3.82 (m, 2H), 2.85 (q, <i>J</i> = 7.54 Hz, 2H), 1.32 (s, 12H), 1.16 (t, <i>J</i> = 7.61 Hz, 3H), 0.91â0.99 (m, 2H), â0.02 to 0.02 (m, 9H).</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 4,4-Diethoxy-3-[6-[2-ethyl-5-fluoro-4-(2-trimethylsilanylethoxymethoxy)phenyl]-1-(tetrahydropyran-2-yl)-1<i>H</i>-indazole-3-carboximidoyl]aminopiperidine-1-carboxylic Acid <i>tert</i>-Butyl Ester (<b>54</b>)</h3><div class="NLM_p last">To a solution of <b>48</b> (31.4 g, 59.5 mmol) in ethanol (140 mL) was added a solution of <b>57</b> (US-2004/0229862, 18.02 g, 62.48 mmol) in ethanol (100 mL). Acetic acid (6.81 mL, 119 mmol) was added, and the reaction mixture was heated at 50 Â°C for 18 h. The reaction mixture was concentrated in vacuo and azeotroped with toluene (100 mL) to give the title compound <b>54</b> (54.7 g, 117%) which was used as is without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.23 (br s, 1H), 7.51 (br s, 1H), 7.32â7.43 (m, 2H), 7.18â7.30 (m, 4H), 7.16 (d, <i>J</i> = 8.40 Hz, 1H), 7.04 (d, <i>J</i> = 11.52 Hz, 1H), 5.77 (br s, 1H), 5.31 (d, <i>J</i> = 8.20 Hz, 2H), 4.04 (t, <i>J</i> = 10.45 Hz, 1H), 3.82â3.92 (m, 2H), 3.48â3.82 (m, 7H), 2.81 (br s, 1H), 2.67 (br s, 3H), 2.55 (q, <i>J</i> = 7.42 Hz, 2H), 2.09â2.32 (m, 3H), 1.92 (br s, 2H), 1.65â1.84 (m, 3H), 1.14â1.24 (m, 5H), 1.10 (t, <i>J</i> = 7.52 Hz, 3H), 0.98â1.04 (m, 2H), 0.00â0.07 (m, 9H). LCMS found 784 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 5-Ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-yl)-1<i>H</i>-indazol-6-yl]phenol Dihydrochloric Acid Salt (<b>55</b>)</h3><div class="NLM_p last">To a solution of <b>54</b> (46.65 g, 55.27 mmol) in ethanol (200 mL) was added concentrated hydrochloric acid (12M, 100 mL, 1.2 mol), and the resulting solution was stirred at ambient temperature for 18 h. The reaction mixture was concentrated in vacuo and azeotroped with toluene (100 mL) and dichloromethane (2 Ã 100 mL). The resulting gum was dried under vacuum for 3 h. The crude material was triturated in acetonitrile (300 mL), and the resulting solid was collected by filtration. The solid was dissolved in ethanol (250 mL) and treated with concentrated hydrochloric acid (12 M, 77.2 mL, 927 mmol). The resulting solution was heated at 40 Â°C for 18 h, then at 50 Â°C for 2 h. The solvents were removed in vacuo, and the resulting gum was triturated in acetonitrile (200 mL). The solid that formed was collected by filtration, washed with further acetonitrile (200 mL), and dried under vacuum to give the title compound <b>55</b> (23.5 g, 88% dihydrochloride salt). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) Î´ 8.22 (d, <i>J</i> = 8.40 Hz, 1H), 7.59 (s, 1H), 7.33â7.41 (m, 1H), 6.95 (d, <i>J</i> = 11.52 Hz, 1H), 6.91 (d, <i>J</i> = 8.98 Hz, 1H), 4.56 (s, 2H), 3.73 (t, <i>J</i> = 6.05 Hz, 2H), 3.23 (t, <i>J</i> = 5.86 Hz, 2H), 2.53 (q, <i>J</i> = 7.61 Hz, 2H), 1.02â1.10 (m, 3H). LCMS found 378 [M + H]<sup>+</sup>.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01634">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15543" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15543" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b01634" class="ext-link">10.1021/acs.jmedchem.6b01634</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01634/suppl_file/jm6b01634_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">General chemistry experimental procedures; all synthetic procedures and analytical data with synthesis schemes; selected HPLC and NMR spectra of <b>2</b>; kinase inhibition panels for selected compounds and polypharmacology and broad kinase inhibition profile for <b>2</b>; biology experimental procedures; table of crystallography information (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01634/suppl_file/jm6b01634_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01634/suppl_file/jm6b01634_si_001.csv">jm6b01634_si_001.csv (1.73 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01634/suppl_file/jm6b01634_si_002.pdf">jm6b01634_si_002.pdf (2.59 MB)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes are the following: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LXK">3LXK</a> for <b>1</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ7">5TQ7</a> for <b>4</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ3">5TQ3</a> for <b>5</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ4">5TQ4</a> for <b>13</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ5">5TQ5</a> for <b>16</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ8">5TQ8</a> for <b>2</b>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.6b01634" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63660" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63660" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Jones</span> - <span class="hlFld-Affiliation affiliation">â Medicine Design, â¡Pharmacokinetics, Dynamics and Metabolism, and Â§Inflammation and
Immunology Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">â¥Medicine Design, and â¥Medicinal Sciences, Pfizer
Inc., 445 Eastern Point Road, Groton, Connecticut 06340, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">#Worldwide Medicinal Chemistry, âStructural Biology
and Biophysics, and âPharmaceutical
Sciences, Pfizer Ltd., Ramsgate Road, Sandwich, CT13 9NJ, U.K.</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8637-9530" title="Orcid link">http://orcid.org/0000-0001-8637-9530</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d3a3b6a7b6a1fdb9bcbdb6a0e193a3b5baa9b6a1fdb0bcbe"><span class="__cf_email__" data-cfemail="6010051405124e0a0f0e051352201006091a05124e030f0d">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">R. Ian Storer</span> - <span class="hlFld-Affiliation affiliation">â Medicine Design, â¡Pharmacokinetics, Dynamics and Metabolism, and Â§Inflammation and
Immunology Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">â¥Medicine Design, and â¥Medicinal Sciences, Pfizer
Inc., 445 Eastern Point Road, Groton, Connecticut 06340, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">#Worldwide Medicinal Chemistry, âStructural Biology
and Biophysics, and âPharmaceutical
Sciences, Pfizer Ltd., Ramsgate Road, Sandwich, CT13 9NJ, U.K.</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#95fcf4fbbbe6e1fae7f0e7d5f4e6e1e7f4eff0fbf0f6f4bbf6faf8"><span class="__cf_email__" data-cfemail="e78e8689c9949388958295a786949395869d8289828486c984888a">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yogesh A. Sabnis</span> - <span class="hlFld-Affiliation affiliation">â Medicine Design, â¡Pharmacokinetics, Dynamics and Metabolism, and Â§Inflammation and
Immunology Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">â¥Medicine Design, and â¥Medicinal Sciences, Pfizer
Inc., 445 Eastern Point Road, Groton, Connecticut 06340, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">#Worldwide Medicinal Chemistry, âStructural Biology
and Biophysics, and âPharmaceutical
Sciences, Pfizer Ltd., Ramsgate Road, Sandwich, CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Florian M. Wakenhut</span> - <span class="hlFld-Affiliation affiliation">â Medicine Design, â¡Pharmacokinetics, Dynamics and Metabolism, and Â§Inflammation and
Immunology Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">â¥Medicine Design, and â¥Medicinal Sciences, Pfizer
Inc., 445 Eastern Point Road, Groton, Connecticut 06340, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">#Worldwide Medicinal Chemistry, âStructural Biology
and Biophysics, and âPharmaceutical
Sciences, Pfizer Ltd., Ramsgate Road, Sandwich, CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gavin A. Whitlock</span> - <span class="hlFld-Affiliation affiliation">â Medicine Design, â¡Pharmacokinetics, Dynamics and Metabolism, and Â§Inflammation and
Immunology Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">â¥Medicine Design, and â¥Medicinal Sciences, Pfizer
Inc., 445 Eastern Point Road, Groton, Connecticut 06340, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">#Worldwide Medicinal Chemistry, âStructural Biology
and Biophysics, and âPharmaceutical
Sciences, Pfizer Ltd., Ramsgate Road, Sandwich, CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katherine S. England</span> - <span class="hlFld-Affiliation affiliation">â Medicine Design, â¡Pharmacokinetics, Dynamics and Metabolism, and Â§Inflammation and
Immunology Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">â¥Medicine Design, and â¥Medicinal Sciences, Pfizer
Inc., 445 Eastern Point Road, Groton, Connecticut 06340, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">#Worldwide Medicinal Chemistry, âStructural Biology
and Biophysics, and âPharmaceutical
Sciences, Pfizer Ltd., Ramsgate Road, Sandwich, CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takasuke Mukaiyama</span> - <span class="hlFld-Affiliation affiliation">â Medicine Design, â¡Pharmacokinetics, Dynamics and Metabolism, and Â§Inflammation and
Immunology Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">â¥Medicine Design, and â¥Medicinal Sciences, Pfizer
Inc., 445 Eastern Point Road, Groton, Connecticut 06340, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">#Worldwide Medicinal Chemistry, âStructural Biology
and Biophysics, and âPharmaceutical
Sciences, Pfizer Ltd., Ramsgate Road, Sandwich, CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christoph M. Dehnhardt</span> - <span class="hlFld-Affiliation affiliation">â Medicine Design, â¡Pharmacokinetics, Dynamics and Metabolism, and Â§Inflammation and
Immunology Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">â¥Medicine Design, and â¥Medicinal Sciences, Pfizer
Inc., 445 Eastern Point Road, Groton, Connecticut 06340, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">#Worldwide Medicinal Chemistry, âStructural Biology
and Biophysics, and âPharmaceutical
Sciences, Pfizer Ltd., Ramsgate Road, Sandwich, CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jotham W. Coe</span> - <span class="hlFld-Affiliation affiliation">â Medicine Design, â¡Pharmacokinetics, Dynamics and Metabolism, and Â§Inflammation and
Immunology Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">â¥Medicine Design, and â¥Medicinal Sciences, Pfizer
Inc., 445 Eastern Point Road, Groton, Connecticut 06340, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">#Worldwide Medicinal Chemistry, âStructural Biology
and Biophysics, and âPharmaceutical
Sciences, Pfizer Ltd., Ramsgate Road, Sandwich, CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steve W. Kortum</span> - <span class="hlFld-Affiliation affiliation">â Medicine Design, â¡Pharmacokinetics, Dynamics and Metabolism, and Â§Inflammation and
Immunology Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">â¥Medicine Design, and â¥Medicinal Sciences, Pfizer
Inc., 445 Eastern Point Road, Groton, Connecticut 06340, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">#Worldwide Medicinal Chemistry, âStructural Biology
and Biophysics, and âPharmaceutical
Sciences, Pfizer Ltd., Ramsgate Road, Sandwich, CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jill E. Chrencik</span> - <span class="hlFld-Affiliation affiliation">â Medicine Design, â¡Pharmacokinetics, Dynamics and Metabolism, and Â§Inflammation and
Immunology Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">â¥Medicine Design, and â¥Medicinal Sciences, Pfizer
Inc., 445 Eastern Point Road, Groton, Connecticut 06340, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">#Worldwide Medicinal Chemistry, âStructural Biology
and Biophysics, and âPharmaceutical
Sciences, Pfizer Ltd., Ramsgate Road, Sandwich, CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David G. Brown</span> - <span class="hlFld-Affiliation affiliation">â Medicine Design, â¡Pharmacokinetics, Dynamics and Metabolism, and Â§Inflammation and
Immunology Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">â¥Medicine Design, and â¥Medicinal Sciences, Pfizer
Inc., 445 Eastern Point Road, Groton, Connecticut 06340, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">#Worldwide Medicinal Chemistry, âStructural Biology
and Biophysics, and âPharmaceutical
Sciences, Pfizer Ltd., Ramsgate Road, Sandwich, CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rhys M. Jones</span> - <span class="hlFld-Affiliation affiliation">â Medicine Design, â¡Pharmacokinetics, Dynamics and Metabolism, and Â§Inflammation and
Immunology Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">â¥Medicine Design, and â¥Medicinal Sciences, Pfizer
Inc., 445 Eastern Point Road, Groton, Connecticut 06340, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">#Worldwide Medicinal Chemistry, âStructural Biology
and Biophysics, and âPharmaceutical
Sciences, Pfizer Ltd., Ramsgate Road, Sandwich, CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John R. Murphy</span> - <span class="hlFld-Affiliation affiliation">â Medicine Design, â¡Pharmacokinetics, Dynamics and Metabolism, and Â§Inflammation and
Immunology Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">â¥Medicine Design, and â¥Medicinal Sciences, Pfizer
Inc., 445 Eastern Point Road, Groton, Connecticut 06340, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">#Worldwide Medicinal Chemistry, âStructural Biology
and Biophysics, and âPharmaceutical
Sciences, Pfizer Ltd., Ramsgate Road, Sandwich, CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thean Yeoh</span> - <span class="hlFld-Affiliation affiliation">â Medicine Design, â¡Pharmacokinetics, Dynamics and Metabolism, and Â§Inflammation and
Immunology Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">â¥Medicine Design, and â¥Medicinal Sciences, Pfizer
Inc., 445 Eastern Point Road, Groton, Connecticut 06340, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">#Worldwide Medicinal Chemistry, âStructural Biology
and Biophysics, and âPharmaceutical
Sciences, Pfizer Ltd., Ramsgate Road, Sandwich, CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Morgan</span> - <span class="hlFld-Affiliation affiliation">â Medicine Design, â¡Pharmacokinetics, Dynamics and Metabolism, and Â§Inflammation and
Immunology Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">â¥Medicine Design, and â¥Medicinal Sciences, Pfizer
Inc., 445 Eastern Point Road, Groton, Connecticut 06340, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">#Worldwide Medicinal Chemistry, âStructural Biology
and Biophysics, and âPharmaceutical
Sciences, Pfizer Ltd., Ramsgate Road, Sandwich, CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Iain Kilty</span> - <span class="hlFld-Affiliation affiliation">â Medicine Design, â¡Pharmacokinetics, Dynamics and Metabolism, and Â§Inflammation and
Immunology Research
Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">â¥Medicine Design, and â¥Medicinal Sciences, Pfizer
Inc., 445 Eastern Point Road, Groton, Connecticut 06340, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">#Worldwide Medicinal Chemistry, âStructural Biology
and Biophysics, and âPharmaceutical
Sciences, Pfizer Ltd., Ramsgate Road, Sandwich, CT13 9NJ, U.K.</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): The authors were all full-time employees of Pfizer at the time this work was completed, and all funding for the work was provided by Pfizer.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e3318-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73115" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73115" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This research used resources at the Industrial Macromolecular Crystallography Association Collaborative Access Team (IMCA-CAT) beamline 17-ID, supported by the companies of the Industrial Macromolecular Crystallography Association through a contract with Hauptman-Woodward Medical Research Institute. This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract DE-AC02-06CH11357. Use of the LS-CAT Sector 21 was supported by the Michigan Economic Development Corporation and the Michigan Technology Tri-Corridor (Grant 085P1000817). The Advanced Light Source is supported by the Director, Office of Science, Office of Basic Energy Sciences, of the U.S. Department of Energy under Contract DE-AC02-05CH11231. We thank Diamond Light Source for access to beamline I04-1 that contributed to the results presented here. We thank Adrian Barnard and Hinnah Campwala for in vitro assays. We thank Katy Hulland, David Lamb, Susan Fish, Cedric Hubeau, and John Kubera for in vivo studies.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i43" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i43"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i44" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i44"> Abbreviations Used</h2><tr><td class="NLM_term">AcOH</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">br</td><td class="NLM_def"><p class="first last">broad</p></td></tr><tr><td class="NLM_term">CDCl<sub>3</sub></td><td class="NLM_def"><p class="first last">chloroform-<i>d</i><sub>1</sub></p></td></tr><tr><td class="NLM_term">CI</td><td class="NLM_def"><p class="first last">confidence interval (95% unless otherwise stated)</p></td></tr><tr><td class="NLM_term">Î´</td><td class="NLM_def"><p class="first last">chemical shift</p></td></tr><tr><td class="NLM_term">d</td><td class="NLM_def"><p class="first last">doublet</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethylsulfoxide</p></td></tr><tr><td class="NLM_term">DoA</td><td class="NLM_def"><p class="first last">duration of action</p></td></tr><tr><td class="NLM_term">ELSD</td><td class="NLM_def"><p class="first last">evaporative light scattering detector</p></td></tr><tr><td class="NLM_term">ESI</td><td class="NLM_def"><p class="first last">electrospray ionization</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">Et<sub>2</sub>O</td><td class="NLM_def"><p class="first last">diethyl ether</p></td></tr><tr><td class="NLM_term">GM-CSF</td><td class="NLM_def"><p class="first last">granulocyte macrophage colony-stimulating factor</p></td></tr><tr><td class="NLM_term">h</td><td class="NLM_def"><p class="first last">hour(s)</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high performance liquid chromatography</p></td></tr><tr><td class="NLM_term">HRMS</td><td class="NLM_def"><p class="first last">high resolution mass spectrum</p></td></tr><tr><td class="NLM_term">IFN</td><td class="NLM_def"><p class="first last">interferon</p></td></tr><tr><td class="NLM_term">IL</td><td class="NLM_def"><p class="first last">interleukin</p></td></tr><tr><td class="NLM_term">i.t.</td><td class="NLM_def"><p class="first last">intratracheal</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">Tyk</td><td class="NLM_def"><p class="first last">tyrosine linase</p></td></tr><tr><td class="NLM_term">LRMS</td><td class="NLM_def"><p class="first last">low resolution mass spectrum</p></td></tr><tr><td class="NLM_term">M</td><td class="NLM_def"><p class="first last">molarity</p></td></tr><tr><td class="NLM_term">m</td><td class="NLM_def"><p class="first last">multiplet</p></td></tr><tr><td class="NLM_term">Me</td><td class="NLM_def"><p class="first last">methyl</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">mg</td><td class="NLM_def"><p class="first last">milligram</p></td></tr><tr><td class="NLM_term">min</td><td class="NLM_def"><p class="first last">minute(s)</p></td></tr><tr><td class="NLM_term">MHz</td><td class="NLM_def"><p class="first last">megahertz</p></td></tr><tr><td class="NLM_term">mL</td><td class="NLM_def"><p class="first last">milliliter</p></td></tr><tr><td class="NLM_term">mmol</td><td class="NLM_def"><p class="first last">millimole</p></td></tr><tr><td class="NLM_term"><i>m</i>/<i>z</i></td><td class="NLM_def"><p class="first last">mass-to-charge ratio</p></td></tr><tr><td class="NLM_term">N</td><td class="NLM_def"><p class="first last">normal concentration</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>R</sub></td><td class="NLM_def"><p class="first last">retention time</p></td></tr><tr><td class="NLM_term">s</td><td class="NLM_def"><p class="first last">singlet</p></td></tr><tr><td class="NLM_term">t</td><td class="NLM_def"><p class="first last">triplet</p></td></tr><tr><td class="NLM_term">UV-TIC</td><td class="NLM_def"><p class="first last">ultraviolet total ion count</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32325" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32325" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 32 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">OâShea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kontzias, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaoka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span> </span><span class="NLM_article-title">Janus kinase inhibitors in autoimmune diseases</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">ii111</span><span class="NLM_x">â</span> <span class="NLM_lpage">ii115</span><span class="refDoi">Â DOI: 10.1136/annrheumdis-2012-202576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1136%2Fannrheumdis-2012-202576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=23532440" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2013&pages=ii111-ii115&issue=Suppl.+2&author=J.+J.+O%E2%80%99Sheaauthor=A.+Kontziasauthor=K.+Yamaokaauthor=Y.+Tanakaauthor=A.+Laurence&title=Janus+kinase+inhibitors+in+autoimmune+diseases&doi=10.1136%2Fannrheumdis-2012-202576"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2012-202576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2012-202576%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DKontzias%26aufirst%3DA.%26aulast%3DYamaoka%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DLaurence%26aufirst%3DA.%26atitle%3DJanus%2520kinase%2520inhibitors%2520in%2520autoimmune%2520diseases%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2013%26volume%3D72%26issue%3DSuppl.%25202%26spage%3Dii111%26epage%3Dii115%26doi%3D10.1136%2Fannrheumdis-2012-202576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Clark, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telliez, J.-B.</span><span> </span><span class="NLM_article-title">Discovery and development of janus kinase (JAK) inhibitors for inflammatory diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">5023</span><span class="NLM_x">â</span> <span class="NLM_lpage">5038</span><span class="refDoi">Â DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&issue=12&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.-B.+Telliez&title=Discovery+and+development+of+janus+kinase+%28JAK%29+inhibitors+for+inflammatory+diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0lhXVwtQvi_vDw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DDiscovery%2520and%2520development%2520of%2520janus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D12%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span> </span><span class="NLM_article-title">Discovery of CP-690,550: a potent and selective janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">8468</span><span class="NLM_x">â</span> <span class="NLM_lpage">8484</span><span class="refDoi">Â DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&issue=24&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=S.-P.+Changauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+a+potent+and+selective+janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0lhzMPYJpx9q9Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DChang%26aufirst%3DS.-P.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520a%2520potent%2520and%2520selective%2520janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D24%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span><span> </span><span class="NLM_article-title">News in brief</span>.  <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span>),  <span class="NLM_fpage">895</span>, DOI: <span class="refDoi">Â DOI: 10.1038/nrd3911</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1038%2Fnrd3911" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+News+in+brief.+Nat.+Rev.+Drug+Discovery+2012%2C+11+%2812%29%2C+895%2C+DOI%3A+10.1038%2Fnrd3911"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1038%2Fnrd3911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3911%26sid%3Dliteratum%253Aachs%26atitle%3DNews%2520in%2520brief%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26issue%3D12%26spage%3D895%26doi%3D10.1038%2Fnrd3911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3c"><span><span class="NLM_label">(c) </span><div class="note"><p class="first last">Compound <b>1</b> (catalog no. PZ0017) is available from Sigma Aldrich.</p></div>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Compound+1+%28catalog+no.+PZ0017%29+is+available+from+Sigma+Aldrich.."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Burmester, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charles-Schoeman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wollenhaupt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerbini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benda, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koncz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mebus, C.</span><span> </span><span class="NLM_article-title">Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">381</span><span class="NLM_x"> (</span><span class="NLM_issue">9865</span><span class="NLM_x">) </span> <span class="NLM_fpage">451</span><span class="NLM_x">â</span> <span class="NLM_lpage">460</span><span class="refDoi">Â DOI: 10.1016/S0140-6736(12)61424-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1016%2FS0140-6736%2812%2961424-X" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2013&pages=451-460&issue=9865&author=G.+R.+Burmesterauthor=R.+Blancoauthor=C.+Charles-Schoemanauthor=J.+Wollenhauptauthor=C.+Zerbiniauthor=B.+Bendaauthor=D.+Grubenauthor=G.+Wallensteinauthor=S.+Krishnaswamiauthor=S.+H.+Zwillichauthor=T.+Konczauthor=K.+Somaauthor=J.+Bradleyauthor=C.+Mebus&title=Tofacitinib+%28CP-690%2C550%29+in+combination+with+methotrexate+in+patients+with+active+rheumatoid+arthritis+with+an+inadequate+response+to+tumour+necrosis+factor+inhibitors%3A+a+randomised+phase+3+trial&doi=10.1016%2FS0140-6736%2812%2961424-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2961424-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252961424-X%26sid%3Dliteratum%253Aachs%26aulast%3DBurmester%26aufirst%3DG.%2BR.%26aulast%3DBlanco%26aufirst%3DR.%26aulast%3DCharles-Schoeman%26aufirst%3DC.%26aulast%3DWollenhaupt%26aufirst%3DJ.%26aulast%3DZerbini%26aufirst%3DC.%26aulast%3DBenda%26aufirst%3DB.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DWallenstein%26aufirst%3DG.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DKoncz%26aufirst%3DT.%26aulast%3DSoma%26aufirst%3DK.%26aulast%3DBradley%26aufirst%3DJ.%26aulast%3DMebus%26aufirst%3DC.%26atitle%3DTofacitinib%2520%2528CP-690%252C550%2529%2520in%2520combination%2520with%2520methotrexate%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%2520with%2520an%2520inadequate%2520response%2520to%2520tumour%2520necrosis%2520factor%2520inhibitors%253A%2520a%2520randomised%2520phase%25203%2520trial%26jtitle%3DLancet%26date%3D2013%26volume%3D381%26issue%3D9865%26spage%3D451%26epage%3D460%26doi%3D10.1016%2FS0140-6736%2812%2961424-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fleischmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kremer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cush, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulze-Koops, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanik, K. S.</span><span> </span><span class="NLM_article-title">Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">495</span><span class="NLM_x">â</span> <span class="NLM_lpage">507</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1109071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1056%2FNEJMoa1109071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=22873530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1SisrbI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=495-507&issue=6&author=R.+Fleischmannauthor=J.+Kremerauthor=J.+Cushauthor=H.+Schulze-Koopsauthor=C.+A.+Connellauthor=J.+D.+Bradleyauthor=D.+Grubenauthor=G.+V.+Wallensteinauthor=S.+H.+Zwillichauthor=K.+S.+Kanik&title=Placebo-controlled+trial+of+tofacitinib+monotherapy+in+rheumatoid+arthritis&doi=10.1056%2FNEJMoa1109071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis</span></div><div class="casAuthors">Fleischmann, Roy; Kremer, Joel; Cush, John; Schulze-Koops, Hendrik; Connell, Carol A.; Bradley, John D.; Gruben, David; Wallenstein, Gene V.; Zwillich, Samuel H.; Kanik, Keith S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">495-507</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being investigated as a targeted immunomodulator and disease-modifying therapy for rheumatoid arthritis.  In this phase 3, double-blind, placebo-controlled, parallel-group, 6-mo study, 611 patients were randomly assigned, in a 4:4:1:1 ratio, to 5 mg of tofacitinib twice daily, 10 mg of tofacitinib twice daily, placebo for 3 mo followed by 5 mg of tofacitinib twice daily, or placebo for 3 mo followed by 10 mg of tofacitinib twice daily.  The primary end points, assessed at month 3, were the percentage of patients with at least a 20% improvement in the American College of Rheumatol. scale (ACR 20), the change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) scores (which range from 0 to 3, with higher scores indicating greater disability), and the percentage of patients with a Disease Activity Score for 28-joint counts based on the erythrocyte sedimentation rate (DAS28-4[ESR]) of < 2.6 (with scores ranging from 0 to 9.4 and higher scores indicating more disease activity).  At month 3, a higher percentage of patients in the tofacitinib groups than in the placebo groups met the criteria for an ACR 20 response (59.8% in the 5-mg tofacitinib group and 65.7% in the 10-mg tofacitinib group vs. 26.7% in the combined placebo groups).  The redns. from baseline in HAQ-DI scores were greater in the 5-mg and 10-mg tofacitinib groups than in the placebo groups (-0.50 and -0.57 points, resp., vs. -0.19 points).  The percentage of patients with a DAS28-4(ESR) of < 2.6 was not significantly higher with tofacitinib than with placebo (5.6 and 8.7% in the 5-mg and 10-mg tofacitinib groups, resp., and 4.4% with placebo).  Serious infections developed in 6 patients who were receiving tofacitinib.  Common adverse events were headache and upper respiratory tract infection.  Tofacitinib treatment was assocd. with elevations in low-d. lipoprotein cholesterol levels and redns. in neutrophil counts.  In patients with active rheumatoid arthritis, tofacitinib monotherapy was assocd. with redns. in signs and symptoms of rheumatoid arthritis and improvement in phys. function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_3N7ZNJiVkrVg90H21EOLACvtfcHk0liycddJBIXyqA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1SisrbI&md5=02f2ea14deec82cd4d708cae373baec2</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1109071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1109071%26sid%3Dliteratum%253Aachs%26aulast%3DFleischmann%26aufirst%3DR.%26aulast%3DKremer%26aufirst%3DJ.%26aulast%3DCush%26aufirst%3DJ.%26aulast%3DSchulze-Koops%26aufirst%3DH.%26aulast%3DConnell%26aufirst%3DC.%2BA.%26aulast%3DBradley%26aufirst%3DJ.%2BD.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DWallenstein%26aufirst%3DG.%2BV.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DKanik%26aufirst%3DK.%2BS.%26atitle%3DPlacebo-controlled%2520trial%2520of%2520tofacitinib%2520monotherapy%2520in%2520rheumatoid%2520arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26issue%3D6%26spage%3D495%26epage%3D507%26doi%3D10.1056%2FNEJMoa1109071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kremer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleischmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Mola, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaacs, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koncz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riese, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, J.</span><span> </span><span class="NLM_article-title">Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">159</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">253</span><span class="NLM_x">â</span> <span class="NLM_lpage">261</span><span class="refDoi">Â DOI: 10.7326/0003-4819-159-4-201308200-00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.7326%2F0003-4819-159-4-201308200-00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=24026258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A280%3ADC%252BC3sbntl2qsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2013&pages=253-261&issue=4&author=J.+Kremerauthor=Z.-G.+Liauthor=S.+Hallauthor=R.+Fleischmannauthor=M.+Genoveseauthor=E.+Martin-Molaauthor=J.+D.+Isaacsauthor=D.+Grubenauthor=G.+Wallensteinauthor=S.+Krishnaswamiauthor=S.+H.+Zwillichauthor=T.+Konczauthor=R.+Rieseauthor=J.+Bradley&title=Tofacitinib+in+combination+with+nonbiologic+disease-modifying+antirheumatic+drugs+in+patients+with+active+rheumatoid+arthritis%3A+a+randomized+trial&doi=10.7326%2F0003-4819-159-4-201308200-00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4c</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial</span></div><div class="casAuthors">Kremer Joel; Li Zhan-Guo; Hall Stephen; Fleischmann Roy; Genovese Mark; Martin-Mola Emilio; Isaacs John D; Gruben David; Wallenstein Gene; Krishnaswami Sriram; Zwillich Samuel H; Koncz Tamas; Riese Richard; Bradley John</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">253-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Many patients with rheumatoid arthritis (RA) do not achieve adequate and safe responses with disease-modifying antirheumatic drugs (DMARDs).  Tofacitinib is a novel, oral, Janus kinase inhibitor that treats RA.  OBJECTIVE:  To evaluate the efficacy and safety of tofacitinib in combination with nonbiologic DMARDs.  DESIGN:  1-year, double-blind, randomized trial (ClinicalTrials.gov: NCT00856544).  SETTING:  114 centers in 19 countries.  PATIENTS:  792 patients with active RA despite nonbiologic DMARD therapy.  INTERVENTION:  Patients were randomly assigned 4:4:1:1 to oral tofacitinib, 5 mg or 10 mg twice daily, or placebo advanced to tofacitinib, 5 mg or 10 mg twice daily.  MEASUREMENTS:  Primary end points were 20% improvement in American College of Rheumatology (ACR20) criteria; Disease Activity Score for 28-joint counts based on the erythrocyte sedimentation rate (DAS28-4[ESR]) of less than 2.6; DAS28-4(ESR)-defined remission, change in Health Assessment Questionnaire Disability Index (HAQ-DI) score, and safety assessments.  RESULTS:  Mean treatment differences for ACR20 response rates (month 6) for the 5-mg and 10-mg tofacitinib groups compared with the combined placebo groups were 21.2% (95% CI, 12.2% to 30.3%; P < 0.001) and 25.8% (CI, 16.8% to 34.8%; P < 0.001), respectively.  The HAQ-DI scores (month 3) and DAS28-4(ESR) less than 2.6 response rates (month 6) were also superior in the tofacitinib groups versus placebo.  The incidence rates of serious adverse events for patients receiving 5-mg tofacitinib, 10-mg tofacitinib, or placebo were 6.9, 7.3, or 10.9 events per 100 patient-years of exposure, respectively.  In the tofacitinib groups, 2 cases of tuberculosis, 2 cases of other opportunistic infections, 3 cardiovascular events, and 4 deaths occurred.  Neutrophil counts decreased, hemoglobin and low- and high-density lipoprotein cholesterol levels increased, and serum creatinine levels had small increases in the tofacitinib groups.  LIMITATIONS:  Placebo groups were smaller and of shorter duration.  Patients received primarily methotrexate.  The ability to assess drug combinations other than tofacitinib plus methotrexate was limited.  CONCLUSION:  Tofacitinib improved disease control in patients with active RA despite treatment with nonbiologic DMARDs, primarily methotrexate.  PRIMARY FUNDING SOURCE:  Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQtavUaLESyEFMGsG_HTXYFfW6udTcc2ebXg64QZfgiULntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbntl2qsg%253D%253D&md5=3751f0ebd16a232dce5f09b124c8c55c</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-159-4-201308200-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-159-4-201308200-00006%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.-G.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DFleischmann%26aufirst%3DR.%26aulast%3DGenovese%26aufirst%3DM.%26aulast%3DMartin-Mola%26aufirst%3DE.%26aulast%3DIsaacs%26aufirst%3DJ.%2BD.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DWallenstein%26aufirst%3DG.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DKoncz%26aufirst%3DT.%26aulast%3DRiese%26aufirst%3DR.%26aulast%3DBradley%26aufirst%3DJ.%26atitle%3DTofacitinib%2520in%2520combination%2520with%2520nonbiologic%2520disease-modifying%2520antirheumatic%2520drugs%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%253A%2520a%2520randomized%2520trial%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2013%26volume%3D159%26issue%3D4%26spage%3D253%26epage%3D261%26doi%3D10.7326%2F0003-4819-159-4-201308200-00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Lee, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleischmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koncz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Vollenhoven, R. F.</span><span> </span><span class="NLM_article-title">Tofacitinib versus methotrexate in rheumatoid arthritis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x"> (</span><span class="NLM_issue">25</span><span class="NLM_x">) </span> <span class="NLM_fpage">2377</span><span class="NLM_x">â</span> <span class="NLM_lpage">2386</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1310476</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1056%2FNEJMoa1310476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=24941177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ajtL%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=2377-2386&issue=25&author=E.+B.+Leeauthor=R.+Fleischmannauthor=S.+Hallauthor=B.+Wilkinsonauthor=J.+D.+Bradleyauthor=D.+Grubenauthor=T.+Konczauthor=S.+Krishnaswamiauthor=G.+V.+Wallensteinauthor=C.+Zangauthor=S.+H.+Zwillichauthor=R.+F.+van+Vollenhoven&title=Tofacitinib+versus+methotrexate+in+rheumatoid+arthritis&doi=10.1056%2FNEJMoa1310476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4dR"><div class="casContent"><span class="casTitleNuber">4d</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib versus methotrexate in rheumatoid arthritis</span></div><div class="casAuthors">Lee, Eun Bong; Fleischmann, Roy; Hall, Stephen; Wilkinson, Bethanie; Bradley, John D.; Gruben, David; Koncz, Tamas; Krishnaswami, Sriram; Wallenstein, Gene V.; Zang, Chuanbo; Zwillich, Samuel H.; van Vollenhoven, Ronald F.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2377-2386, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Methotrexate is the most frequently used first-line antirheumatic drug.  We report the findings of a phase 3 study of monotherapy with tofacitinib, an oral Janus kinase inhibitor, as compared with methotrexate monotherapy in patients with rheumatoid arthritis who had not previously received methotrexate or therapeutic doses of methotrexate. methods We randomly assigned 958 patients to receive 5 mg or 10 mg of tofacitinib twice daily or methotrexate at a dose that was incrementally increased to 20 mg per wk over 8 wk; 956 patients received a study drug.  The coprimary end points at month 6 were the mean change from baseline in the van der Heijde modified total Sharp score (which ranges from 0 to 448, with higher scores indicating greater structural joint damage) and the proportion of patients with an American College of Rheumatol. (ACR) 70 response (â¥70% redn. in the no. of both tender and swollen joints and â¥70% improvement in three of five other criteria: the patient's assessment of pain, level of disability, C-reactive protein level or erythrocyte sedimentation rate, global assessment of disease by the patient, and global assessment of disease by the physician). results Mean changes in the modified total Sharp score from baseline to month 6 were significantly smaller in the tofacitinib groups than in the methotrexate group, but changes were modest in all three groups (0.2 points in the 5-mg tofacitinib group and <0.1 point in the 10-mg tofacitinib group, as compared with 0.8 points in the methotrexate group [P<0.001 for both comparisons]).  Among the patients receiving tofacitinib, 25.5% in the 5-mg group and 37.7% in the 10-mg group had an ACR 70 response at month 6, as compared with 12.0% of patients in the methotrexate group (P<0.001 for both comparisons).  Herpes zoster developed in 31 of 770 patients who received tofacitinib (4.0%) and in 2 of 186 patients who received methotrexate (1.1%).  Confirmed cases of cancer (including three cases of lymphoma) developed in 5 patients who received tofacitinib and in 1 patient who received methotrexate.  Tofacitinib was assocd. with increases in creatinine levels and in low-d. and high-d. lipoprotein cholesterol levels. conclusions In patients who had not previously received methotrexate or therapeutic doses of methotrexate, tofacitinib monotherapy was superior to methotrexate in reducing signs and symptoms of rheumatoid arthritis and inhibiting the progression of structural joint damage.  The benefits of tofacitinib need to be considered in the context of the risks of adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeTn9l50rIrrVg90H21EOLACvtfcHk0lh00h9yT3jG4w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ajtL%252FM&md5=8b8058a1091555f957b4da7ae6e95db4</span></div><a href="/servlet/linkout?suffix=cit4d&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1310476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1310476%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DFleischmann%26aufirst%3DR.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DBradley%26aufirst%3DJ.%2BD.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKoncz%26aufirst%3DT.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DWallenstein%26aufirst%3DG.%2BV.%26aulast%3DZang%26aufirst%3DC.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3Dvan%2BVollenhoven%26aufirst%3DR.%2BF.%26atitle%3DTofacitinib%2520versus%2520methotrexate%2520in%2520rheumatoid%2520arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26issue%3D25%26spage%3D2377%26epage%3D2386%26doi%3D10.1056%2FNEJMoa1310476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">van der Heijde, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleischmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keystone, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kremer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerbini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardiel, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nash, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tegzova, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyman, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benda, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connell, C. A.</span><span> </span><span class="NLM_article-title">Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">559</span><span class="NLM_x">â</span> <span class="NLM_lpage">570</span><span class="refDoi">Â DOI: 10.1002/art.37816</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1002%2Fart.37816" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=23348607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtlGqsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=559-570&issue=3&author=D.+van+der+Heijdeauthor=Y.+Tanakaauthor=R.+Fleischmannauthor=E.+Keystoneauthor=J.+Kremerauthor=C.+Zerbiniauthor=M.+H.+Cardielauthor=S.+Cohenauthor=P.+Nashauthor=Y.-W.+Songauthor=D.+Tegzovaauthor=B.+T.+Wymanauthor=D.+Grubenauthor=B.+Bendaauthor=G.+Wallensteinauthor=S.+Krishnaswamiauthor=S.+H.+Zwillichauthor=J.+D.+Bradleyauthor=C.+A.+Connell&title=Tofacitinib+%28CP-690%2C550%29+in+patients+with+rheumatoid+arthritis+receiving+methotrexate%3A+twelve-month+data+from+a+twenty-four-month+phase+III+randomized+radiographic+study&doi=10.1002%2Fart.37816"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4eR"><div class="casContent"><span class="casTitleNuber">4e</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study</span></div><div class="casAuthors">van der Heijde, Desiree; Tanaka, Yoshiya; Fleischmann, Roy; Keystone, Edward; Kremer, Joel; Zerbini, Cristiano; Cardiel, Mario H.; Cohen, Stanley; Nash, Peter; Song, Yeong-Wook; Tegzova, Dana; Wyman, Bradley T.; Gruben, David; Benda, Birgitta; Wallenstein, Gene; Krishnaswami, Sriram; Zwillich, Samuel H.; Bradley, John D.; Connell, Carol A.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">559-570</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: The purpose of this 24-mo phase III study was to examine structural preservation with tofacitinib in patients with rheumatoid arthritis (RA) with an inadequate response to methotrexate (MTX).  Data from a planned 12-mo interim anal. are reported.  Methods: In this double-blind, parallel-group, placebo-controlled study, patients receiving background MTX were randomized 4:4:1:1 to tofacitinib at 5 mg twice daily, tofacitinib at 10 mg twice daily, placebo to tofacitinib at 5 mg twice daily, and placebo to tofacitinib at 10 mg twice daily.  At month 3, nonresponder placebo-treated patients were advanced in a blinded manner to receive tofacitinib as indicated above; remaining placebo-treated patients were advanced at 6 mo.  Four primary efficacy end points were all analyzed in a step-down procedure.  Results: At month 6, response rates according to the American College of Rheumatol. 20% improvement criteria for tofacitinib at 5 mg and 10 mg twice daily were higher than those for placebo (51.5% and 61.8%, resp., vs. 25.3%; both P < 0.0001).  At month 6, least squares mean (LSM) changes in total modified Sharp/van der Heijde score for tofacitinib at 5 mg and 10 mg twice daily were 0.12 and 0.06, resp., vs. 0.47 for placebo (P = 0.0792 and P â¤ 0.05, resp.).  At month 3, LSM changes in the Health Assessment Questionnaire disability index score for tofacitinib at 5 mg and 10 mg twice daily were -0.40 (significance not declared due to step-down procedure) and -0.54 (P < 0.0001), resp., vs. -0.15 for placebo.  At month 6, rates of remission (defined as a value <2.6 for the 4-variable Disease Activity Score in 28 joints using the erythrocyte sedimentation rate) for tofacitinib at 5 mg and 10 mg twice daily were 7.2% (significance not declared due to step-down procedure) and 16.0% (P < 0.0001), resp., vs. 1.6% for placebo.  The safety profile was consistent with findings in previous studies.  Conclusion: Data from this 12-mo interim anal. demonstrate that tofacitinib inhibits progression of structural damage and improves disease activity in patients with RA who are receiving MTX.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo13qQ8LjyKorVg90H21EOLACvtfcHk0lipWXEO481iMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtlGqsrg%253D&md5=0d30a733a323fb11fc65b0f1d0b638bc</span></div><a href="/servlet/linkout?suffix=cit4e&amp;dbid=16384&amp;doi=10.1002%2Fart.37816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.37816%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BHeijde%26aufirst%3DD.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DFleischmann%26aufirst%3DR.%26aulast%3DKeystone%26aufirst%3DE.%26aulast%3DKremer%26aufirst%3DJ.%26aulast%3DZerbini%26aufirst%3DC.%26aulast%3DCardiel%26aufirst%3DM.%2BH.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DNash%26aufirst%3DP.%26aulast%3DSong%26aufirst%3DY.-W.%26aulast%3DTegzova%26aufirst%3DD.%26aulast%3DWyman%26aufirst%3DB.%2BT.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DBenda%26aufirst%3DB.%26aulast%3DWallenstein%26aufirst%3DG.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DBradley%26aufirst%3DJ.%2BD.%26aulast%3DConnell%26aufirst%3DC.%2BA.%26atitle%3DTofacitinib%2520%2528CP-690%252C550%2529%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%2520receiving%2520methotrexate%253A%2520twelve-month%2520data%2520from%2520a%2520twenty-four-month%2520phase%2520III%2520randomized%2520radiographic%2520study%26jtitle%3DArthritis%2520Rheum.%26date%3D2013%26volume%3D65%26issue%3D3%26spage%3D559%26epage%3D570%26doi%3D10.1002%2Fart.37816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">van Vollenhoven, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleischmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijide, J. A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forejtova, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koncz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B.</span><span> </span><span class="NLM_article-title">Tofacitinib or adalimumab versus placebo in rheumatoid arthritis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">508</span><span class="NLM_x">â</span> <span class="NLM_lpage">519</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1112072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1056%2FNEJMoa1112072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=22873531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1SisrbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=508-519&issue=6&author=R.+F.+van+Vollenhovenauthor=R.+Fleischmannauthor=S.+Cohenauthor=E.+B.+Leeauthor=J.+A.+G.+Meijideauthor=S.+Wagnerauthor=S.+Forejtovaauthor=S.+H.+Zwillichauthor=D.+Grubenauthor=T.+Konczauthor=G.+V.+Wallensteinauthor=S.+Krishnaswamiauthor=J.+D.+Bradleyauthor=B.+Wilkinson&title=Tofacitinib+or+adalimumab+versus+placebo+in+rheumatoid+arthritis&doi=10.1056%2FNEJMoa1112072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4fR"><div class="casContent"><span class="casTitleNuber">4f</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib or adalimumab versus placebo in rheumatoid arthritis</span></div><div class="casAuthors">van Vollenhoven, Ronald F.; Fleischmann, Roy; Cohen, Stanley; Lee, Eun Bong; Meijide, Juan A. Garcia; Wagner, Sylke; Forejtova, Sarka; Zwillich, Samuel H.; Gruben, David; Koncz, Tamas; Wallenstein, Gene V.; Krishnaswami, Sriram; Bradley, John D.; Wilkinson, Bethanie</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">508-519</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BAckground: Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being investigated for the treatment of rheumatoid arthritis.  Methods: In this 12-mo, phase 3 trial, 717 patients who were receiving stable doses of methotrexate were randomly assigned to 5 mg of tofacitinib twice daily, 10 mg of tofacitinib twice daily, 40 mg of adalimumab once every 2 wk, or placebo.  At month 3, patients in the placebo group who did not have a 20% redn. from baseline in the no. of swollen and tender joints were switched in a blinded fashion to either 5 mg or 10 mg of tofacitinib twice daily; at month 6, all patients still receiving placebo were switched to tofacitinib in a blinded fashion.  The three primary outcome measures were a 20% improvement at month 6 in the American College of Rheumatol. scale (ACR 20); the change from baseline to month 3 in the score on the Health Assessment Questionnaire-Disability Index (HAQ-DI) (which ranges from 0 to 3, with higher scores indicating greater disability); and the percentage of patients at month 6 who had a Disease Activity Score for 28-joint counts based on the erythrocyte sedimentation rate (DAS28-4[ESR]) of less than 2.6 (with scores ranging from 0 to 9.4 and higher scores indicating greater disease activity).  Results: At month 6, ACR 20 response rates were higher among patients receiving 5 mg or 10 mg of tofacitinib (51.5% and 52.6%, resp.) and among those receiving adalimumab (47.2%) than among those receiving placebo (28.3%) (P<0.001 for all comparisons).  There were also greater redns. in the HAQ-DI score at month 3 and higher percentages of patients with a DAS28-4(ESR) below 2.6 at month 6 in the active-treatment groups than in the placebo group.  Adverse events occurred more frequently with tofacitinib than with placebo, and pulmonary tuberculosis developed in two patients in the 10-mg tofacitinib group.  Tofacitinib was assocd. with an increase in both low-d. and high-d. lipoprotein cholesterol levels and with redns. in neutrophil counts.  Conclusions: In patients with rheumatoid arthritis receiving background methotrexate, tofacitinib was significantly superior to placebo and was numerically similar to adalimumab in efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA_VjQtntrVLVg90H21EOLACvtfcHk0lipWXEO481iMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1SisrbJ&md5=b241cdff1346e5ddb295369dabb6092c</span></div><a href="/servlet/linkout?suffix=cit4f&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1112072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1112072%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BVollenhoven%26aufirst%3DR.%2BF.%26aulast%3DFleischmann%26aufirst%3DR.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DMeijide%26aufirst%3DJ.%2BA.%2BG.%26aulast%3DWagner%26aufirst%3DS.%26aulast%3DForejtova%26aufirst%3DS.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKoncz%26aufirst%3DT.%26aulast%3DWallenstein%26aufirst%3DG.%2BV.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DBradley%26aufirst%3DJ.%2BD.%26aulast%3DWilkinson%26aufirst%3DB.%26atitle%3DTofacitinib%2520or%2520adalimumab%2520versus%2520placebo%2520in%2520rheumatoid%2520arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26issue%3D6%26spage%3D508%26epage%3D519%26doi%3D10.1056%2FNEJMoa1112072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bachelez, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van de Kerkhof, P. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strohal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubanov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenzuela, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakusevich, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chimenti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papacharalambous, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proulx, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tawadrous, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdez, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolk, R.</span><span> </span><span class="NLM_article-title">Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">386</span><span class="NLM_x"> (</span><span class="NLM_issue">9993</span><span class="NLM_x">) </span> <span class="NLM_fpage">552</span><span class="NLM_x">â</span> <span class="NLM_lpage">561</span><span class="refDoi">Â DOI: 10.1016/S0140-6736(14)62113-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1016%2FS0140-6736%2814%2962113-9" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2015&pages=552-561&issue=9993&author=H.+Bachelezauthor=P.+C.+M.+van+de+Kerkhofauthor=R.+Strohalauthor=A.+Kubanovauthor=F.+Valenzuelaauthor=J.-H.+Leeauthor=V.+Yakusevichauthor=S.+Chimentiauthor=J.+Papacharalambousauthor=J.+Proulxauthor=P.+Guptaauthor=H.+Tanauthor=M.+Tawadrousauthor=H.+Valdezauthor=R.+Wolk&title=Tofacitinib+versus+etanercept+or+placebo+in+moderate-to-severe+chronic+plaque+psoriasis%3A+a+phase+3+randomised+non-inferiority+trial&doi=10.1016%2FS0140-6736%2814%2962113-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2962113-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252962113-9%26sid%3Dliteratum%253Aachs%26aulast%3DBachelez%26aufirst%3DH.%26aulast%3Dvan%2Bde%2BKerkhof%26aufirst%3DP.%2BC.%2BM.%26aulast%3DStrohal%26aufirst%3DR.%26aulast%3DKubanov%26aufirst%3DA.%26aulast%3DValenzuela%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DJ.-H.%26aulast%3DYakusevich%26aufirst%3DV.%26aulast%3DChimenti%26aufirst%3DS.%26aulast%3DPapacharalambous%26aufirst%3DJ.%26aulast%3DProulx%26aufirst%3DJ.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DTawadrous%26aufirst%3DM.%26aulast%3DValdez%26aufirst%3DH.%26aulast%3DWolk%26aufirst%3DR.%26atitle%3DTofacitinib%2520versus%2520etanercept%2520or%2520placebo%2520in%2520moderate-to-severe%2520chronic%2520plaque%2520psoriasis%253A%2520a%2520phase%25203%2520randomised%2520non-inferiority%2520trial%26jtitle%3DLancet%26date%3D2015%26volume%3D386%26issue%3D9993%26spage%3D552%26epage%3D561%26doi%3D10.1016%2FS0140-6736%2814%2962113-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bissonnette, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iversen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sofen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, C. E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romiti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachinsky, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottinghaus, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proulx, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdez, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallbris, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolk, R.</span><span> </span><span class="NLM_article-title">Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial</span> <span class="citation_source-journal">Br. J. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">172</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">1395</span><span class="NLM_x">â</span> <span class="NLM_lpage">1406</span><span class="refDoi">Â DOI: 10.1111/bjd.13551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1111%2Fbjd.13551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=25418186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlChsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=1395-1406&issue=5&author=R.+Bissonnetteauthor=L.+Iversenauthor=H.+Sofenauthor=C.+E.+M.+Griffithsauthor=P.+Foleyauthor=R.+Romitiauthor=M.+Bachinskyauthor=S.+T.+Rottinghausauthor=H.+Tanauthor=J.+Proulxauthor=H.+Valdezauthor=P.+Guptaauthor=L.+Mallbrisauthor=R.+Wolk&title=Tofacitinib+withdrawal+and+retreatment+in+moderate-to-severe+chronic+plaque+psoriasis%3A+a+randomized+controlled+trial&doi=10.1111%2Fbjd.13551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial</span></div><div class="casAuthors">Bissonnette, R.; Iversen, L.; Sofen, H.; Griffiths, C. E. M.; Foley, P.; Romiti, R.; Bachinsky, M.; Rottinghaus, S. T.; Tan, H.; Proulx, J.; Valdez, H.; Gupta, P.; Mallbris, L.; Wolk, R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1395-1406</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Tofacitinib is an oral Janus kinase inhibitor being investigated for the treatment of moderate-to-severe plaque psoriasis.  Objectives : To compare outcomes following tofacitinib withdrawal with outcomes of continuation.  Methods : In this phase 3 study (NCT01186744), patients received tofacitinib 5 mg (n = 331) or 10 mg (n = 335) twice daily for 24 wk.  The patients who achieved both â¥ 75% redn. in Psoriasis Area and Severity Index (PASI 75) score from baseline and Physician's Global Assessment (PGA) of 'clear' or 'almost clear' (PGA response) received a placebo (withdrawal) or the previous dose.  At relapse (> 50% redn. in the PASI improvement during initial treatment) or week 40, the patients received the initial dose.  Results : Initial treatment: 33Â·5% and 55Â·2% achieved both PASI 75 and PGA responses with tofacitinib 5 and 10 mg twice daily, resp., making them eligible for the treatment-withdrawal period.  Withdrawal: 56Â·2%, 62Â·3%, 23Â·3% and 26Â·1% maintained PASI 75 responses with tofacitinib 5, 10 mg, placebo (5 mg) and placebo (10 mg) twice daily, resp.; 49Â·9%, 63Â·9%, 22Â·9% and 18Â·0% maintained PGA responses; and 92Â·3%, 93Â·0%, 32Â·8% and 42Â·9% did not relapse.  Elevations in low-d. lipoprotein-cholesterol levels following initial treatment (mean increase: 8Â·71 mg dL-1 with 5 mg twice daily, 10Â·26 mg dL-1 with 10 mg twice daily) were reversed upon withdrawal.  Retreatment: 36Â·8% and 61Â·0% of patients who relapsed achieved PASI 75 responses with tofacitinib 5 or 10 mg after 16 wk; 44Â·8% and 57Â·1% regained PGA responses.  Conclusions : Patients who received continuous treatment maintained a response more effectively when compared with placebo recipients.  Safety profiles were comparable in both the continuous treatment group and retreatment group.  Of those patients who relapsed, up to 60% recaptured a response with tofacitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohd8n-cEliL7Vg90H21EOLACvtfcHk0ljw5NJLNuxhEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlChsLY%253D&md5=8b0331613f87c7e7030996c4ab1477d2</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1111%2Fbjd.13551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.13551%26sid%3Dliteratum%253Aachs%26aulast%3DBissonnette%26aufirst%3DR.%26aulast%3DIversen%26aufirst%3DL.%26aulast%3DSofen%26aufirst%3DH.%26aulast%3DGriffiths%26aufirst%3DC.%2BE.%2BM.%26aulast%3DFoley%26aufirst%3DP.%26aulast%3DRomiti%26aufirst%3DR.%26aulast%3DBachinsky%26aufirst%3DM.%26aulast%3DRottinghaus%26aufirst%3DS.%2BT.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DProulx%26aufirst%3DJ.%26aulast%3DValdez%26aufirst%3DH.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DMallbris%26aufirst%3DL.%26aulast%3DWolk%26aufirst%3DR.%26atitle%3DTofacitinib%2520withdrawal%2520and%2520retreatment%2520in%2520moderate-to-severe%2520chronic%2520plaque%2520psoriasis%253A%2520a%2520randomized%2520controlled%2520trial%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2015%26volume%3D172%26issue%3D5%26spage%3D1395%26epage%3D1406%26doi%3D10.1111%2Fbjd.13551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Papp, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thaci, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torii, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyring, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mebus, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallbris, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatulych, S.</span><span> </span><span class="NLM_article-title">Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study</span> <span class="citation_source-journal">J. Am. Acad. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">841</span><span class="NLM_x">â</span> <span class="NLM_lpage">850</span><span class="refDoi">Â DOI: 10.1016/j.jaad.2016.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1016%2Fj.jaad.2016.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=26899199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC28XivVCitbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2016&pages=841-850&issue=5&author=K.+A.+Pappauthor=J.+G.+Kruegerauthor=S.+R.+Feldmanauthor=R.+G.+Langleyauthor=D.+Thaciauthor=H.+Toriiauthor=S.+Tyringauthor=R.+Wolkauthor=A.+Gardnerauthor=C.+Mebusauthor=H.+Tanauthor=Y.+Luoauthor=P.+Guptaauthor=L.+Mallbrisauthor=S.+Tatulych&title=Tofacitinib%2C+an+oral+Janus+kinase+inhibitor%2C+for+the+treatment+of+chronic+plaque+psoriasis%3A+Long-term+efficacy+and+safety+results+from+2+randomized+phase-III+studies+and+1+open-label+long-term+extension+study&doi=10.1016%2Fj.jaad.2016.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study</span></div><div class="casAuthors">Papp, Kim A.; Krueger, James G.; Feldman, Steven R.; Langley, Richard G.; Thaci, Diamant; Torii, Hideshi; Tyring, Stephen; Wolk, Robert; Gardner, Annie; Mebus, Charles; Tan, Huaming; Luo, Yingchun; Gupta, Pankaj; Mallbris, Lotus; Tatulych, Svitlana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">841-850</span>CODEN:
                <span class="NLM_cas:coden">JAADDB</span>;
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis.  We sought to report longer-term tofacitinib efficacy and safety in patients with moderate to severe psoriasis.  Data from 2 identical phase-III studies, Oral-treatment Psoriasis Trial Pivotal 1 and 2, were pooled with data from these patients in an ongoing open-label long-term extension study.  Patients (n = 1861) were randomized 2:2:1 to tofacitinib 5 mg, 10 mg, or placebo twice daily (BID).  At week 16, placebo patients were rerandomized to tofacitinib.  Pivotal study participants could enroll into the long-term extension where they received tofacitinib at 10 mg BID for 3 mo, after which dosing could be 5 or 10 mg BID.  At week 28, the proportions of patients randomized to tofacitinib 5 and 10 mg BID achieving 75% or greater redn. in Psoriasis Area and Severity Index score from baseline were 55.6% and 68.8%, and achieving Physician Global Assessment of clear or almost clear were 54.7% and 65.9%.  Efficacy was maintained in most patients through 24 mo.  Serious adverse events and discontinuations because of adverse events were reported in less than 11% of patients over 33 mo of tofacitinib exposure.  There was no dose comparison beyond week 52.  Oral tofacitinib demonstrated sustained efficacy in patients with psoriasis through 2 years, with 10 mg BID providing greater efficacy than 5 mg BID.  No unexpected safety findings were obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhj8uGmv-7pLVg90H21EOLACvtfcHk0lh9cRreaZI3Lw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivVCitbo%253D&md5=242e57c6682bc3fefb55057cd45274db</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2016.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2016.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DKrueger%26aufirst%3DJ.%2BG.%26aulast%3DFeldman%26aufirst%3DS.%2BR.%26aulast%3DLangley%26aufirst%3DR.%2BG.%26aulast%3DThaci%26aufirst%3DD.%26aulast%3DTorii%26aufirst%3DH.%26aulast%3DTyring%26aufirst%3DS.%26aulast%3DWolk%26aufirst%3DR.%26aulast%3DGardner%26aufirst%3DA.%26aulast%3DMebus%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DMallbris%26aufirst%3DL.%26aulast%3DTatulych%26aufirst%3DS.%26atitle%3DTofacitinib%252C%2520an%2520oral%2520Janus%2520kinase%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520chronic%2520plaque%2520psoriasis%253A%2520Long-term%2520efficacy%2520and%2520safety%2520results%2520from%25202%2520randomized%2520phase-III%2520studies%2520and%25201%2520open-label%2520long-term%2520extension%2520study%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2016%26volume%3D74%26issue%3D5%26spage%3D841%26epage%3D850%26doi%3D10.1016%2Fj.jaad.2016.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Papp, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menter, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elewski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottlieb, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thaci, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buonanno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proulx, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolk, R.</span><span> </span><span class="NLM_article-title">Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials</span> <span class="citation_source-journal">Br. J. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">173</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">949</span><span class="NLM_x">â</span> <span class="NLM_lpage">961</span><span class="refDoi">Â DOI: 10.1111/bjd.14018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1111%2Fbjd.14018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=26149717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyns73E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2015&pages=949-961&issue=4&author=K.+A.+Pappauthor=M.+A.+Menterauthor=M.+Abeauthor=B.+Elewskiauthor=S.+R.+Feldmanauthor=A.+B.+Gottliebauthor=R.+Langleyauthor=T.+Lugerauthor=D.+Thaciauthor=M.+Buonannoauthor=P.+Guptaauthor=J.+Proulxauthor=S.+Lanauthor=R.+Wolk&title=Tofacitinib%2C+an+oral+Janus+kinase+inhibitor%2C+for+the+treatment+of+chronic+plaque+psoriasis%3A+results+from+two+randomized%2C+placebo-controlled%2C+phase+III+trials&doi=10.1111%2Fbjd.14018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5dR"><div class="casContent"><span class="casTitleNuber">5d</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials</span></div><div class="casAuthors">Papp, K. A.; Menter, M. A.; Abe, M.; Elewski, B.; Feldman, S. R.; Gottlieb, A. B.; Langley, R.; Luger, T.; Thaci, D.; Buonanno, M.; Gupta, P.; Proulx, J.; Lan, S.; Wolk, R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">949-961</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis.  Objectives : To det. the 16-wk efficacy and safety of two oral tofacitinib doses vs. placebo in patients with moderate-to-severe chronic plaque psoriasis.  Methods : Patients in two similarly designed phase III studies (OPT Pivotal 1, NCT01276639, n = 901; OPT Pivotal 2, NCT01309737, n = 960) were initially randomized 2 : 2 : 1 to tofacitinib 10 or 5 mg or placebo, twice daily.  Coprimary efficacy end points (week 16) included the proportion of patients achieving Physician's Global Assessment (PGA) of 'clear' or 'almost clear' (PGA response) and the proportion achieving â¥ 75% redn. in Psoriasis Area and Severity Index (PASI 75).  Results : Across OPT Pivotal 1 and OPT Pivotal 2, 745 patients received tofacitinib 5 mg, 741 received tofacitinib 10 mg and 373 received placebo.  At week 16, a greater proportion of patients achieved PGA responses with tofacitinib 5 and 10 mg twice daily vs. placebo (OPT Pivotal 1, 41Â·9% and 59Â·2% vs. 9Â·0%; OPT Pivotal 2, 46Â·0% and 59Â·1% vs. 10Â·9%; all P < 0Â·001).  Higher PASI 75 rates were obsd. with tofacitinib vs. placebo (OPT Pivotal 1, 39Â·9%, 59Â·2% and 6Â·2%, resp., for tofacitinib 5 and 10 mg twice daily and placebo; OPT Pivotal 2, 46Â·0%, 59Â·6% and 11Â·4%; all P < 0Â·001 vs. placebo).  Adverse event (AE) rates appeared generally similar across groups; rates of serious AEs, infections, malignancies and discontinuations due to AEs were low.  Twelve patients reported herpes zoster across the tofacitinib treatment groups in both studies vs. none in the resp. placebo groups.  The most common AE across groups was nasopharyngitis.  Conclusions : Oral tofacitinib demonstrated significant efficacy vs. placebo during the initial 16 wk of treatment in patients with moderate-to-severe psoriasis.  Safety findings were consistent with prior studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTWaBXP7bJbLVg90H21EOLACvtfcHk0lh9cRreaZI3Lw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyns73E&md5=2029ed12ccdeaeb36ab87425a8c534c1</span></div><a href="/servlet/linkout?suffix=cit5d&amp;dbid=16384&amp;doi=10.1111%2Fbjd.14018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.14018%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DMenter%26aufirst%3DM.%2BA.%26aulast%3DAbe%26aufirst%3DM.%26aulast%3DElewski%26aufirst%3DB.%26aulast%3DFeldman%26aufirst%3DS.%2BR.%26aulast%3DGottlieb%26aufirst%3DA.%2BB.%26aulast%3DLangley%26aufirst%3DR.%26aulast%3DLuger%26aufirst%3DT.%26aulast%3DThaci%26aufirst%3DD.%26aulast%3DBuonanno%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DProulx%26aufirst%3DJ.%26aulast%3DLan%26aufirst%3DS.%26aulast%3DWolk%26aufirst%3DR.%26atitle%3DTofacitinib%252C%2520an%2520oral%2520Janus%2520kinase%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520chronic%2520plaque%2520psoriasis%253A%2520results%2520from%2520two%2520randomized%252C%2520placebo-controlled%252C%2520phase%2520III%2520trials%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2015%26volume%3D173%26issue%3D4%26spage%3D949%26epage%3D961%26doi%3D10.1111%2Fbjd.14018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sandborn, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vranic, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rousell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niezychowski, W.</span><span> </span><span class="NLM_article-title">Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">616</span><span class="NLM_x">â</span> <span class="NLM_lpage">624</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1112168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1056%2FNEJMoa1112168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=22894574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Chu77K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=616-624&issue=7&author=W.+J.+Sandbornauthor=S.+Ghoshauthor=J.+Panesauthor=I.+Vranicauthor=C.+Suauthor=S.+Rousellauthor=W.+Niezychowski&title=Tofacitinib%2C+an+oral+Janus+kinase+inhibitor%2C+in+active+ulcerative+colitis&doi=10.1056%2FNEJMoa1112168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis</span></div><div class="casAuthors">Sandborn, William J.; Ghosh, Subrata; Panes, Julian; Vranic, Ivana; Su, Chinyu; Rousell, Samantha; Niezychowski, Wojciech</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">616-624</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Ulcerative colitis is a chronic inflammatory disease of the colon for which current treatments are not universally effective.  One addnl. treatment may be tofacitinib (CP-690,550), an oral inhibitor of Janus kinases 1, 2, and 3 with in vitro functional specificity for kinases 1 and 3 over kinase 2, which is expected to block signaling involving gamma chain-contg. cytokines including interleukins 2, 4, 7, 9, 15, and 21.  These cytokines are integral to lymphocyte activation, function, and proliferation.  Methods: In a double-blind, placebo-controlled, phase 2 trial, we evaluated the efficacy of tofacitinib in 194 adults with moderately to severely active ulcerative colitis.  Patients were randomly assigned to receive tofacitinib at a dose of 0.5 mg, 3 mg, 10 mg, or 15 mg or placebo twice daily for 8 wk.  The primary outcome was a clin. response at 8 wk, defined as an abs. decrease from baseline in the score on the Mayo scoring system for assessment of ulcerative colitis activity (possible score, 0 to 12, with higher scores indicating more severe disease) of 3 or more and a relative decrease from baseline of 30% or more with an accompanying decrease in the rectal bleeding subscore of 1 point or more or an abs. rectal bleeding subscore of 0 or 1.  Results: The primary outcome, clin. response at 8 wk, occurred in 32%, 48%, 61%, and 78% of patients receiving tofacitinib at a dose of 0.5 mg (P = 0.39), 3 mg (P = 0.55), 10 mg (P = 0.10), and 15 mg (P<0.001), resp., as compared with 42% of patients receiving placebo.  Clin. remission (defined as a Mayo score â¤2, with no subscore >1) at 8 wk occurred in 13%, 33%, 48%, and 41% of patients receiving tofacitinib at a dose of 0.5 mg (P = 0.76), 3 mg (P = 0.01), 10 mg (P<0.001), and 15 mg (P<0.001), resp., as compared with 10% of patients receiving placebo.  There was a dose-dependent increase in both low-d. and high-d. lipoprotein cholesterol.  Three patients treated with tofacitinib had an abs. neutrophil count of less than 1500.  Conclusions: Patients with moderately to severely active ulcerative colitis treated with tofacitinib were more likely to have clin. response and remission than those receiving placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ_Al47Ev_6rVg90H21EOLACvtfcHk0liJDqrJDvX9gg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Chu77K&md5=1ae8898c6de9bd24113b1f0a8e7fbed8</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1112168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1112168%26sid%3Dliteratum%253Aachs%26aulast%3DSandborn%26aufirst%3DW.%2BJ.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DPanes%26aufirst%3DJ.%26aulast%3DVranic%26aufirst%3DI.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DRousell%26aufirst%3DS.%26aulast%3DNiezychowski%26aufirst%3DW.%26atitle%3DTofacitinib%252C%2520an%2520oral%2520Janus%2520kinase%2520inhibitor%252C%2520in%2520active%2520ulcerative%2520colitis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26issue%3D7%26spage%3D616%26epage%3D624%26doi%3D10.1056%2FNEJMoa1112168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sandborn, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâHaens, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vermeir, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danese, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faegan, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinisch, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niezychowski, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawendy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodworth, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukherjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healey, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span> </span><span class="NLM_article-title">Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate-to-severe ulcerative colitis: results from 2 phase 3 randomised controlled trials</span> <span class="citation_source-journal">J. Crohn's Colitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">OP019</span><span class="NLM_x">) </span> <span class="NLM_fpage">S15</span><span class="refDoi">Â DOI: 10.1093/ecco-jcc/jjw019.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1093%2Fecco-jcc%2Fjjw019.018" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=S15&issue=OP019&author=W.+J.+Sandbornauthor=G.+D%E2%80%99Haensauthor=S.+Vermeirauthor=S.+Schreiberauthor=S.+Daneseauthor=J.+Panesauthor=B.+G.+Faeganauthor=W.+Reinischauthor=W.+Niezychowskiauthor=G.+Friedmanauthor=N.+Lawendyauthor=D.+Yuauthor=D.+Woodworthauthor=A.+Mukherjeeauthor=P.+Healeyauthor=H.+Zhangauthor=C.+Su&title=Efficacy+and+safety+of+oral+tofacitinib+as+induction+therapy+in+patients+with+moderate-to-severe+ulcerative+colitis%3A+results+from+2+phase+3+randomised+controlled+trials&doi=10.1093%2Fecco-jcc%2Fjjw019.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1093%2Fecco-jcc%2Fjjw019.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fecco-jcc%252Fjjw019.018%26sid%3Dliteratum%253Aachs%26aulast%3DSandborn%26aufirst%3DW.%2BJ.%26aulast%3DD%25E2%2580%2599Haens%26aufirst%3DG.%26aulast%3DVermeir%26aufirst%3DS.%26aulast%3DSchreiber%26aufirst%3DS.%26aulast%3DDanese%26aufirst%3DS.%26aulast%3DPanes%26aufirst%3DJ.%26aulast%3DFaegan%26aufirst%3DB.%2BG.%26aulast%3DReinisch%26aufirst%3DW.%26aulast%3DNiezychowski%26aufirst%3DW.%26aulast%3DFriedman%26aufirst%3DG.%26aulast%3DLawendy%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DWoodworth%26aufirst%3DD.%26aulast%3DMukherjee%26aufirst%3DA.%26aulast%3DHealey%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSu%26aufirst%3DC.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520oral%2520tofacitinib%2520as%2520induction%2520therapy%2520in%2520patients%2520with%2520moderate-to-severe%2520ulcerative%2520colitis%253A%2520results%2520from%25202%2520phase%25203%2520randomised%2520controlled%2520trials%26jtitle%3DJ.%2520Crohn%2527s%2520Colitis%26date%3D2016%26volume%3D10%26issue%3DOP019%26spage%3DS15%26doi%3D10.1093%2Fecco-jcc%2Fjjw019.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">DâHaens, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feagan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moscariello, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healey, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niezychowski, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marren, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maller, E.</span><span> </span><span class="NLM_article-title">Efficacy and safety of oral tofacitinib for maintenance therapy in patients with moderate-to-severe Crohnâs disease: results of a Phase 2b randomised placebo-controlled trial</span> <span class="citation_source-journal">J. Crohns Colitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">OP021</span><span class="NLM_x">) </span> <span class="NLM_fpage">S17</span><span class="refDoi">Â DOI: 10.1093/ecco-jcc/jjw019.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1093%2Fecco-jcc%2Fjjw019.020" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=S17&issue=OP021&author=G.+D%E2%80%99Haensauthor=P.+Higginsauthor=J.+Colombelauthor=B.+Feaganauthor=M.+Moscarielloauthor=G.+Chanauthor=P.+Healeyauthor=W.+Niezychowskiauthor=W.+Wangauthor=A.+Marrenauthor=E.+Maller&title=Efficacy+and+safety+of+oral+tofacitinib+for+maintenance+therapy+in+patients+with+moderate-to-severe+Crohn%E2%80%99s+disease%3A+results+of+a+Phase+2b+randomised+placebo-controlled+trial&doi=10.1093%2Fecco-jcc%2Fjjw019.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1093%2Fecco-jcc%2Fjjw019.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fecco-jcc%252Fjjw019.020%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Haens%26aufirst%3DG.%26aulast%3DHiggins%26aufirst%3DP.%26aulast%3DColombel%26aufirst%3DJ.%26aulast%3DFeagan%26aufirst%3DB.%26aulast%3DMoscariello%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DHealey%26aufirst%3DP.%26aulast%3DNiezychowski%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DMarren%26aufirst%3DA.%26aulast%3DMaller%26aufirst%3DE.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520oral%2520tofacitinib%2520for%2520maintenance%2520therapy%2520in%2520patients%2520with%2520moderate-to-severe%2520Crohn%25E2%2580%2599s%2520disease%253A%2520results%2520of%2520a%2520Phase%25202b%2520randomised%2520placebo-controlled%2520trial%26jtitle%3DJ.%2520Crohns%2520Colitis%26date%3D2016%26volume%3D10%26issue%3DOP021%26spage%3DS17%26doi%3D10.1093%2Fecco-jcc%2Fjjw019.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Panes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bushmakin, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappelleri, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamolo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healey, P.</span><span> </span><span class="NLM_article-title">Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes</span> <span class="citation_source-journal">BMC Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">14</span><span class="refDoi">Â DOI: 10.1186/s12876-015-0239-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1186%2Fs12876-015-0239-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=25651782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtlKmsLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=14&author=J.+Panesauthor=C.+Suauthor=A.+G.+Bushmakinauthor=J.+C.+Cappelleriauthor=C.+Mamoloauthor=P.+Healey&title=Randomized+trial+of+tofacitinib+in+active+ulcerative+colitis%3A+analysis+of+efficacy+based+on+patient-reported+outcomes&doi=10.1186%2Fs12876-015-0239-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes</span></div><div class="casAuthors">Panes, Julian; Su, Chinyu; Bushmakin, Andrew G.; Cappelleri, Joseph C.; Mamolo, Carla; Healey, Paul</div><div class="citationInfo"><span class="NLM_cas:title">BMC Gastroenterology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14</span>CODEN:
                <span class="NLM_cas:coden">BGMABE</span>;
        ISSN:<span class="NLM_cas:issn">1471-230X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Tofacitinib, a novel, oral Janus kinase inhibitor, demonstrated a dose-dependent efficacy for induction of clin. response and remission in patients with active ulcerative colitis (UC).  The objective of the current study was to det. the effect of tofacitinib on patient-reported outcomes (PROs).  Methods: Eligible patients (â¥18 years of age) with a diagnosis of active UC (total Mayo score of 6-12 points and moderately-to-severely active disease on sigmoidoscopy) were randomized in a 2:2:2:3:3 ratio to receive oral tofacitinib 0.5 mg, 3 mg, 10 mg, or 15 mg, or placebo twice daily (BID) for 8 wk.  PROs were assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ) and the Inflammatory Bowel Disease Patient-Reported Treatment Impact (IBD PRTI) survey.  Results: At Week 8, mean IBDQ total scores had improved relative to baseline across all five treatment groups (baseline range 123.2-134.5; Week 8 range 149.6-175.4).  Improvement from baseline was significantly greater (P = 0.001) for tofacitinib 15 mg BID vs. placebo.  For tofacitinib 15 mg BID, most patients reported satisfaction or extreme satisfaction, definite preference for tofacitinib, and definite willingness to use tofacitinib again on the IBD PRTI at week 8.  Patients achieving endoscopic remission (Mayo endoscopy score of 0) had significantly higher IBDQ scores and favorable PRTI scores than those not achieving endoscopic remission.  Conclusions: Short-term treatment with tofacitinib BID was assocd. with dose-dependent improvement in health-related quality of life and patient preferences for tofacitinib.  The results complement previously reported efficacy and safety data for the Phase II study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra9eRYjzZ9yrVg90H21EOLACvtfcHk0liUAvajwz-W5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtlKmsLs%253D&md5=fbcbe109b8c2f64ccfa78e022cee507c</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1186%2Fs12876-015-0239-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12876-015-0239-9%26sid%3Dliteratum%253Aachs%26aulast%3DPanes%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DBushmakin%26aufirst%3DA.%2BG.%26aulast%3DCappelleri%26aufirst%3DJ.%2BC.%26aulast%3DMamolo%26aufirst%3DC.%26aulast%3DHealey%26aufirst%3DP.%26atitle%3DRandomized%2520trial%2520of%2520tofacitinib%2520in%2520active%2520ulcerative%2520colitis%253A%2520analysis%2520of%2520efficacy%2520based%2520on%2520patient-reported%2520outcomes%26jtitle%3DBMC%2520Gastroenterol.%26date%3D2015%26volume%3D15%26spage%3D14%26doi%3D10.1186%2Fs12876-015-0239-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Sandborn, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vranic, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niezychowski, W.</span><span> </span><span class="NLM_article-title">A Phase 2 study of tofacitinib, an oral janus kinase inhibitor, in patients with Crohnâs disease</span> <span class="citation_source-journal">Clin. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1485</span><span class="NLM_x">â</span> <span class="NLM_lpage">1493</span><span class="refDoi">Â DOI: 10.1016/j.cgh.2014.01.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1016%2Fj.cgh.2014.01.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=24480677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvV2ktb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=1485-1493&issue=9&author=W.+J.+Sandbornauthor=S.+Ghoshauthor=J.+Panesauthor=I.+Vranicauthor=W.+Wangauthor=W.+Niezychowski&title=A+Phase+2+study+of+tofacitinib%2C+an+oral+janus+kinase+inhibitor%2C+in+patients+with+Crohn%E2%80%99s+disease&doi=10.1016%2Fj.cgh.2014.01.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn's Disease</span></div><div class="casAuthors">Sandborn, William J.; Ghosh, Subrata; Panes, Julian; Vranic, Ivana; Wang, Wenjin; Niezychowski, Wojciech</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Gastroenterology and Hepatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1485-1493.e2</span>CODEN:
                <span class="NLM_cas:coden">CGHLAW</span>;
        ISSN:<span class="NLM_cas:issn">1542-3565</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Tofacitinib, an orally administered Janus kinase inhibitor, blocks signaling through Î³-chain-contg. cytokines (interleukins 2, 4, 7, 9, 15, and 21).  We performed a phase 2 trial to measure its efficacy in patients with moderate-to-severe active Crohn's disease.Patients (N = 139; age, â¥18 y) with moderate-to-severe active Crohn's disease were assigned randomly to groups given 1 mg (n = 36), 5 mg (n = 34), or 15 mg (n = 35) tofacitinib or placebo (n = 34), twice daily for 4 wk, at 48 centers in 12 countries.  The primary end point was the proportion of clin. responders at week 4 (decrease from baseline in the Crohn's Disease Activity Index score of â¥70 points [Response-70]).  Secondary end points included clin. remission (Crohn's Disease Activity Index score of <150 points) at week 4.A clin. response was obsd. in 36% (P = .467), 58% (P = .466), and 46% (P â¥ .999) of patients given the 1-, 5-, and 15-mg doses of tofacitinib, compared with 47% of patients given placebo.  Clin. remission was obsd. in 31% (P = .417), 24% (P = .776), and 14% (P = .540) of patients given the 1-, 5-, and 15-mg doses of tofacitinib, compared with 21% of patients given placebo.  The 15-mg dose of tofacitinib reduced levels of C-reactive protein and fecal calprotectin from baseline.  Adverse and serious adverse events were similar among groups.  Dose-dependent increases in low- and high-d. lipoprotein cholesterol were obsd. in patients given the 5- or 15-mg doses of tofacitinib.There were no significant differences in the percentage of patients with moderate-to-severe active Crohn's disease who achieved clin. responses (Response-70) or clin. remission after 4 wk' administration of tofacitinib (1, 5, or 15 mg) or placebo twice daily.  However, a large percentage of patients given placebo achieved Response-70 or remission.  Redns. in C-reactive protein and fecal calprotectin levels among patients given the 15-mg dose of tofacitinib indicate its biol. activity.  ClinicalTrials.gov no.: NCT00615199.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqonzbSQIILgLVg90H21EOLACvtfcHk0liUAvajwz-W5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvV2ktb4%253D&md5=f8ea15cbaa9b3d0809f667c7d46ead14</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1016%2Fj.cgh.2014.01.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cgh.2014.01.029%26sid%3Dliteratum%253Aachs%26aulast%3DSandborn%26aufirst%3DW.%2BJ.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DPanes%26aufirst%3DJ.%26aulast%3DVranic%26aufirst%3DI.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DNiezychowski%26aufirst%3DW.%26atitle%3DA%2520Phase%25202%2520study%2520of%2520tofacitinib%252C%2520an%2520oral%2520janus%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520Crohn%25E2%2580%2599s%2520disease%26jtitle%3DClin.%2520Gastroenterol.%2520Hepatol.%26date%3D2014%26volume%3D12%26issue%3D9%26spage%3D1485%26epage%3D1493%26doi%3D10.1016%2Fj.cgh.2014.01.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span>Pfizer press release: Pfizer announces positive top-line results from second phase 3 trial of oral Xeljanz (tofacitinib citrate) in adults with psoriatic arthritis. June 7,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="http://www.pfizer.com" class="extLink">www.pfizer.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pfizer+press+release%3A+Pfizer+announces+positive+top-line+results+from+second+phase+3+trial+of+oral+Xeljanz+%28tofacitinib+citrate%29+in+adults+with+psoriatic+arthritis.+June+7%2C+2016%3B+www.pfizer.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">van der Heijde, D. D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drescher, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleishaker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrikx, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanik, K.</span><span> </span><span class="NLM_article-title">Tofacitinib in patients with ankylosing spondylitis: a phase 2, 16-week, randomized, placebo-controlled, dose-ranging study</span> <span class="citation_source-journal">Arthritis Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">5L</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=5L&author=D.+D.+A.+van+der+Heijdeauthor=J.+C.+Weiauthor=E.+Drescherauthor=D.+Fleishakerauthor=T.+Hendrikxauthor=D.+Liauthor=S.+Menonauthor=K.+Kanik&title=Tofacitinib+in+patients+with+ankylosing+spondylitis%3A+a+phase+2%2C+16-week%2C+randomized%2C+placebo-controlled%2C+dose-ranging+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BHeijde%26aufirst%3DD.%2BD.%2BA.%26aulast%3DWei%26aufirst%3DJ.%2BC.%26aulast%3DDrescher%26aufirst%3DE.%26aulast%3DFleishaker%26aufirst%3DD.%26aulast%3DHendrikx%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DKanik%26aufirst%3DK.%26atitle%3DTofacitinib%2520in%2520patients%2520with%2520ankylosing%2520spondylitis%253A%2520a%2520phase%25202%252C%252016-week%252C%2520randomized%252C%2520placebo-controlled%252C%2520dose-ranging%2520study%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2015%26volume%3D67%26spage%3D5L" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Wollenhaupt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverfield, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nduaka, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benda, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komuro, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riese, R. J.</span><span> </span><span class="NLM_article-title">Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies</span> <span class="citation_source-journal">J. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">837</span><span class="NLM_x">â</span> <span class="NLM_lpage">852</span><span class="refDoi">Â DOI: 10.3899/jrheum.130683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.3899%2Fjrheum.130683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=24692527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyiurbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2014&pages=837-852&issue=5&author=J.+Wollenhauptauthor=J.+Silverfieldauthor=E.+B.+Leeauthor=J.+R.+Curtisauthor=S.+P.+Woodauthor=K.+Somaauthor=C.+I.+Nduakaauthor=B.+Bendaauthor=D.+Grubenauthor=H.+Nakamuraauthor=Y.+Komuroauthor=S.+H.+Zwillichauthor=L.+Wangauthor=R.+J.+Riese&title=Safety+and+efficacy+of+tofacitinib%2C+an+oral+janus+kinase+inhibitor%2C+for+the+treatment+of+rheumatoid+arthritis+in+open-label%2C+longterm+extension+studies&doi=10.3899%2Fjrheum.130683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies</span></div><div class="casAuthors">Wollenhaupt, Juergen; Silverfield, Joel; Lee, Eun Bong; Curtis, Jeffrey R.; Wood, Susan P.; Soma, Koshika; Nduaka, Chudy I.; Benda, Birgitta; Gruben, David; Nakamura, Hiroyuki; Komuro, Yoshihiro; Zwillich, Samuel H.; Wang, Lisy; Riese, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">837-852</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">Objective: To describe the longterm safety and efficacy profile of tofacitinib in patients with moderate to severe active rheumatoid arthritis (RA).  Methods: Data were pooled from 2 open-label studies (NCT00413699, NCT00661661) involving patients who had participated in qualifying phase I, II, or III index studies of tofacitinib.  Safety data included over 60 mo of observation; efficacy data are reported up to Month 48.  Treatment was initiated with tofacitinib 5 or 10 mg twice daily.  Primary endpoints were adverse events (AE) and lab. safety data.  Secondary endpoints included American College of Rheumatol. (ACR) response rates, and Disease Activity Score (28 joints) (DAS28)-4[erythrocyte sedimentation rate (ESR)] and Health Assessment Questionnaire-Disability Index (HAQ-DI) assessments.  Results: Overall, 4102 patients were treated for 5963 patient-years; mean (max.) treatment duration was 531 (1844) days; 20.8% of patients discontinued treatment over 60 mo.  The most common AE were nasopharyngitis (12.7%) and upper respiratory tract infection (10.5%).  Serious AE were reported in 15.4% of patients with an exposure-estd. incidence rate of 11.1 events/100 patient-years.  Serious infections were reported in 4.5% of patients with an exposure-estd. incidence rate of 3.1 events/100 patient-years (95% CI: 2.66-3.55).  Mean values for lab. variables were stable over time and consistent with phase II and III studies.  Persistent efficacy was demonstrated through Month 48, as measured by ACR response rate (ACR20/50/70) DAS28-4-ESR, and HAQ-DI.  Safety and efficacy were similar for patients receiving tofacitinib as monotherapy or with background nonbiol. disease-modifying antirheumatic drugs.  Conclusion: Tofacitinib demonstrated consistent safety and persistent efficacy over 48 mo in patients with RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-Scjk1FOYMrVg90H21EOLACvtfcHk0lhjbNw7CMC8SQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyiurbJ&md5=0c8cf68569627b3948b6c275ec69d8df</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.130683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.130683%26sid%3Dliteratum%253Aachs%26aulast%3DWollenhaupt%26aufirst%3DJ.%26aulast%3DSilverfield%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DCurtis%26aufirst%3DJ.%2BR.%26aulast%3DWood%26aufirst%3DS.%2BP.%26aulast%3DSoma%26aufirst%3DK.%26aulast%3DNduaka%26aufirst%3DC.%2BI.%26aulast%3DBenda%26aufirst%3DB.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DKomuro%26aufirst%3DY.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRiese%26aufirst%3DR.%2BJ.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520tofacitinib%252C%2520an%2520oral%2520janus%2520kinase%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%2520in%2520open-label%252C%2520longterm%2520extension%2520studies%26jtitle%3DJ.%2520Rheumatol.%26date%3D2014%26volume%3D41%26issue%3D5%26spage%3D837%26epage%3D852%26doi%3D10.3899%2Fjrheum.130683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Coe, J. W.; Dehnhardt, C. M.; Jones, P.; Kortum, S. W.; Sabnis, Y. A.; Wakenhut, F. M.; Whitlock, G. A.</span><span> </span><span class="NLM_article-title">Indazoles</span>. WO2013014567 A1,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=J.+W.+Coe&author=C.+M.+Dehnhardt&author=P.+Jones&author=S.+W.+Kortum&author=Y.+A.+Sabnis&author=F.+M.+Wakenhut&author=G.+A.+Whitlock&title=Indazoles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCoe%26aufirst%3DJ.%2BW.%26atitle%3DIndazoles%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><div class="note"><p class="first last">Compound <b>2</b> (catalog no. PZ0324) is available from Sigma Aldrich.</p></div>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Compound+2+%28catalog+no.+PZ0324%29+is+available+from+Sigma+Aldrich.."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Barnes, P. J.</span><span> </span><span class="NLM_article-title">New anti-inflammatory targets for chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">543</span><span class="NLM_x">â</span> <span class="NLM_lpage">59</span><span class="refDoi">Â DOI: 10.1038/nrd4025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1038%2Fnrd4025" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=543-59&issue=7&author=P.+J.+Barnes&title=New+anti-inflammatory+targets+for+chronic+obstructive+pulmonary+disease&doi=10.1038%2Fnrd4025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd4025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4025%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DNew%2520anti-inflammatory%2520targets%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26issue%3D7%26spage%3D543%26epage%3D59%26doi%3D10.1038%2Fnrd4025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jones, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coghlan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Entwistle, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeder, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenyon, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selby, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevethick, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span> </span><span class="NLM_article-title">Inhalation by design: dual pharmacology Î²-2 agonists/M3 antagonists for the treatment of COPD</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">2759</span><span class="NLM_x">â</span> <span class="NLM_lpage">2763</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2010.10.132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1016%2Fj.bmcl.2010.10.132" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2759-2763&issue=9&author=L.+H.+Jonesauthor=H.+Baldockauthor=M.+E.+Bunnageauthor=J.+Burrowsauthor=N.+Clarkeauthor=M.+Coghlanauthor=D.+Entwistleauthor=D.+Fairmanauthor=N.+Feederauthor=C.+Fultonauthor=L.+Hiltonauthor=K.+Jamesauthor=R.+M.+Jonesauthor=A.+S.+Kenyonauthor=S.+Marshallauthor=S.+D.+Newmanauthor=R.+Osborneauthor=S.+Patelauthor=M.+D.+Selbyauthor=E.+F.+Stuartauthor=M.+A.+Trevethickauthor=K.+N.+Wrightauthor=D.+A.+Price&title=Inhalation+by+design%3A+dual+pharmacology+%CE%B2-2+agonists%2FM3+antagonists+for+the+treatment+of+COPD&doi=10.1016%2Fj.bmcl.2010.10.132"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.10.132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.10.132%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DBaldock%26aufirst%3DH.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DClarke%26aufirst%3DN.%26aulast%3DCoghlan%26aufirst%3DM.%26aulast%3DEntwistle%26aufirst%3DD.%26aulast%3DFairman%26aufirst%3DD.%26aulast%3DFeeder%26aufirst%3DN.%26aulast%3DFulton%26aufirst%3DC.%26aulast%3DHilton%26aufirst%3DL.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DR.%2BM.%26aulast%3DKenyon%26aufirst%3DA.%2BS.%26aulast%3DMarshall%26aufirst%3DS.%26aulast%3DNewman%26aufirst%3DS.%2BD.%26aulast%3DOsborne%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DSelby%26aufirst%3DM.%2BD.%26aulast%3DStuart%26aufirst%3DE.%2BF.%26aulast%3DTrevethick%26aufirst%3DM.%2BA.%26aulast%3DWright%26aufirst%3DK.%2BN.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26atitle%3DInhalation%2520by%2520design%253A%2520dual%2520pharmacology%2520%25CE%25B2-2%2520agonists%252FM3%2520antagonists%2520for%2520the%2520treatment%2520of%2520COPD%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26issue%3D9%26spage%3D2759%26epage%3D2763%26doi%3D10.1016%2Fj.bmcl.2010.10.132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hilton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenyon, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coghlan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Entwistle, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeder, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laouar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lunn, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selby, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spence, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Summerhill, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevethick, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeadon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L. H.</span><span> </span><span class="NLM_article-title">Optimized glucuronidation of dual pharmacology Î²-2 agonists/M3 antagonists for the treatment of COPD</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">870</span><span class="NLM_x">â</span> <span class="NLM_lpage">876</span><span class="refDoi">Â DOI: 10.1039/c1md00140j</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1039%2Fc1md00140j" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=870-876&author=L.+Hiltonauthor=R.+Osborneauthor=A.+S.+Kenyonauthor=H.+Baldockauthor=M.+E.+Bunnageauthor=J.+Burrowsauthor=N.+Clarkeauthor=M.+Coghlanauthor=D.+Entwistleauthor=D.+Fairmanauthor=N.+Feederauthor=K.+Jamesauthor=R.+M.+Jonesauthor=N.+Laouarauthor=G.+Lunnauthor=S.+Marshallauthor=S.+D.+Newmanauthor=S.+Patelauthor=M.+D.+Selbyauthor=F.+Spenceauthor=E.+F.+Stuartauthor=S.+Summerhillauthor=M.+A.+Trevethickauthor=K.+N.+Wrightauthor=M.+Yeadonauthor=D.+A.+Priceauthor=L.+H.+Jones&title=Optimized+glucuronidation+of+dual+pharmacology+%CE%B2-2+agonists%2FM3+antagonists+for+the+treatment+of+COPD&doi=10.1039%2Fc1md00140j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1039%2Fc1md00140j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1md00140j%26sid%3Dliteratum%253Aachs%26aulast%3DHilton%26aufirst%3DL.%26aulast%3DOsborne%26aufirst%3DR.%26aulast%3DKenyon%26aufirst%3DA.%2BS.%26aulast%3DBaldock%26aufirst%3DH.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DClarke%26aufirst%3DN.%26aulast%3DCoghlan%26aufirst%3DM.%26aulast%3DEntwistle%26aufirst%3DD.%26aulast%3DFairman%26aufirst%3DD.%26aulast%3DFeeder%26aufirst%3DN.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DR.%2BM.%26aulast%3DLaouar%26aufirst%3DN.%26aulast%3DLunn%26aufirst%3DG.%26aulast%3DMarshall%26aufirst%3DS.%26aulast%3DNewman%26aufirst%3DS.%2BD.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DSelby%26aufirst%3DM.%2BD.%26aulast%3DSpence%26aufirst%3DF.%26aulast%3DStuart%26aufirst%3DE.%2BF.%26aulast%3DSummerhill%26aufirst%3DS.%26aulast%3DTrevethick%26aufirst%3DM.%2BA.%26aulast%3DWright%26aufirst%3DK.%2BN.%26aulast%3DYeadon%26aufirst%3DM.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DJones%26aufirst%3DL.%2BH.%26atitle%3DOptimized%2520glucuronidation%2520of%2520dual%2520pharmacology%2520%25CE%25B2-2%2520agonists%252FM3%2520antagonists%2520for%2520the%2520treatment%2520of%2520COPD%26jtitle%3DMedChemComm%26date%3D2011%26volume%3D2%26spage%3D870%26epage%3D876%26doi%3D10.1039%2Fc1md00140j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Glossop, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C. A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewthwaite, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeadon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perros-Huguet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevethick, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeder, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spence, F. J.</span><span> </span><span class="NLM_article-title">Inhalation by design: novel ultra-long-acting Î²2-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">6640</span><span class="NLM_x">â</span> <span class="NLM_lpage">6652</span><span class="refDoi">Â DOI: 10.1021/jm1005989</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1005989" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6640-6652&issue=18&author=P.+A.+Glossopauthor=C.+A.+L.+Laneauthor=D.+A.+Priceauthor=M.+E.+Bunnageauthor=R.+A.+Lewthwaiteauthor=K.+Jamesauthor=A.+D.+Brownauthor=M.+Yeadonauthor=C.+Perros-Huguetauthor=M.+A.+Trevethickauthor=N.+P.+Clarkeauthor=R.+Websterauthor=R.+M.+Jonesauthor=J.+L.+Burrowsauthor=N.+Feederauthor=S.+C.+J.+Taylorauthor=F.+J.+Spence&title=Inhalation+by+design%3A+novel+ultra-long-acting+%CE%B22-adrenoreceptor+agonists+for+inhaled+once-daily+treatment+of+asthma+and+chronic+obstructive+pulmonary+disease+that+utilize+a+sulfonamide+agonist+headgroup&doi=10.1021%2Fjm1005989"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1021%2Fjm1005989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1005989%26sid%3Dliteratum%253Aachs%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DLane%26aufirst%3DC.%2BA.%2BL.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DA.%2BD.%26aulast%3DYeadon%26aufirst%3DM.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DTrevethick%26aufirst%3DM.%2BA.%26aulast%3DClarke%26aufirst%3DN.%2BP.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DR.%2BM.%26aulast%3DBurrows%26aufirst%3DJ.%2BL.%26aulast%3DFeeder%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DS.%2BC.%2BJ.%26aulast%3DSpence%26aufirst%3DF.%2BJ.%26atitle%3DInhalation%2520by%2520design%253A%2520novel%2520ultra-long-acting%2520%25CE%25B22-adrenoreceptor%2520agonists%2520for%2520inhaled%2520once-daily%2520treatment%2520of%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%2520that%2520utilize%2520a%2520sulfonamide%2520agonist%2520headgroup%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D18%26spage%3D6640%26epage%3D6652%26doi%3D10.1021%2Fjm1005989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Millan, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodd, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairman, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilty, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaitre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewthwaite, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahnke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathias, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philip, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefaniak, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeadon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, C.</span><span> </span><span class="NLM_article-title">Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">7797</span><span class="NLM_x">â</span> <span class="NLM_lpage">7814</span><span class="refDoi">Â DOI: 10.1021/jm200677b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200677b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7797-7814&issue=22&author=D.+S.+Millanauthor=M.+E.+Bunnageauthor=J.+L.+Burrowsauthor=K.+J.+Butcherauthor=P.+G.+Doddauthor=T.+J.+Evansauthor=D.+A.+Fairmanauthor=S.+J.+Hughesauthor=I.+C.+Kiltyauthor=A.+Lemaitreauthor=R.+A.+Lewthwaiteauthor=A.+Mahnkeauthor=J.+P.+Mathiasauthor=J.+Philipauthor=R.+T.+Smithauthor=M.+H.+Stefaniakauthor=M.+Yeadonauthor=C.+Phillips&title=Design+and+synthesis+of+inhaled+p38+inhibitors+for+the+treatment+of+chronic+obstructive+pulmonary+disease&doi=10.1021%2Fjm200677b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=10.1021%2Fjm200677b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200677b%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DD.%2BS.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DBurrows%26aufirst%3DJ.%2BL.%26aulast%3DButcher%26aufirst%3DK.%2BJ.%26aulast%3DDodd%26aufirst%3DP.%2BG.%26aulast%3DEvans%26aufirst%3DT.%2BJ.%26aulast%3DFairman%26aufirst%3DD.%2BA.%26aulast%3DHughes%26aufirst%3DS.%2BJ.%26aulast%3DKilty%26aufirst%3DI.%2BC.%26aulast%3DLemaitre%26aufirst%3DA.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DMahnke%26aufirst%3DA.%26aulast%3DMathias%26aufirst%3DJ.%2BP.%26aulast%3DPhilip%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DR.%2BT.%26aulast%3DStefaniak%26aufirst%3DM.%2BH.%26aulast%3DYeadon%26aufirst%3DM.%26aulast%3DPhillips%26aufirst%3DC.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520inhaled%2520p38%2520inhibitors%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D22%26spage%3D7797%26epage%3D7814%26doi%3D10.1021%2Fjm200677b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="note"><p class="first last">Compound <b>3</b> (catalog no. PZ0151) is available from Sigma Aldrich.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Pan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karns, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herr, A. E.</span><span> </span><span class="NLM_article-title">Microfluidic electrophoretic mobility shift assays for quantitative biochemical analysis</span> <span class="citation_source-journal">Electrophoresis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">2078</span><span class="NLM_x">â</span> <span class="NLM_lpage">2090</span><span class="refDoi">Â DOI: 10.1002/elps.201300500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1002%2Felps.201300500" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=2078-2090&issue=15&author=Y.+Panauthor=K.+Karnsauthor=A.+E.+Herr&title=Microfluidic+electrophoretic+mobility+shift+assays+for+quantitative+biochemical+analysis&doi=10.1002%2Felps.201300500"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Felps.201300500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Felps.201300500%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DY.%26aulast%3DKarns%26aufirst%3DK.%26aulast%3DHerr%26aufirst%3DA.%2BE.%26atitle%3DMicrofluidic%2520electrophoretic%2520mobility%2520shift%2520assays%2520for%2520quantitative%2520biochemical%2520analysis%26jtitle%3DElectrophoresis%26date%3D2014%26volume%3D35%26issue%3D15%26spage%3D2078%26epage%3D2090%26doi%3D10.1002%2Felps.201300500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery?</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">1230</span><span class="NLM_x">â</span> <span class="NLM_lpage">1241</span><span class="refDoi">Â DOI: 10.1021/cb500129t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500129t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1230-1241&issue=6&author=Z.+Zhaoauthor=H.+Wuauthor=L.+Wangauthor=Y.+Liuauthor=S.+Knappauthor=Q.+Liuauthor=N.+S.+Gray&title=Exploration+of+type+II+binding+mode%3A+a+privileged+approach+for+kinase+inhibitor+focused+drug+discovery%3F&doi=10.1021%2Fcb500129t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span></div><div class="casAuthors">Zhao, Zheng; Wu, Hong; Wang, Li; Liu, Yi; Knapp, Stefan; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1230-1241</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ATP site of kinases displays remarkable conformational flexibility when accommodating chem. diverse small mol. inhibitors.  The so-called activation segment, whose conformation controls catalytic activity and access to the substrate binding pocket, can undergo a large conformational change with the active state assuming a 'DFG-in' and an inactive state assuming a 'DFG-out' conformation.  Compds. that preferentially bind to the DFG-out conformation are typically called 'type II' inhibitors in contrast to 'type I' inhibitors that bind to the DFG-in conformation.  This review surveys the large no. of type II inhibitors that have been developed and provides an anal. of their crystallog. detd. binding modes.  Using a small library of type II inhibitors, we demonstrate that more than 200 kinases can be targeted, suggesting that type II inhibitors may not be intrinsically more selective than type I inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4jYt6Db3Ap7Vg90H21EOLACvtfcHk0lhPHf0r9sq8xw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D&md5=95bf185ff7f973eda5a65f4096bfaa82</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fcb500129t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500129t%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DExploration%2520of%2520type%2520II%2520binding%2520mode%253A%2520a%2520privileged%2520approach%2520for%2520kinase%2520inhibitor%2520focused%2520drug%2520discovery%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26issue%3D6%26spage%3D1230%26epage%3D1241%26doi%3D10.1021%2Fcb500129t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Berman, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henrick, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, H.</span><span> </span><span class="NLM_article-title">Announcing the worldwide Protein Data Bank</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">980</span><span class="refDoi">Â DOI: 10.1038/nsb1203-980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1038%2Fnsb1203-980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=14634627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFOmsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2003&pages=980&author=H.+M.+Bermanauthor=K.+Henrickauthor=H.+Nakamura&title=Announcing+the+worldwide+Protein+Data+Bank&doi=10.1038%2Fnsb1203-980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Announcing the worldwide Protein Data Bank</span></div><div class="casAuthors">Berman, Helen; Henrick, Kim; Nakamura, Haruki</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">980</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplInmv2AD6cbVg90H21EOLACvtfcHk0ljVFeoFMk2eWw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFOmsbY%253D&md5=8146ff5fc67f64e31b2f8c475473879c</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1038%2Fnsb1203-980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb1203-980%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DH.%2BM.%26aulast%3DHenrick%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DH.%26atitle%3DAnnouncing%2520the%2520worldwide%2520Protein%2520Data%2520Bank%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2003%26volume%3D10%26spage%3D980%26doi%3D10.1038%2Fnsb1203-980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rose, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prlic, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bluhm, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodsell, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westbrook, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zardecki, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berman, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourne, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burley, S. K.</span><span> </span><span class="NLM_article-title">The RCSB Protein Data Bank: views of structural biology for basic and applied research and education</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">D345</span><span class="NLM_x">â</span> <span class="NLM_lpage">D356</span><span class="refDoi">Â DOI: 10.1093/nar/gku1214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1093%2Fnar%2Fgku1214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=25428375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtV2itr%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=D345-D356&author=P.+W.+Roseauthor=A.+Prlicauthor=C.+Biauthor=W.+F.+Bluhmauthor=C.+H.+Christieauthor=S.+Duttaauthor=R.+K.+Greenauthor=D.+S.+Goodsellauthor=J.+D.+Westbrookauthor=J.+Wooauthor=J.+Youngauthor=C.+Zardeckiauthor=H.+M.+Bermanauthor=P.+E.+Bourneauthor=S.+K.+Burley&title=The+RCSB+Protein+Data+Bank%3A+views+of+structural+biology+for+basic+and+applied+research+and+education&doi=10.1093%2Fnar%2Fgku1214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">The RCSB protein data bank: views of structural biology for basic and applied research and education</span></div><div class="casAuthors">Rose, Peter W.; Prlic, Andreas; Bi, Chunxiao; Bluhm, Wolfgang F.; Christie, Cole H.; Dutta, Shuchismita; Green, Rachel Kramer; Goodsell, David S.; Westbrook, John D.; Woo, Jesse; Young, Jasmine; Zardecki, Christine; Berman, Helen M.; Bourne, Philip E.; Burley, Stephen K.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D345-D356</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  The RCSB Protein Data Bank provides access to 3D structures of biol. macromols. and is one of the leading resources in biol. and biomedicine worldwide.  Our efforts over the past 2 years focused on enabling a deeper understanding of structural biol. and providing new structural views of biol. that support both basic and applied research and education.  Herein, we describe recently introduced data annotations including integration with external biol. resources, such as gene and drug databases, new visualization tools and improved support for the mobile web.  We also describe access to data files, web services and open access software components to enable software developers to more effectively mine the PDB archive and related annotations.  Our efforts are aimed at expanding the role of 3D structure in understanding biol. and medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-p1ymUjOOkrVg90H21EOLACvtfcHk0ljVFeoFMk2eWw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtV2itr%252FO&md5=fe95bef159c997e2195a9ae469d9ae4b</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgku1214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgku1214%26sid%3Dliteratum%253Aachs%26aulast%3DRose%26aufirst%3DP.%2BW.%26aulast%3DPrlic%26aufirst%3DA.%26aulast%3DBi%26aufirst%3DC.%26aulast%3DBluhm%26aufirst%3DW.%2BF.%26aulast%3DChristie%26aufirst%3DC.%2BH.%26aulast%3DDutta%26aufirst%3DS.%26aulast%3DGreen%26aufirst%3DR.%2BK.%26aulast%3DGoodsell%26aufirst%3DD.%2BS.%26aulast%3DWestbrook%26aufirst%3DJ.%2BD.%26aulast%3DWoo%26aufirst%3DJ.%26aulast%3DYoung%26aufirst%3DJ.%26aulast%3DZardecki%26aufirst%3DC.%26aulast%3DBerman%26aufirst%3DH.%2BM.%26aulast%3DBourne%26aufirst%3DP.%2BE.%26aulast%3DBurley%26aufirst%3DS.%2BK.%26atitle%3DThe%2520RCSB%2520Protein%2520Data%2520Bank%253A%2520views%2520of%2520structural%2520biology%2520for%2520basic%2520and%2520applied%2520research%2520and%2520education%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2015%26volume%3D43%26spage%3DD345%26epage%3DD356%26doi%3D10.1093%2Fnar%2Fgku1214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Kania, R. S.; Bender, S. L.; Borchardt, A. J.; Braganza, J. F.; Cripps, S. J.; Hua, Y.; Johnson, M. D.; Johnson, T. O.,  Jr.; Luu, H. T.; Palmer, C. L.; Reich, S. H.; Tempczyk-russell, A. M.; Teng, M.; Thomas, C.; Varney, M. D.; Wallace, M. B.</span><span> </span><span class="NLM_article-title">Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use</span>. WO2001002369,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=R.+S.+Kania&author=S.+L.+Bender&author=A.+J.+Borchardt&author=J.+F.+Braganza&author=S.+J.+Cripps&author=Y.+Hua&author=M.+D.+Johnson&author=T.+O.+Johnson&author=H.+T.+Luu&author=C.+L.+Palmer&author=S.+H.+Reich&author=A.+M.+Tempczyk-russell&author=M.+Teng&author=C.+Thomas&author=M.+D.+Varney&author=M.+B.+Wallace&title=Indazole+compounds+and+pharmaceutical+compositions+for+inhibiting+protein+kinases%2C+and+methods+for+their+use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKania%26aufirst%3DR.%2BS.%26atitle%3DIndazole%2520compounds%2520and%2520pharmaceutical%2520compositions%2520for%2520inhibiting%2520protein%2520kinases%252C%2520and%2520methods%2520for%2520their%2520use%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Zuccotto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angiolini, M.</span><span> </span><span class="NLM_article-title">Through the "gatekeeper door": exploiting the active kinase conformation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">2681</span><span class="NLM_x">â</span> <span class="NLM_lpage">2694</span><span class="refDoi">Â DOI: 10.1021/jm901443h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901443h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2681-2694&issue=7&author=F.+Zuccottoauthor=E.+Ardiniauthor=E.+Casaleauthor=M.+Angiolini&title=Through+the+%22gatekeeper+door%22%3A+exploiting+the+active+kinase+conformation&doi=10.1021%2Fjm901443h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm901443h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901443h%26sid%3Dliteratum%253Aachs%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DAngiolini%26aufirst%3DM.%26atitle%3DThrough%2520the%2520%2522gatekeeper%2520door%2522%253A%2520exploiting%2520the%2520active%2520kinase%2520conformation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D7%26spage%3D2681%26epage%3D2694%26doi%3D10.1021%2Fjm901443h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Thorarensen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banker, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fensome, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telliez, J.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juba, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czerwinski, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casimiro-Garcia, A.</span><span> </span><span class="NLM_article-title">ATP-mediated kinome selectivity: the missing link in understanding the contribution of individual JAK kinase isoforms to cellular signaling</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1552</span><span class="NLM_x">â</span> <span class="NLM_lpage">1558</span><span class="refDoi">Â DOI: 10.1021/cb5002125</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5002125" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1552-1558&issue=7&author=A.+Thorarensenauthor=M.+E.+Bankerauthor=A.+Fensomeauthor=J.-B.+Telliezauthor=B.+Jubaauthor=F.+Vincentauthor=R.+M.+Czerwinskiauthor=A.+Casimiro-Garcia&title=ATP-mediated+kinome+selectivity%3A+the+missing+link+in+understanding+the+contribution+of+individual+JAK+kinase+isoforms+to+cellular+signaling&doi=10.1021%2Fcb5002125"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fcb5002125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5002125%26sid%3Dliteratum%253Aachs%26aulast%3DThorarensen%26aufirst%3DA.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DJuba%26aufirst%3DB.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26atitle%3DATP-mediated%2520kinome%2520selectivity%253A%2520the%2520missing%2520link%2520in%2520understanding%2520the%2520contribution%2520of%2520individual%2520JAK%2520kinase%2520isoforms%2520to%2520cellular%2520signaling%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26issue%3D7%26spage%3D1552%26epage%3D1558%26doi%3D10.1021%2Fcb5002125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Ritchie, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, S. J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickett, S. D.</span><span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">3/4</span><span class="NLM_x">) </span> <span class="NLM_fpage">164</span><span class="NLM_x">â</span> <span class="NLM_lpage">171</span><span class="refDoi">Â DOI: 10.1016/j.drudis.2010.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1016%2Fj.drudis.2010.11.014" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=164-171&issue=3%2F4&author=T.+J.+Ritchieauthor=S.+J.+F.+MacDonaldauthor=R.+J.+Youngauthor=S.+D.+Pickett&title=The+impact+of+aromatic+ring+count+on+compound+developability%3A+further+insights+by+examining+carbo-+and+hetero-aromatic+and+-aliphatic+ring+types&doi=10.1016%2Fj.drudis.2010.11.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacDonald%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%253A%2520further%2520insights%2520by%2520examining%2520carbo-%2520and%2520hetero-aromatic%2520and%2520-aliphatic%2520ring%2520types%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26issue%3D3%252F4%26spage%3D164%26epage%3D171%26doi%3D10.1016%2Fj.drudis.2010.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Walker, M. A.</span><span> </span><span class="NLM_article-title">Novel tactics for designing water-soluble molecules in drug discovery</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1421</span><span class="NLM_x">â</span> <span class="NLM_lpage">1433</span><span class="refDoi">Â DOI: 10.1517/17460441.2014.960839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1517%2F17460441.2014.960839" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1421-1433&issue=12&author=M.+A.+Walker&title=Novel+tactics+for+designing+water-soluble+molecules+in+drug+discovery&doi=10.1517%2F17460441.2014.960839"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1517%2F17460441.2014.960839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2014.960839%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DM.%2BA.%26atitle%3DNovel%2520tactics%2520for%2520designing%2520water-soluble%2520molecules%2520in%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2014%26volume%3D9%26issue%3D12%26spage%3D1421%26epage%3D1433%26doi%3D10.1517%2F17460441.2014.960839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Lovering, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bikker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humblet, C.</span><span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">6752</span><span class="NLM_x">â</span> <span class="NLM_lpage">6756</span><span class="refDoi">Â DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&issue=21&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0lgaxCUeiGEfDw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D21%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Patton, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byron, P. R.</span><span> </span><span class="NLM_article-title">Inhaling medicines: delivering drugs to the body through the lungs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">67</span><span class="NLM_x">â</span> <span class="NLM_lpage">74</span><span class="refDoi">Â DOI: 10.1038/nrd2153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1038%2Fnrd2153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=17195033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlGktbbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=67-74&issue=1&author=J.+S.+Pattonauthor=P.+R.+Byron&title=Inhaling+medicines%3A+delivering+drugs+to+the+body+through+the+lungs&doi=10.1038%2Fnrd2153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Inhaling medicines: delivering drugs to the body through the lungs</span></div><div class="casAuthors">Patton, John S.; Byron, Peter R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-74</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Remarkably, with the exception of anesthetic gases, the ancient human practice of inhaling substances into the lungs for systemic effect has only just begun to be adopted by modern medicine.  Treatment of asthma by inhaled drugs began in earnest in the 1950s, and now such 'topical' or targeted treatment with inhaled drugs is considered for treating many other lung diseases.  More recently, major advances have led to increasing interest in systemic delivery of drugs by inhalation.  Small mols. can be delivered with very rapid action, low metab. and high bioavailability; and macromols. can be delivered without injections, as highlighted by the recent approval of the first inhaled insulin product.  Here, we review these advances, and discuss aspects of lung physiol. and formulation compn. that influence the systemic delivery of inhaled therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT_qTU0rDV17Vg90H21EOLACvtfcHk0lgaxCUeiGEfDw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlGktbbL&md5=81a851de5e01f016f0978cd64fbee624</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnrd2153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2153%26sid%3Dliteratum%253Aachs%26aulast%3DPatton%26aufirst%3DJ.%2BS.%26aulast%3DByron%26aufirst%3DP.%2BR.%26atitle%3DInhaling%2520medicines%253A%2520delivering%2520drugs%2520to%2520the%2520body%2520through%2520the%2520lungs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26issue%3D1%26spage%3D67%26epage%3D74%26doi%3D10.1038%2Fnrd2153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Hsu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, A. W.</span><span> </span><span class="NLM_article-title">JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis</span> <span class="citation_source-journal">J. Immunol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">2014</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">7</span><span class="refDoi">Â DOI: 10.1155/2014/283617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1155%2F2014%2F283617" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=1-7&author=L.+Hsuauthor=A.+W.+Armstrong&title=JAK+inhibitors%3A+treatment+efficacy+and+safety+profile+in+patients+with+psoriasis&doi=10.1155%2F2014%2F283617"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1155%2F2014%2F283617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2014%252F283617%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DL.%26aulast%3DArmstrong%26aufirst%3DA.%2BW.%26atitle%3DJAK%2520inhibitors%253A%2520treatment%2520efficacy%2520and%2520safety%2520profile%2520in%2520patients%2520with%2520psoriasis%26jtitle%3DJ.%2520Immunol.%2520Res.%26date%3D2014%26volume%3D2014%26spage%3D1%26epage%3D7%26doi%3D10.1155%2F2014%2F283617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Patricelli, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szardenings, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liyanage, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomanbhoy, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aban, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozarich, J. W.</span><span> </span><span class="NLM_article-title">Functional interrogation of the kinome using nucleotide acyl phosphates</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">350</span><span class="NLM_x">â</span> <span class="NLM_lpage">358</span><span class="refDoi">Â DOI: 10.1021/bi062142x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi062142x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtlaru7rO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=350-358&issue=2&author=M.+P.+Patricelliauthor=A.+K.+Szardeningsauthor=M.+Liyanageauthor=T.+K.+Nomanbhoyauthor=M.+Wuauthor=H.+Weissigauthor=A.+Abanauthor=D.+Chunauthor=S.+Tannerauthor=J.+W.+Kozarich&title=Functional+interrogation+of+the+kinome+using+nucleotide+acyl+phosphates&doi=10.1021%2Fbi062142x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Functional Interrogation of the Kinome Using Nucleotide Acyl Phosphates</span></div><div class="casAuthors">Patricelli, Matthew P.; Szardenings, A. Katrin; Liyanage, Marek; Nomanbhoy, Tyzoon K.; Wu, Min; Weissig, Helge; Aban, Arwin; Chun, Doris; Tanner, Stephen; Kozarich, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">350-358</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The central role of protein kinases in signal transduction pathways has generated intense interest in targeting these enzymes for a wide range of therapeutic indications.  Here we report a method for identifying and quantifying protein kinases in any biol. sample or tissue from any species.  The procedure relies on acyl phosphate-contg. nucleotides, prepd. from a biotin deriv. and ATP or ADP.  The acyl phosphate probes react selectively and covalently at the ATP binding sites of at least 75% of the known human protein kinases.  Biotinylated peptide fragments from labeled proteomes are captured and then sequenced and identified using a mass spectrometry-based anal. platform to det. the kinases present and their relative levels.  Further, direct competition between the probes and inhibitors can be assessed to det. inhibitor potency and selectivity against native protein kinases, as well as hundreds of other ATPases.  The ability to broadly profile kinase activities in native proteomes offers an exciting prospect for both target discovery and inhibitor selectivity profiling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiUQQGW0LLn7Vg90H21EOLACvtfcHk0liacKK9LG7fLA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtlaru7rO&md5=a912b834ff5456f09f1c45ddceb15dca</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fbi062142x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi062142x%26sid%3Dliteratum%253Aachs%26aulast%3DPatricelli%26aufirst%3DM.%2BP.%26aulast%3DSzardenings%26aufirst%3DA.%2BK.%26aulast%3DLiyanage%26aufirst%3DM.%26aulast%3DNomanbhoy%26aufirst%3DT.%2BK.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DWeissig%26aufirst%3DH.%26aulast%3DAban%26aufirst%3DA.%26aulast%3DChun%26aufirst%3DD.%26aulast%3DTanner%26aufirst%3DS.%26aulast%3DKozarich%26aufirst%3DJ.%2BW.%26atitle%3DFunctional%2520interrogation%2520of%2520the%2520kinome%2520using%2520nucleotide%2520acyl%2520phosphates%26jtitle%3DBiochemistry%26date%3D2007%26volume%3D46%26issue%3D2%26spage%3D350%26epage%3D358%26doi%3D10.1021%2Fbi062142x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Siewert, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller-Esterl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starr, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaper, F.</span><span> </span><span class="NLM_article-title">Different protein turnover of interleukin-6-type cytokine signalling components</span> <span class="citation_source-journal">Eur. J. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">265</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">251</span><span class="NLM_x">â</span> <span class="NLM_lpage">257</span><span class="refDoi">Â DOI: 10.1046/j.1432-1327.1999.00719.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1046%2Fj.1432-1327.1999.00719.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10491180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADyaK1MXmsFKks7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=1999&pages=251-257&issue=1&author=E.+Siewertauthor=W.+Muller-Esterlauthor=R.+Starrauthor=P.+C.+Heinrichauthor=F.+Schaper&title=Different+protein+turnover+of+interleukin-6-type+cytokine+signalling+components&doi=10.1046%2Fj.1432-1327.1999.00719.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Different protein turnover of interleukin-6-type cytokine signalling components</span></div><div class="casAuthors">Siewert, Elmar; Muller-Esterl, Werner; Starr, Robin; Heinrich, Peter C.; Schaper, Fred</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">265</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">251-257</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Interleukin (IL)-6 and IL-6-type cytokines signal through the gp130/Jak/STAT signal transduction pathway.  The key components involved are the signal transducing receptor subunit gp130, the Janus kinases Jak1, Jak2 and Tyk2, STAT1 and STAT3 of the family of signal transducers and activators of transcription, the protein tyrosine phosphatase SHP2 and the suppressors of cytokine signalling SOCS1, SOCS2 and SOCS3.  Whereas considerable information has been accumulated concerning the time-course of activation for the individual signalling mols., data on the availability of the proteins involved in IL-6-type cytokine signal transduction are scarce.  Nevertheless, availability of these mols., detd. by the balance of protein synthesis and degrdn., also influences IL-6-type cytokine signal transduction.  Here, we present a comprehensive set of data on the half-lives of the key mols. involved in the IL-6 signal transduction pathway.  The turnover rates for the various proteins differ substantially.  Three groups of signalling proteins can be discriminated: whereas the feedback inhibitors SOCS1, SOCS2 and SOCS3 are very short-lived, STAT1, STAT3 and SHP2 have an extremely slow turnover rate.  Interestingly, the half-life of STAT3Î², a splice variant of STAT3Î±, is reduced to almost 50% of the half-life of STAT3Î±.  The Janus kinases Jak1, Jak2, Tyk2 and gp130 show intermediate half-lives.  The data imply that signalling components activated by post-translational modifications are long-lived whereas the activity of very short-lived proteins is regulated mainly at the transcriptional level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrykEOWrPY1qrVg90H21EOLACvtfcHk0lhZFbb9yPHLsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsFKks7g%253D&md5=9a92232aa03148d1a70e5a9c2cd89733</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1046%2Fj.1432-1327.1999.00719.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1432-1327.1999.00719.x%26sid%3Dliteratum%253Aachs%26aulast%3DSiewert%26aufirst%3DE.%26aulast%3DMuller-Esterl%26aufirst%3DW.%26aulast%3DStarr%26aufirst%3DR.%26aulast%3DHeinrich%26aufirst%3DP.%2BC.%26aulast%3DSchaper%26aufirst%3DF.%26atitle%3DDifferent%2520protein%2520turnover%2520of%2520interleukin-6-type%2520cytokine%2520signalling%2520components%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1999%26volume%3D265%26issue%3D1%26spage%3D251%26epage%3D257%26doi%3D10.1046%2Fj.1432-1327.1999.00719.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Diez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voldoire, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubiralta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segarra, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pages, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palacios, J. M.</span><span> </span><span class="NLM_article-title">Synthetic applications of 2-aryl-4-piperidones. X. Synthesis of 3-aminopiperidines, potential substances P antagonists</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">5143</span><span class="NLM_x">â</span> <span class="NLM_lpage">56</span><span class="refDoi">Â DOI: 10.1016/0040-4020(95)98710-Y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1016%2F0040-4020%2895%2998710-Y" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1995&pages=5143-56&issue=17&author=A.+Diezauthor=A.+Voldoireauthor=I.+Lopezauthor=M.+Rubiraltaauthor=V.+Segarraauthor=L.+Pagesauthor=J.+M.+Palacios&title=Synthetic+applications+of+2-aryl-4-piperidones.+X.+Synthesis+of+3-aminopiperidines%2C+potential+substances+P+antagonists&doi=10.1016%2F0040-4020%2895%2998710-Y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2F0040-4020%2895%2998710-Y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4020%252895%252998710-Y%26sid%3Dliteratum%253Aachs%26aulast%3DDiez%26aufirst%3DA.%26aulast%3DVoldoire%26aufirst%3DA.%26aulast%3DLopez%26aufirst%3DI.%26aulast%3DRubiralta%26aufirst%3DM.%26aulast%3DSegarra%26aufirst%3DV.%26aulast%3DPages%26aufirst%3DL.%26aulast%3DPalacios%26aufirst%3DJ.%2BM.%26atitle%3DSynthetic%2520applications%2520of%25202-aryl-4-piperidones.%2520X.%2520Synthesis%2520of%25203-aminopiperidines%252C%2520potential%2520substances%2520P%2520antagonists%26jtitle%3DTetrahedron%26date%3D1995%26volume%3D51%26issue%3D17%26spage%3D5143%26epage%3D56%26doi%3D10.1016%2F0040-4020%2895%2998710-Y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Flohr, A.; Jakob-Roetne, R.; Norcross, R. D.; Riemer, C.</span><span> </span><span class="NLM_article-title">Imidazolyl benzothiazoles as adenosine receptor ligands, processes for their preparations, pharmaceutical formulations and uses thereof</span>. US20040229862,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=A.+Flohr&author=R.+Jakob-Roetne&author=R.+D.+Norcross&author=C.+Riemer&title=Imidazolyl+benzothiazoles+as+adenosine+receptor+ligands%2C+processes+for+their+preparations%2C+pharmaceutical+formulations+and+uses+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFlohr%26aufirst%3DA.%26atitle%3DImidazolyl%2520benzothiazoles%2520as%2520adenosine%2520receptor%2520ligands%252C%2520processes%2520for%2520their%2520preparations%252C%2520pharmaceutical%2520formulations%2520and%2520uses%2520thereof%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Ramis, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calama, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domenech, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carreno, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calaf, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordoba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alberti, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Alba, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bach, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prats, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miralpeix, M.</span><span> </span><span class="NLM_article-title">New inhaled JAK inhibitor LAS194046 inhibits allergen-induced airway inflammation in Brown Norway rats</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 58</span><span class="NLM_x">) </span> <span class="NLM_fpage">1508</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2014&pages=1508&issue=Suppl.+58&author=I.+Ramisauthor=E.+Calamaauthor=A.+Domenechauthor=C.+Carrenoauthor=E.+Calafauthor=M.+Cordobaauthor=J.+Albertiauthor=J.+De+Albaauthor=J.+Bachauthor=N.+Pratsauthor=M.+Miralpeix&title=New+inhaled+JAK+inhibitor+LAS194046+inhibits+allergen-induced+airway+inflammation+in+Brown+Norway+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRamis%26aufirst%3DI.%26aulast%3DCalama%26aufirst%3DE.%26aulast%3DDomenech%26aufirst%3DA.%26aulast%3DCarreno%26aufirst%3DC.%26aulast%3DCalaf%26aufirst%3DE.%26aulast%3DCordoba%26aufirst%3DM.%26aulast%3DAlberti%26aufirst%3DJ.%26aulast%3DDe%2BAlba%26aufirst%3DJ.%26aulast%3DBach%26aufirst%3DJ.%26aulast%3DPrats%26aufirst%3DN.%26aulast%3DMiralpeix%26aufirst%3DM.%26atitle%3DNew%2520inhaled%2520JAK%2520inhibitor%2520LAS194046%2520inhibits%2520allergen-induced%2520airway%2520inflammation%2520in%2520Brown%2520Norway%2520rats%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2014%26volume%3D44%26issue%3DSuppl.%252058%26spage%3D1508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Ritzen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soerensen, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dack, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greve, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jerre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnerup, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rytved, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagger-Bahnsen, J.</span><span> </span><span class="NLM_article-title">Fragment-based discovery of 6-arylindazole JAK inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">641</span><span class="NLM_x">â</span> <span class="NLM_lpage">646</span><span class="refDoi">Â DOI: 10.1021/acsmedchemlett.6b00087</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00087" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=641-646&issue=6&author=A.+Ritzenauthor=M.+D.+Soerensenauthor=K.+N.+Dackauthor=D.+R.+Greveauthor=A.+Jerreauthor=M.+A.+Carnerupauthor=K.+A.+Rytvedauthor=J.+Bagger-Bahnsen&title=Fragment-based+discovery+of+6-arylindazole+JAK+inhibitors&doi=10.1021%2Facsmedchemlett.6b00087"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00087%26sid%3Dliteratum%253Aachs%26aulast%3DRitzen%26aufirst%3DA.%26aulast%3DSoerensen%26aufirst%3DM.%2BD.%26aulast%3DDack%26aufirst%3DK.%2BN.%26aulast%3DGreve%26aufirst%3DD.%2BR.%26aulast%3DJerre%26aufirst%3DA.%26aulast%3DCarnerup%26aufirst%3DM.%2BA.%26aulast%3DRytved%26aufirst%3DK.%2BA.%26aulast%3DBagger-Bahnsen%26aufirst%3DJ.%26atitle%3DFragment-based%2520discovery%2520of%25206-arylindazole%2520JAK%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D6%26spage%3D641%26epage%3D646%26doi%3D10.1021%2Facsmedchemlett.6b00087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Baell, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, G. A.</span><span> </span><span class="NLM_article-title">New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">2719</span><span class="NLM_x">â</span> <span class="NLM_lpage">2740</span><span class="refDoi">Â DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&issue=7&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+substructure+filters+for+removal+of+pan+assay+interference+compounds+%28PAINS%29+from+screening+libraries+and+for+their+exclusion+in+bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0liN3PJwA9tKYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520substructure%2520filters%2520for%2520removal%2520of%2520pan%2520assay%2520interference%2520compounds%2520%2528PAINS%2529%2520from%2520screening%2520libraries%2520and%2520for%2520their%2520exclusion%2520in%2520bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D7%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3a','cit3b','cit3c'],'ref4':['cit4a','cit4b','cit4c','cit4d','cit4e','cit4f'],'ref5':['cit5a','cit5b','cit5c','cit5d'],'ref6':['cit6a','cit6b'],'ref7':['cit7a','cit7b','cit7c'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11a','cit11b'],'ref12':['cit12'],'ref13':['cit13a','cit13b','cit13c','cit13d'],'ref14':[],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17a','cit17b'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 28 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yan He, Jintao Yang, Qimeng Liu, Xinying Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Xuesen Fan</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Î²-Methylsulfonylated N-Heterocycles from Saturated Cyclic Amines with the Insertion of Sulfur Dioxide. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (23)
                                     , 15600-15609. <a href="https://doi.org/10.1021/acs.joc.0c02368" title="DOI URL">https://doi.org/10.1021/acs.joc.0c02368</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c02368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c02368%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252B%2525CE%2525B2-Methylsulfonylated%252BN-Heterocycles%252Bfrom%252BSaturated%252BCyclic%252BAmines%252Bwith%252Bthe%252BInsertion%252Bof%252BSulfur%252BDioxide%26aulast%3DHe%26aufirst%3DYan%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D06102020%26date%3D12112020%26volume%3D85%26issue%3D23%26spage%3D15600%26epage%3D15609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Joseph Katigbak, Haotian Li, David Rooklin, <span class="NLM_string-name hlFld-ContribAuthor">Yingkai Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">AlphaSpace 2.0: Representing Concave Biomolecular Surfaces Using Î²-Clusters. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (3)
                                     , 1494-1508. <a href="https://doi.org/10.1021/acs.jcim.9b00652" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00652</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00652%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DAlphaSpace%252B2.0%25253A%252BRepresenting%252BConcave%252BBiomolecular%252BSurfaces%252BUsing%252B%2525CE%2525B2-Clusters%26aulast%3DKatigbak%26aufirst%3DJoseph%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D04082019%26date%3D11022020%26date%3D29012020%26volume%3D60%26issue%3D3%26spage%3D1494%26epage%3D1508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Minjian Yang, Bingzhong Tao, Chengjuan Chen, Wenqiang Jia, Shaolei Sun, Tiantai Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Xiaojian Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Machine Learning Models Based on Molecular Fingerprints and an Extreme Gradient Boosting Method Lead to the Discovery of JAK2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2019,</strong> <em>59 </em>
                                    (12)
                                     , 5002-5012. <a href="https://doi.org/10.1021/acs.jcim.9b00798" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00798</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00798%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DMachine%252BLearning%252BModels%252BBased%252Bon%252BMolecular%252BFingerprints%252Band%252Ban%252BExtreme%252BGradient%252BBoosting%252BMethod%252BLead%252Bto%252Bthe%252BDiscovery%252Bof%252BJAK2%252BInhibitors%26aulast%3DYang%26aufirst%3DMinjian%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D15092019%26date%3D04122019%26date%3D20112019%26volume%3D59%26issue%3D12%26spage%3D5002%26epage%3D5012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jordi Bach, Paul Eastwood, Jacob GonzÃ¡lez, Elena GÃ³mez, Juan Antonio Alonso, Silvia Fonquerna, Estrella Lozoya, Adela Orellana, MÃ³nica Maldonado, Elena Calaf, Joan AlbertÃ­, Juan PÃ©rez, Ana AndrÃ©s, Neus Prats, Cristina CarreÃ±o, Elena Calama, Jorge De Alba, Marta Calbet, Montserrat Miralpeix, <span class="NLM_string-name hlFld-ContribAuthor">Isabel Ramis</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) Inhibitors for the Inhaled Treatment of Respiratory Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (20)
                                     , 9045-9060. <a href="https://doi.org/10.1021/acs.jmedchem.9b00533" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00533</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00533%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252B2-Imidazopyridine%252Band%252B2-Aminopyridone%252BPurinones%252Bas%252BPotent%252BPan-Janus%252BKinase%252B%252528JAK%252529%252BInhibitors%252Bfor%252Bthe%252BInhaled%252BTreatment%252Bof%252BRespiratory%252BDiseases%26aulast%3DBach%26aufirst%3DJordi%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D27032019%26date%3D14102019%26volume%3D62%26issue%3D20%26spage%3D9045%26epage%3D9060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Alexander Gontcharov, Javier Magano, Lacey Samp, Tim L. Houck, Peter R. Rose, Anil Rane, Jotham W. Coe, Steven W. Kortum, SeungWon Chung, Peter Jones, <span class="NLM_string-name hlFld-ContribAuthor">David Pattavina</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a Scalable Synthesis for an Inhaled pan-JAK Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2019,</strong> <em>23 </em>
                                    (9)
                                     , 1990-2000. <a href="https://doi.org/10.1021/acs.oprd.9b00253" title="DOI URL">https://doi.org/10.1021/acs.oprd.9b00253</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.9b00253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.9b00253%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DDevelopment%252Bof%252Ba%252BScalable%252BSynthesis%252Bfor%252Ban%252BInhaled%252Bpan-JAK%252BInhibitor%26aulast%3DGontcharov%26aufirst%3DAlexander%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D04062019%26date%3D06082019%26date%3D24072019%26volume%3D23%26issue%3D9%26spage%3D1990%26epage%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mark Bell, David Foley, Claire Naylor, Gavin Wood, Colin Robinson, Jennifer Riley, Ola Epemolu, Lucy Ellis, Paul Scullion, Yoko Shishikura, Maria Osuna-Cabello, Liam Ferguson, Erika Pinto, Daniel Fletcher, Elad Katz, W. H. Irwin McLean, Paul Wyatt, Kevin D Read, <span class="NLM_string-name hlFld-ContribAuthor">Andrew Woodland</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Soft-Drug Topical Tool Modulators of Sphingosine-1-phosphate Receptor 1 (S1PR1). </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (3)
                                     , 341-347. <a href="https://doi.org/10.1021/acsmedchemlett.8b00616" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00616</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00616%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BSoft-Drug%252BTopical%252BTool%252BModulators%252Bof%252BSphingosine-1-phosphate%252BReceptor%252B1%252B%252528S1PR1%252529%26aulast%3DBell%26aufirst%3DMark%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D07122018%26date%3D14022019%26date%3D19022019%26date%3D14022019%26volume%3D10%26issue%3D3%26spage%3D341%26epage%3D347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, <span class="NLM_string-name hlFld-ContribAuthor">Jonas BostrÃ¶m</span>. </span><span class="cited-content_cbyCitation_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9442-9468. <a href="https://doi.org/10.1021/acs.jmedchem.8b00675" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhere%252BDo%252BRecent%252BSmall%252BMolecule%252BClinical%252BDevelopment%252BCandidates%252BCome%252BFrom%25253F%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27042018%26date%3D09072018%26date%3D19062018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marian C. Bryan, <span class="NLM_string-name hlFld-ContribAuthor">Naomi S. Rajapaksa</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (20)
                                     , 9030-9058. <a href="https://doi.org/10.1021/acs.jmedchem.8b00667" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00667</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00667%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BImmunological%252BDisorders%25253A%252BRecent%252BAdvances%26aulast%3DBryan%26aufirst%3DMarian%2BC.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D26042018%26date%3D15062018%26date%3D05062018%26volume%3D61%26issue%3D20%26spage%3D9030%26epage%3D9058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Barbara  Morzyk-Ociepa</span>, <span class="hlFld-ContribAuthor ">Ksenia  Szmigiel-Bakalarz</span>, <span class="hlFld-ContribAuthor ">Markus  Nentwig</span>, <span class="hlFld-ContribAuthor ">Oliver  Oeckler</span>, <span class="hlFld-ContribAuthor ">Magdalena  Malik</span>. </span><span class="cited-content_cbyCitation_article-title">Structural (X-ray), spectroscopic (FT-IR, FT-Raman) and computational (DFT) analysis of intermolecular interactions in 1H-indazole-3-carbaldehyde. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2021,</strong> <em>1237 </em>, 130318. <a href="https://doi.org/10.1016/j.molstruc.2021.130318" title="DOI URL">https://doi.org/10.1016/j.molstruc.2021.130318</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2021.130318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2021.130318%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DStructural%252B%252528X-ray%252529%25252C%252Bspectroscopic%252B%252528FT-IR%25252C%252BFT-Raman%252529%252Band%252Bcomputational%252B%252528DFT%252529%252Banalysis%252Bof%252Bintermolecular%252Binteractions%252Bin%252B1H-indazole-3-carbaldehyde%26aulast%3DMorzyk-Ociepa%26aufirst%3DBarbara%26date%3D2021%26volume%3D1237%26spage%3D130318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiamin  Zheng</span>, <span class="hlFld-ContribAuthor ">Jun  Wu</span>, <span class="hlFld-ContribAuthor ">Xiao  Ding</span>, <span class="hlFld-ContribAuthor ">Hong C.  Shen</span>, <span class="hlFld-ContribAuthor ">Ge  Zou</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>38 </em>, 127862. <a href="https://doi.org/10.1016/j.bmcl.2021.127862" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127862</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127862%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSmall%252Bmolecule%252Bapproaches%252Bto%252Btreat%252Bautoimmune%252Band%252Binflammatory%252Bdiseases%252B%252528Part%252BI%252529%25253A%252BKinase%252Binhibitors%26aulast%3DZheng%26aufirst%3DJiamin%26date%3D2021%26volume%3D38%26spage%3D127862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Danilo K.S.  Sales</span>, <span class="hlFld-ContribAuthor ">LÃ­lian M.T.  SimplÃ­cio</span>, <span class="hlFld-ContribAuthor ">Carlos D.S.  da Silva</span>, <span class="hlFld-ContribAuthor ">Carolina M.B.  Enju</span>, <span class="hlFld-ContribAuthor ">Vanessa B.  Silva</span>, <span class="hlFld-ContribAuthor ">TÃ©rcio de F.  Paulo</span>, <span class="hlFld-ContribAuthor ">Ivanilson P.  Santos</span>, <span class="hlFld-ContribAuthor ">Helenita C.  Quadros</span>, <span class="hlFld-ContribAuthor ">CÃ¡ssio S.  Meira</span>, <span class="hlFld-ContribAuthor ">Milena B.P.  Soares</span>, <span class="hlFld-ContribAuthor ">Luiz G. de F.  Lopes</span>, <span class="hlFld-ContribAuthor ">Eduardo H.S.  de Sousa</span>, <span class="hlFld-ContribAuthor ">Denise S.  de SÃ¡</span>. </span><span class="cited-content_cbyCitation_article-title">A bis-indazolic ruthenium(II) complex: Reactivity and biological studies on cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Inorganica Chimica Acta</span><span> <strong>2021,</strong> <em>516 </em>, 120125. <a href="https://doi.org/10.1016/j.ica.2020.120125" title="DOI URL">https://doi.org/10.1016/j.ica.2020.120125</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ica.2020.120125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ica.2020.120125%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganica%2520Chimica%2520Acta%26atitle%3DA%252Bbis-indazolic%252Bruthenium%252528II%252529%252Bcomplex%25253A%252BReactivity%252Band%252Bbiological%252Bstudies%252Bon%252Bcancer%252Bcells%26aulast%3DSales%26aufirst%3DDanilo%2BK.S.%26date%3D2021%26volume%3D516%26spage%3D120125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ali A.  Zarrin</span>, <span class="hlFld-ContribAuthor ">Katherine  Bao</span>, <span class="hlFld-ContribAuthor ">Patrick  Lupardus</span>, <span class="hlFld-ContribAuthor ">Domagoj  Vucic</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase inhibition in autoimmunity and inflammation. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2021,</strong> <em>20 </em>
                                    (1)
                                     , 39-63. <a href="https://doi.org/10.1038/s41573-020-0082-8" title="DOI URL">https://doi.org/10.1038/s41573-020-0082-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41573-020-0082-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41573-020-0082-8%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DKinase%252Binhibition%252Bin%252Bautoimmunity%252Band%252Binflammation%26aulast%3DZarrin%26aufirst%3DAli%2BA.%26date%3D2021%26date%3D2020%26volume%3D20%26issue%3D1%26spage%3D39%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anne  Westermeyer</span>, <span class="hlFld-ContribAuthor ">GÃ©rard  Guillamot</span>, <span class="hlFld-ContribAuthor ">Phannarath  Phansavath</span>, <span class="hlFld-ContribAuthor ">Virginie  Ratovelomanana-Vidal</span>. </span><span class="cited-content_cbyCitation_article-title">Electrophilic ring fluorination of 3,5-disubstituted pyrazoles: application to the formal synthesis of a neprilysin inhibitor key intermediate. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2020,</strong> <em>44 </em>
                                    (47)
                                     , 20535-20543. <a href="https://doi.org/10.1039/D0NJ05222A" title="DOI URL">https://doi.org/10.1039/D0NJ05222A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0NJ05222A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0NJ05222A%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DElectrophilic%252Bring%252Bfluorination%252Bof%252B3%25252C5-disubstituted%252Bpyrazoles%25253A%252Bapplication%252Bto%252Bthe%252Bformal%252Bsynthesis%252Bof%252Ba%252Bneprilysin%252Binhibitor%252Bkey%252Bintermediate%26aulast%3DWestermeyer%26aufirst%3DAnne%26date%3D2020%26date%3D2020%26volume%3D44%26issue%3D47%26spage%3D20535%26epage%3D20543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Federica  Lo Bello</span>, <span class="hlFld-ContribAuthor ">Philip M.  Hansbro</span>, <span class="hlFld-ContribAuthor ">Chantal  Donovan</span>, <span class="hlFld-ContribAuthor ">Irene  Coppolino</span>, <span class="hlFld-ContribAuthor ">Sharon  Mumby</span>, <span class="hlFld-ContribAuthor ">Ian M.  Adcock</span>, <span class="hlFld-ContribAuthor ">Gaetano  Caramori</span>. </span><span class="cited-content_cbyCitation_article-title">New drugs under development for COPD. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Emerging Drugs</span><span> <strong>2020,</strong> <em>25 </em>
                                    (4)
                                     , 419-431. <a href="https://doi.org/10.1080/14728214.2020.1819982" title="DOI URL">https://doi.org/10.1080/14728214.2020.1819982</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14728214.2020.1819982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14728214.2020.1819982%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Emerging%2520Drugs%26atitle%3DNew%252Bdrugs%252Bunder%252Bdevelopment%252Bfor%252BCOPD%26aulast%3DLo%2BBello%26aufirst%3DFederica%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D4%26spage%3D419%26epage%3D431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuo  Ren</span>, <span class="hlFld-ContribAuthor ">Yanwei  Xing</span>, <span class="hlFld-ContribAuthor ">Chengbo  Wang</span>, <span class="hlFld-ContribAuthor ">Fengqi  Jiang</span>, <span class="hlFld-ContribAuthor ">Guangyu  Liu</span>, <span class="hlFld-ContribAuthor ">Ziyi  Li</span>, <span class="hlFld-ContribAuthor ">Tao  Jiang</span>, <span class="hlFld-ContribAuthor ">Yuekun  Zhu</span>, <span class="hlFld-ContribAuthor ">Daxun  Piao</span>. </span><span class="cited-content_cbyCitation_article-title">Fraxetin inhibits the growth of colon adenocarcinoma cells via the Janus kinase 2/signal transducer and activator of transcription 3 signalling pathway. </span><span class="cited-content_cbyCitation_journal-name">The International Journal of Biochemistry & Cell Biology</span><span> <strong>2020,</strong> <em>125 </em>, 105777. <a href="https://doi.org/10.1016/j.biocel.2020.105777" title="DOI URL">https://doi.org/10.1016/j.biocel.2020.105777</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biocel.2020.105777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biocel.2020.105777%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520International%2520Journal%2520of%2520Biochemistry%2520%2526%2520Cell%2520Biology%26atitle%3DFraxetin%252Binhibits%252Bthe%252Bgrowth%252Bof%252Bcolon%252Badenocarcinoma%252Bcells%252Bvia%252Bthe%252BJanus%252Bkinase%252B2%25252Fsignal%252Btransducer%252Band%252Bactivator%252Bof%252Btranscription%252B3%252Bsignalling%252Bpathway%26aulast%3DRen%26aufirst%3DShuo%26date%3D2020%26volume%3D125%26spage%3D105777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muhammad Usman  Mirza</span>, <span class="hlFld-ContribAuthor ">Matheus  Froeyen</span>. </span><span class="cited-content_cbyCitation_article-title">Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical Analysis</span><span> <strong>2020,</strong> <em>10 </em>
                                    (4)
                                     , 320-328. <a href="https://doi.org/10.1016/j.jpha.2020.04.008" title="DOI URL">https://doi.org/10.1016/j.jpha.2020.04.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jpha.2020.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jpha.2020.04.008%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520Analysis%26atitle%3DStructural%252Belucidation%252Bof%252BSARS-CoV-2%252Bvital%252Bproteins%25253A%252BComputational%252Bmethods%252Breveal%252Bpotential%252Bdrug%252Bcandidates%252Bagainst%252Bmain%252Bprotease%25252C%252BNsp12%252Bpolymerase%252Band%252BNsp13%252Bhelicase%26aulast%3DMirza%26aufirst%3DMuhammad%2BUsman%26date%3D2020%26volume%3D10%26issue%3D4%26spage%3D320%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvio  Aprile</span>, <span class="hlFld-ContribAuthor ">Marta  Serafini</span>, <span class="hlFld-ContribAuthor ">Tracey  Pirali</span>. </span><span class="cited-content_cbyCitation_article-title">Soft drugs for dermatological applications: recent trends. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2019,</strong> <em>24 </em>
                                    (12)
                                     , 2234-2246. <a href="https://doi.org/10.1016/j.drudis.2019.08.007" title="DOI URL">https://doi.org/10.1016/j.drudis.2019.08.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2019.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2019.08.007%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DSoft%252Bdrugs%252Bfor%252Bdermatological%252Bapplications%25253A%252Brecent%252Btrends%26aulast%3DAprile%26aufirst%3DSilvio%26date%3D2019%26volume%3D24%26issue%3D12%26spage%3D2234%26epage%3D2246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark  Zak</span>, <span class="hlFld-ContribAuthor ">Hart S.  Dengler</span>, <span class="hlFld-ContribAuthor ">Naomi S.  Rajapaksa</span>. </span><span class="cited-content_cbyCitation_article-title">Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (20)
                                     , 126658. <a href="https://doi.org/10.1016/j.bmcl.2019.126658" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126658%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DInhaled%252BJanus%252BKinase%252B%252528JAK%252529%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Basthma%26aulast%3DZak%26aufirst%3DMark%26date%3D2019%26volume%3D29%26issue%3D20%26spage%3D126658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Donglu  Zhang</span>, <span class="hlFld-ContribAuthor ">Cornelis E.C.A.  Hop</span>, <span class="hlFld-ContribAuthor ">Gabriela  Patilea-Vrana</span>, <span class="hlFld-ContribAuthor ">Gautham  Gampa</span>, <span class="hlFld-ContribAuthor ">Herana Kamal  Seneviratne</span>, <span class="hlFld-ContribAuthor ">Jashvant D.  Unadkat</span>, <span class="hlFld-ContribAuthor ">Jane R.  Kenny</span>, <span class="hlFld-ContribAuthor ">Karthik  Nagapudi</span>, <span class="hlFld-ContribAuthor ">Li  Di</span>, <span class="hlFld-ContribAuthor ">Lian  Zhou</span>, <span class="hlFld-ContribAuthor ">Mark  Zak</span>, <span class="hlFld-ContribAuthor ">Matthew R.  Wright</span>, <span class="hlFld-ContribAuthor ">NamandjÃ© N.  Bumpus</span>, <span class="hlFld-ContribAuthor ">Richard  Zang</span>, <span class="hlFld-ContribAuthor ">Xingrong  Liu</span>, <span class="hlFld-ContribAuthor ">Yurong  Lai</span>, <span class="hlFld-ContribAuthor ">S. Cyrus  Khojasteh</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Concentration Asymmetry in Tissues and Plasma for Small MoleculeâRelated Therapeutic Modalities. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2019,</strong> <em>47 </em>
                                    (10)
                                     , 1122-1135. <a href="https://doi.org/10.1124/dmd.119.086744" title="DOI URL">https://doi.org/10.1124/dmd.119.086744</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.119.086744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.119.086744%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DDrug%252BConcentration%252BAsymmetry%252Bin%252BTissues%252Band%252BPlasma%252Bfor%252BSmall%252BMolecule%2525E2%252580%252593Related%252BTherapeutic%252BModalities%26aulast%3DZhang%26aufirst%3DDonglu%26date%3D2019%26date%3D2019%26volume%3D47%26issue%3D10%26spage%3D1122%26epage%3D1135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marta  Calbet</span>, <span class="hlFld-ContribAuthor ">Isabel  Ramis</span>, <span class="hlFld-ContribAuthor ">Elena  Calama</span>, <span class="hlFld-ContribAuthor ">Cristina  CarreÃ±o</span>, <span class="hlFld-ContribAuthor ">Stephane  Paris</span>, <span class="hlFld-ContribAuthor ">Monica  Maldonado</span>, <span class="hlFld-ContribAuthor ">Adelina  Orellana</span>, <span class="hlFld-ContribAuthor ">Elena  Calaf</span>, <span class="hlFld-ContribAuthor ">Montse  Pauta</span>, <span class="hlFld-ContribAuthor ">Jorge  De Alba</span>, <span class="hlFld-ContribAuthor ">Jordi  Bach</span>, <span class="hlFld-ContribAuthor ">Montserrat  Miralpeix</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Inhaled Pan-JAK Inhibitor, LAS194046, Reduces Allergen-Induced Airway Inflammation, Late Asthmatic Response, and pSTAT Activation in Brown Norway Rats. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2019,</strong> <em>370 </em>
                                    (2)
                                     , 137-147. <a href="https://doi.org/10.1124/jpet.119.256263" title="DOI URL">https://doi.org/10.1124/jpet.119.256263</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.119.256263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.119.256263%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DNovel%252BInhaled%252BPan-JAK%252BInhibitor%25252C%252BLAS194046%25252C%252BReduces%252BAllergen-Induced%252BAirway%252BInflammation%25252C%252BLate%252BAsthmatic%252BResponse%25252C%252Band%252BpSTAT%252BActivation%252Bin%252BBrown%252BNorway%252BRats%26aulast%3DCalbet%26aufirst%3DMarta%26date%3D2019%26date%3D2019%26volume%3D370%26issue%3D2%26spage%3D137%26epage%3D147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesca  Musumeci</span>, <span class="hlFld-ContribAuthor ">Chiara  Greco</span>, <span class="hlFld-ContribAuthor ">Ilaria  Giacchello</span>, <span class="hlFld-ContribAuthor ">Anna Lucia  Fallacara</span>, <span class="hlFld-ContribAuthor ">Munjed M.  Ibrahim</span>, <span class="hlFld-ContribAuthor ">Giancarlo  Grossi</span>, <span class="hlFld-ContribAuthor ">Chiara  Brullo</span>, <span class="hlFld-ContribAuthor ">Silvia  Schenone</span>. </span><span class="cited-content_cbyCitation_article-title">An Update on JAK Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2019,</strong> <em>26 </em>
                                    (10)
                                     , 1806-1832. <a href="https://doi.org/10.2174/0929867325666180327093502" title="DOI URL">https://doi.org/10.2174/0929867325666180327093502</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867325666180327093502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867325666180327093502%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DAn%252BUpdate%252Bon%252BJAK%252BInhibitors%26aulast%3DMusumeci%26aufirst%3DFrancesca%26date%3D2019%26volume%3D26%26issue%3D10%26spage%3D1806%26epage%3D1832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Franziska  Roth-Walter</span>, <span class="hlFld-ContribAuthor ">Ian M.  Adcock</span>, <span class="hlFld-ContribAuthor ">Cristina  Benito-Villalvilla</span>, <span class="hlFld-ContribAuthor ">Rodolfo  Bianchini</span>, <span class="hlFld-ContribAuthor ">Leif  Bjermer</span>, <span class="hlFld-ContribAuthor ">Gaetano  Caramori</span>, <span class="hlFld-ContribAuthor ">Luigi  Cari</span>, <span class="hlFld-ContribAuthor ">KianÂ Fan  Chung</span>, <span class="hlFld-ContribAuthor ">Zuzana  Diamant</span>, <span class="hlFld-ContribAuthor ">Ibon  Eguiluz-Gracia</span>, <span class="hlFld-ContribAuthor ">EdwardÂ F.  Knol</span>, <span class="hlFld-ContribAuthor ">Antonios G. A.  Kolios</span>, <span class="hlFld-ContribAuthor ">Francesca  Levi-Schaffer</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Nocentini</span>, <span class="hlFld-ContribAuthor ">Oscar  Palomares</span>, <span class="hlFld-ContribAuthor ">Pier Giorgio  Puzzovio</span>, <span class="hlFld-ContribAuthor ">FrankÂ A.  Redegeld</span>, <span class="hlFld-ContribAuthor ">Betty C. A. M.  van Esch</span>, <span class="hlFld-ContribAuthor ">Cristiana  Stellato</span>. </span><span class="cited-content_cbyCitation_article-title">Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI Taskforce on Immunopharmacology position paper. </span><span class="cited-content_cbyCitation_journal-name">Allergy</span><span> <strong>2019,</strong> <em>74 </em>
                                    (3)
                                     , 432-448. <a href="https://doi.org/10.1111/all.13642" title="DOI URL">https://doi.org/10.1111/all.13642</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/all.13642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fall.13642%26sid%3Dliteratum%253Aachs%26jtitle%3DAllergy%26atitle%3DComparing%252Bbiologicals%252Band%252Bsmall%252Bmolecule%252Bdrug%252Btherapies%252Bfor%252Bchronic%252Brespiratory%252Bdiseases%25253A%252BAn%252BEAACI%252BTaskforce%252Bon%252BImmunopharmacology%252Bposition%252Bpaper%26aulast%3DRoth-Walter%26aufirst%3DFranziska%26date%3D2019%26date%3D2019%26volume%3D74%26issue%3D3%26spage%3D432%26epage%3D448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying  Liu</span>, <span class="hlFld-ContribAuthor ">Xinhua  Wang</span>, <span class="hlFld-ContribAuthor ">Shuang  Zeng</span>, <span class="hlFld-ContribAuthor ">Xiane  Zhang</span>, <span class="hlFld-ContribAuthor ">Jimin  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Zhang</span>, <span class="hlFld-ContribAuthor ">Xinhuan  Chen</span>, <span class="hlFld-ContribAuthor ">Wanjing  Yang</span>, <span class="hlFld-ContribAuthor ">Yili  Yang</span>, <span class="hlFld-ContribAuthor ">Ziming  Dong</span>, <span class="hlFld-ContribAuthor ">Jingyu  Zhu</span>, <span class="hlFld-ContribAuthor ">Xin  Xu</span>, <span class="hlFld-ContribAuthor ">Fang  Tian</span>. </span><span class="cited-content_cbyCitation_article-title">The natural polyphenol curcumin induces apoptosis by suppressing STAT3 signaling in esophageal squamous cell carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Experimental & Clinical Cancer Research</span><span> <strong>2018,</strong> <em>37 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13046-018-0959-0" title="DOI URL">https://doi.org/10.1186/s13046-018-0959-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13046-018-0959-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13046-018-0959-0%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Experimental%2520%2526%2520Clinical%2520Cancer%2520Research%26atitle%3DThe%252Bnatural%252Bpolyphenol%252Bcurcumin%252Binduces%252Bapoptosis%252Bby%252Bsuppressing%252BSTAT3%252Bsignaling%252Bin%252Besophageal%252Bsquamous%252Bcell%252Bcarcinoma%26aulast%3DLiu%26aufirst%3DYing%26date%3D2018%26date%3D2018%26volume%3D37%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Massimo  Gadina</span>, <span class="hlFld-ContribAuthor ">Catrina  Johnson</span>, <span class="hlFld-ContribAuthor ">Daniella  Schwartz</span>, <span class="hlFld-ContribAuthor ">Michael  Bonelli</span>, <span class="hlFld-ContribAuthor ">Sarfaraz  Hasni</span>, <span class="hlFld-ContribAuthor ">Yuka  Kanno</span>, <span class="hlFld-ContribAuthor ">Paul  Changelian</span>, <span class="hlFld-ContribAuthor ">Arian  Laurence</span>, <span class="hlFld-ContribAuthor ">John J.  O'Shea</span>. </span><span class="cited-content_cbyCitation_article-title">Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. </span><span class="cited-content_cbyCitation_journal-name">Journal of Leukocyte Biology</span><span> <strong>2018,</strong> <em>104 </em>
                                    (3)
                                     , 499-514. <a href="https://doi.org/10.1002/JLB.5RI0218-084R" title="DOI URL">https://doi.org/10.1002/JLB.5RI0218-084R</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/JLB.5RI0218-084R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2FJLB.5RI0218-084R%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Leukocyte%2520Biology%26atitle%3DTranslational%252Band%252Bclinical%252Badvances%252Bin%252BJAK-STAT%252Bbiology%25253A%252BThe%252Bpresent%252Band%252Bfuture%252Bof%252Bjakinibs%26aulast%3DGadina%26aufirst%3DMassimo%26date%3D2018%26date%3D2018%26volume%3D104%26issue%3D3%26spage%3D499%26epage%3D514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna-Marie  Hosking</span>, <span class="hlFld-ContribAuthor ">Margit  Juhasz</span>, <span class="hlFld-ContribAuthor ">Natasha Atanaskova  Mesinkovska</span>. </span><span class="cited-content_cbyCitation_article-title">Topical Janus kinase inhibitors: A review of applications in dermatology. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Academy of Dermatology</span><span> <strong>2018,</strong> <em>79 </em>
                                    (3)
                                     , 535-544. <a href="https://doi.org/10.1016/j.jaad.2018.04.018" title="DOI URL">https://doi.org/10.1016/j.jaad.2018.04.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jaad.2018.04.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jaad.2018.04.018%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Academy%2520of%2520Dermatology%26atitle%3DTopical%252BJanus%252Bkinase%252Binhibitors%25253A%252BA%252Breview%252Bof%252Bapplications%252Bin%252Bdermatology%26aulast%3DHosking%26aufirst%3DAnna-Marie%26date%3D2018%26volume%3D79%26issue%3D3%26spage%3D535%26epage%3D544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Zhan</span>, <span class="hlFld-ContribAuthor ">Xiao  Ding</span>, <span class="hlFld-ContribAuthor ">Hailong  Wang</span>, <span class="hlFld-ContribAuthor ">Haihua  Yu</span>, <span class="hlFld-ContribAuthor ">Feng  Ren</span>. </span><span class="cited-content_cbyCitation_article-title">A mild and efficient THP protection of indazoles and benzyl alcohols in water. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2018,</strong> <em>59 </em>
                                    (22)
                                     , 2150-2153. <a href="https://doi.org/10.1016/j.tetlet.2018.02.061" title="DOI URL">https://doi.org/10.1016/j.tetlet.2018.02.061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2018.02.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2018.02.061%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DA%252Bmild%252Band%252Befficient%252BTHP%252Bprotection%252Bof%252Bindazoles%252Band%252Bbenzyl%252Balcohols%252Bin%252Bwater%26aulast%3DZhan%26aufirst%3DYang%26date%3D2018%26volume%3D59%26issue%3D22%26spage%3D2150%26epage%3D2153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sandip Gangadhar  Balwe</span>, <span class="hlFld-ContribAuthor ">Yeon Tae  Jeong</span>. </span><span class="cited-content_cbyCitation_article-title">One-step construction of complex polyheterocycles
              via
              a sequential post-GBB cyclization/spiro ring expansion triggered by a [1,5]-hydride shift. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2018,</strong> <em>5 </em>
                                    (10)
                                     , 1628-1632. <a href="https://doi.org/10.1039/C8QO00071A" title="DOI URL">https://doi.org/10.1039/C8QO00071A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8QO00071A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8QO00071A%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DOne-step%252Bconstruction%252Bof%252Bcomplex%252Bpolyheterocycles%252Bvia%252Ba%252Bsequential%252Bpost-GBB%252Bcyclization%25252Fspiro%252Bring%252Bexpansion%252Btriggered%252Bby%252Ba%252B%25255B1%25252C5%25255D-hydride%252Bshift%26aulast%3DBalwe%26aufirst%3DSandip%2BGangadhar%26date%3D2018%26date%3D2018%26volume%3D5%26issue%3D10%26spage%3D1628%26epage%3D1632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna E.  Kersh</span>, <span class="hlFld-ContribAuthor ">Spencer  Ng</span>, <span class="hlFld-ContribAuthor ">Yun Min  Chang</span>, <span class="hlFld-ContribAuthor ">Maiko  Sasaki</span>, <span class="hlFld-ContribAuthor ">Susan N.  Thomas</span>, <span class="hlFld-ContribAuthor ">Haydn T.  Kissick</span>, <span class="hlFld-ContribAuthor ">Gregory B.  Lesinski</span>, <span class="hlFld-ContribAuthor ">Ragini R.  Kudchadkar</span>, <span class="hlFld-ContribAuthor ">Edmund K.  Waller</span>, <span class="hlFld-ContribAuthor ">Brian P.  Pollack</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Clinical Pharmacology</span><span> <strong>2018,</strong> <em>58 </em>
                                    (1)
                                     , 7-24. <a href="https://doi.org/10.1002/jcph.1028" title="DOI URL">https://doi.org/10.1002/jcph.1028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcph.1028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcph.1028%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Clinical%2520Pharmacology%26atitle%3DTargeted%252BTherapies%25253A%252BImmunologic%252BEffects%252Band%252BPotential%252BApplications%252BOutside%252Bof%252BCancer%26aulast%3DKersh%26aufirst%3DAnna%2BE.%26date%3D2018%26date%3D2017%26volume%3D58%26issue%3D1%26spage%3D7%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0031.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0001.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of tofacitinib (<b>1</b>) and novel pan-JAK inhibitor (<b>2</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0002.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Overlaid X-ray cocrystal structures illustrating binding mode of tofacitinib (<b>1</b>) (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LXK">3LXK</a>) and <b>4</b> (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ7">5TQ7</a>) bound to JAK2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0003.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray cocrystal structure of <b>5</b> bound to JAK2 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ3">5TQ3</a>) overlaid on protein from cocrystal with <b>4</b> to illustrate movement of the methionine gatekeeper residue. Numbers correspond to hydrogen bonding distances in angstroms.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0004.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Heat map showing kinase inhibition profile of <b>5</b> dosed at 1 Î¼M against a panel of 36 kinases at the ATP <i>K</i><sub>m</sub> concentration. Colors correspond to % inhibition of a given kinase as per the color legend shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0005.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Crystal structures of amides <b>13</b> (upper picture, PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ4">5TQ4</a>) and <b>16</b> (lower picture, PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ5">5TQ5</a>) bound to JAK2. The triad of amino acids restricting exit of more sterically demanding amides from the binding pocket is illustrated in cyan. Numbers correspond to hydrogen bonding distances in angstroms.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0006.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Benzimidazole to imidazopiperidine transformation, showing increasing saturation and sp<sup>3</sup> count in our lead series.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0007.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Heat map showing kinase inhibition profile of <b>2</b> dosed at 1 Î¼M against a panel of 36 kinases. Colors correspond to % inhibition of a given kinase as per the color legend shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0008.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. X-ray cocrystal structure of <b>2</b> bound to JAK2 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ8">5TQ8</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0009.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. SEM images of solid <b>2</b> following crystallization (left-hand panel) and subsequent micronization (right-hand panel).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0010.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Effects of intratracheal administration of <b>2</b> on IL-6 (i.t.) induced increases in lung phosphorylated STAT3 in the mouse. Left hand panel represents absolute quantity of phosphorylated pSTAT in mouse lung. Right hand panel represents the percentage inhibition Â± 95% CI calculated from the difference in geometric mean values between vehicle/IL-6-treated and vehicle/saline-treated groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0011.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Effects on mouse ear swelling following IL-23 injection and treatment with a topical formulation of <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0012.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Effects of i.t. administration of <b>2</b> on inhibition of STAT phosphorylation in the lungs and blood. Data show the effect on IL-6-induced lung phosphorylated STAT3 or GM-CSF-induced blood phosphorylated STAT5 with values representing the percentage inhibition Â± 95% CI calculated from the difference in geometric mean values between vehicle/IL-6-treated and vehicle/saline-treated groups: <i>N</i> = 6 (lung) and <i>N</i> = 3 (blood).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0013.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Effects of i.t. administration of <b>2</b> on JAK1 target occupancy. Values represent the % occupancy over time with a dose of 10 Î¼g (left-hand graph) or 100 Î¼g (right-hand graph).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0014.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Tofacitinib Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 3,3â²-disulfanediyldiphenol, Bu<sub>3</sub>P, toluene, 100 Â°C, 3 h, 69%; (b) potassium peroxymonosulfate, H<sub>2</sub>O, THF, IPA, rt, 1 h, 95%.</p></p></figure><figure data-id="sch2" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0015.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Retrosynthesis for Preparation of Target Indazoles</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0016.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Indazoles<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) benzene-1,2-diamine, NH<sub>4</sub>Br, MeOH, 0 Â°C to rt, 18 h, 52%; (b) NaH, THF, 0 Â°C, 30 min, then (2-trimethylsilyl)ethoxymethyl chloride, 2 h, 58%; (c) bis(pinacolato)diboron, (dppf)PdCl<sub>2</sub>, KOAc, 1,4-dioxane, 100 Â°C, 15 h, 97%; (d) 4-bromo-3-(propan-2-yl)phenol <b>30</b> or 4-bromo-3-propylphenol <b>29</b>, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, DME, 150 Â°C, 1 h, 22â30%; (e) conc HCl, MeOH, 60 Â°C, 18 h, 56â88%; (f) NBS, MeCN, 0 Â°C to rt, 18 h, 84%.</p></p></figure><figure data-id="sch4" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0017.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) NaH, THF, 0 Â°C 1 h, then (2-trimethylsilyl)ethoxymethyl chloride, 0 Â°C to rt, 16 h, 99%; (b) <b>33</b> or <b>34</b>, (Ph<sub>3</sub>P)<sub>4</sub>Pd, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, H<sub>2</sub>O, 100 Â°C, 15 h, 68â71%; (c) benzene-1,2-diamine, Na<sub>2</sub>SO<sub>3</sub>, DMA, 100 Â°C 16 h, 65â70%; (d) conc HCl, MeOH, 60 Â°C, 16 h, 80â82%; (e) BBr<sub>3</sub>, DCM, rt, 72 h, 20â54%; (f) NBS, MeCN, 0 Â°C to rt, 18 h; (g) bis(pinacolato)diboron, (Ph<sub>3</sub>P)<sub>4</sub>Pd, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 100 Â°C, 15 h, 33â38% over 2 steps.</p></p></figure><figure data-id="sch5" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0018.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) NaH, THF, 0 Â°C 1 h, then (2-trimethylsilyl)ethoxymethyl chloride, 0 Â°C to rt, 16 h, 99%; (b) <b>39</b>, (Ph<sub>3</sub>P)<sub>4</sub>Pd, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, H<sub>2</sub>O, 100 Â°C, 16 h, 94%; (c) glyoxal, NH<sub>4</sub>OH, MeOH, THF, rt, 16 h, 18%; (d) TBAF, THF, 1,2-diaminoethane, 80 Â°C, 16 h, 35%; (e) (2-trimethylsilyl)ethoxymethyl chloride, DIEA, DCM, rt, 18 h, 83%; (f) bis(pinacolato)diboron, (Ph<sub>3</sub>P)<sub>4</sub>Pd, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 100 Â°C, 16 h, 21%.</p></p></figure><figure data-id="sch6" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0019.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaClO<sub>2</sub>, 2-methylbut-2-ene, NaH<sub>2</sub>PO<sub>4</sub>, <sup><i>t</i></sup>BuOH, H<sub>2</sub>O, rt, 1 h, 72%; (b) TBAF, THF, 1,2-diaminoethane, rt, 16 h, 41%; (c) methylamine or dimethylamine hydrochloride, EDC, HOBT, 4-methylmorpholine, DMF, rt, 16 h, 60â63%; (d) 2-methyl-5-aminopyridine, HATU, TEA, DMAP, DMA, 30 Â°C, 16 h; (e) (i) hydroxylamine hydrochloride, Et<sub>3</sub>N, MeCN, 60 Â°C, 1.5 h; (ii) trichloroacetyl chloride, Et<sub>3</sub>N, MeCN, 60 Â°C, 16 h, 82%; (f) 30% H<sub>2</sub>O<sub>2</sub>, KOH, EtOH, rt, 4 h, 82%; (g) TBAF, THF, 1,2-diaminoethane, 60 Â°C, 3 h, 63%.</p></p></figure><figure data-id="sch7" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0020.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 7. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) <b>39</b>, (dppf)PdCl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, DME, H<sub>2</sub>O, 140 Â°C, 1 h, 79%; (b) KOH, DMF, rt, 5 min, then I<sub>2</sub>, rt, 30 min, 84%; (c) NaH, THF, 0 Â°C 15 min, then (2-trimethylsilyl)ethoxymethyl chloride, 0 Â°C to rt, 16 h, 40%; (d) (Me<sub>3</sub>Sn)<sub>2</sub>, (Ph<sub>3</sub>P)<sub>4</sub>Pd, toluene, 80 Â°C, 16 h, 69%; (e) <b>46</b>, CuI, (Ph<sub>3</sub>P)<sub>4</sub>Pd, THF, 65 Â°C, 90 h, 26%; (f) Pd(OH)<sub>2</sub>/C, H<sub>2</sub> 200 psi, EtOH, 60 Â°C, 24 h, 86%; (g) conc HCl, MeOH, 64 Â°C, 18 h, 100%; (h) CH<sub>2</sub>O 37% in H<sub>2</sub>O, NaBH(OAc)<sub>3</sub>, DIEA, DMF, AcOH, rt, 16 h, 50%; (i) Ac<sub>2</sub>O or (MeSO<sub>2</sub>)<sub>2</sub>O, Et<sub>3</sub>N, DMF, rt, 16 h, 13â30%; (j) Boc<sub>2</sub>O, Et<sub>3</sub>N, DCM, 0 Â°C to rt, 16 h, 85%; (k) <i>n</i>-BuLi, THF, â78 Â°C, then I<sub>2</sub>, 1.25 h, 33%.</p></p></figure><figure data-id="sch8" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0021.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 8. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 3,4-dihydro-2<i>H</i>-pyran, pTSA, DCM, 0 Â°C to rt, 16 h, 73%; (b) hydroxylamine hydrochloride, Et<sub>3</sub>N, MeCN, 60 Â°C, 3 h, then TFAA, Et<sub>3</sub>N, MeCN, 0 Â°C to rt, 2 h, 99%; (c) <b>51</b>, (Ph<sub>3</sub>P)<sub>4</sub>Pd, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, H<sub>2</sub>O, 110 Â°C, 18 h, 81%; (d) NaOMe, MeOH, rt, 18 h, 100%; (e) <b>53</b>, AcOH, EtOH, 50 Â°C, 18 h, 45%; (f) conc HCl, EtOH, rt, 18 h, 100%; (g) conc HCl, EtOH, 65 Â°C, 18 h, 80%; (h) CuBr<sub>2</sub>, MeCN, rt, 16 h, 100%; (i) (2-trimethylsilyl)ethoxymethyl chloride, DIEA, DCM, rt, 18 h, 86%; (j) bis(pinacolato)diboron, Pd(dppf)Cl<sub>2</sub>, KOAc, 1,4-dioxane, 100 Â°C, 18 h, 100%.</p></p></figure><figure data-id="sch9" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/medium/jm-2016-016348_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0022.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 9. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-2/acs.jmedchem.6b01634/20170120/images/large/jm-2016-016348_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01634&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>57</b>, AcOH, EtOH, 50 Â°C, 18 h, 100%; (b) conc HCl, EtOH, rt, 18 h, 88%; (c) 4-fluorobenzoic acid or <b>58</b>, HATU, DIEA, DMF, rt, 18 h, 89%;</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i45">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03468" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03468" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 32 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">OâShea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kontzias, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaoka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span> </span><span class="NLM_article-title">Janus kinase inhibitors in autoimmune diseases</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">ii111</span><span class="NLM_x">â</span> <span class="NLM_lpage">ii115</span><span class="refDoi">Â DOI: 10.1136/annrheumdis-2012-202576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1136%2Fannrheumdis-2012-202576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=23532440" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2013&pages=ii111-ii115&issue=Suppl.+2&author=J.+J.+O%E2%80%99Sheaauthor=A.+Kontziasauthor=K.+Yamaokaauthor=Y.+Tanakaauthor=A.+Laurence&title=Janus+kinase+inhibitors+in+autoimmune+diseases&doi=10.1136%2Fannrheumdis-2012-202576"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2012-202576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2012-202576%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DKontzias%26aufirst%3DA.%26aulast%3DYamaoka%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DLaurence%26aufirst%3DA.%26atitle%3DJanus%2520kinase%2520inhibitors%2520in%2520autoimmune%2520diseases%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2013%26volume%3D72%26issue%3DSuppl.%25202%26spage%3Dii111%26epage%3Dii115%26doi%3D10.1136%2Fannrheumdis-2012-202576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Clark, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telliez, J.-B.</span><span> </span><span class="NLM_article-title">Discovery and development of janus kinase (JAK) inhibitors for inflammatory diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">5023</span><span class="NLM_x">â</span> <span class="NLM_lpage">5038</span><span class="refDoi">Â DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&issue=12&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.-B.+Telliez&title=Discovery+and+development+of+janus+kinase+%28JAK%29+inhibitors+for+inflammatory+diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0lhK1WpCQHwroA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DDiscovery%2520and%2520development%2520of%2520janus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D12%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span> </span><span class="NLM_article-title">Discovery of CP-690,550: a potent and selective janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">8468</span><span class="NLM_x">â</span> <span class="NLM_lpage">8484</span><span class="refDoi">Â DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&issue=24&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=S.-P.+Changauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+a+potent+and+selective+janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0lisj3KigLu24g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DChang%26aufirst%3DS.-P.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520a%2520potent%2520and%2520selective%2520janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D24%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span><span> </span><span class="NLM_article-title">News in brief</span>.  <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span>),  <span class="NLM_fpage">895</span>, DOI: <span class="refDoi">Â DOI: 10.1038/nrd3911</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1038%2Fnrd3911" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+News+in+brief.+Nat.+Rev.+Drug+Discovery+2012%2C+11+%2812%29%2C+895%2C+DOI%3A+10.1038%2Fnrd3911"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1038%2Fnrd3911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3911%26sid%3Dliteratum%253Aachs%26atitle%3DNews%2520in%2520brief%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26issue%3D12%26spage%3D895%26doi%3D10.1038%2Fnrd3911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3c"><span><span class="NLM_label">(c) </span><div class="note"><p class="first last">Compound <b>1</b> (catalog no. PZ0017) is available from Sigma Aldrich.</p></div>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Compound+1+%28catalog+no.+PZ0017%29+is+available+from+Sigma+Aldrich.."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Burmester, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charles-Schoeman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wollenhaupt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerbini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benda, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koncz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mebus, C.</span><span> </span><span class="NLM_article-title">Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">381</span><span class="NLM_x"> (</span><span class="NLM_issue">9865</span><span class="NLM_x">) </span> <span class="NLM_fpage">451</span><span class="NLM_x">â</span> <span class="NLM_lpage">460</span><span class="refDoi">Â DOI: 10.1016/S0140-6736(12)61424-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1016%2FS0140-6736%2812%2961424-X" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2013&pages=451-460&issue=9865&author=G.+R.+Burmesterauthor=R.+Blancoauthor=C.+Charles-Schoemanauthor=J.+Wollenhauptauthor=C.+Zerbiniauthor=B.+Bendaauthor=D.+Grubenauthor=G.+Wallensteinauthor=S.+Krishnaswamiauthor=S.+H.+Zwillichauthor=T.+Konczauthor=K.+Somaauthor=J.+Bradleyauthor=C.+Mebus&title=Tofacitinib+%28CP-690%2C550%29+in+combination+with+methotrexate+in+patients+with+active+rheumatoid+arthritis+with+an+inadequate+response+to+tumour+necrosis+factor+inhibitors%3A+a+randomised+phase+3+trial&doi=10.1016%2FS0140-6736%2812%2961424-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2961424-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252961424-X%26sid%3Dliteratum%253Aachs%26aulast%3DBurmester%26aufirst%3DG.%2BR.%26aulast%3DBlanco%26aufirst%3DR.%26aulast%3DCharles-Schoeman%26aufirst%3DC.%26aulast%3DWollenhaupt%26aufirst%3DJ.%26aulast%3DZerbini%26aufirst%3DC.%26aulast%3DBenda%26aufirst%3DB.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DWallenstein%26aufirst%3DG.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DKoncz%26aufirst%3DT.%26aulast%3DSoma%26aufirst%3DK.%26aulast%3DBradley%26aufirst%3DJ.%26aulast%3DMebus%26aufirst%3DC.%26atitle%3DTofacitinib%2520%2528CP-690%252C550%2529%2520in%2520combination%2520with%2520methotrexate%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%2520with%2520an%2520inadequate%2520response%2520to%2520tumour%2520necrosis%2520factor%2520inhibitors%253A%2520a%2520randomised%2520phase%25203%2520trial%26jtitle%3DLancet%26date%3D2013%26volume%3D381%26issue%3D9865%26spage%3D451%26epage%3D460%26doi%3D10.1016%2FS0140-6736%2812%2961424-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fleischmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kremer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cush, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulze-Koops, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanik, K. S.</span><span> </span><span class="NLM_article-title">Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">495</span><span class="NLM_x">â</span> <span class="NLM_lpage">507</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1109071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1056%2FNEJMoa1109071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=22873530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1SisrbI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=495-507&issue=6&author=R.+Fleischmannauthor=J.+Kremerauthor=J.+Cushauthor=H.+Schulze-Koopsauthor=C.+A.+Connellauthor=J.+D.+Bradleyauthor=D.+Grubenauthor=G.+V.+Wallensteinauthor=S.+H.+Zwillichauthor=K.+S.+Kanik&title=Placebo-controlled+trial+of+tofacitinib+monotherapy+in+rheumatoid+arthritis&doi=10.1056%2FNEJMoa1109071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis</span></div><div class="casAuthors">Fleischmann, Roy; Kremer, Joel; Cush, John; Schulze-Koops, Hendrik; Connell, Carol A.; Bradley, John D.; Gruben, David; Wallenstein, Gene V.; Zwillich, Samuel H.; Kanik, Keith S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">495-507</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being investigated as a targeted immunomodulator and disease-modifying therapy for rheumatoid arthritis.  In this phase 3, double-blind, placebo-controlled, parallel-group, 6-mo study, 611 patients were randomly assigned, in a 4:4:1:1 ratio, to 5 mg of tofacitinib twice daily, 10 mg of tofacitinib twice daily, placebo for 3 mo followed by 5 mg of tofacitinib twice daily, or placebo for 3 mo followed by 10 mg of tofacitinib twice daily.  The primary end points, assessed at month 3, were the percentage of patients with at least a 20% improvement in the American College of Rheumatol. scale (ACR 20), the change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) scores (which range from 0 to 3, with higher scores indicating greater disability), and the percentage of patients with a Disease Activity Score for 28-joint counts based on the erythrocyte sedimentation rate (DAS28-4[ESR]) of < 2.6 (with scores ranging from 0 to 9.4 and higher scores indicating more disease activity).  At month 3, a higher percentage of patients in the tofacitinib groups than in the placebo groups met the criteria for an ACR 20 response (59.8% in the 5-mg tofacitinib group and 65.7% in the 10-mg tofacitinib group vs. 26.7% in the combined placebo groups).  The redns. from baseline in HAQ-DI scores were greater in the 5-mg and 10-mg tofacitinib groups than in the placebo groups (-0.50 and -0.57 points, resp., vs. -0.19 points).  The percentage of patients with a DAS28-4(ESR) of < 2.6 was not significantly higher with tofacitinib than with placebo (5.6 and 8.7% in the 5-mg and 10-mg tofacitinib groups, resp., and 4.4% with placebo).  Serious infections developed in 6 patients who were receiving tofacitinib.  Common adverse events were headache and upper respiratory tract infection.  Tofacitinib treatment was assocd. with elevations in low-d. lipoprotein cholesterol levels and redns. in neutrophil counts.  In patients with active rheumatoid arthritis, tofacitinib monotherapy was assocd. with redns. in signs and symptoms of rheumatoid arthritis and improvement in phys. function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_3N7ZNJiVkrVg90H21EOLACvtfcHk0lgOoreglIvoXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1SisrbI&md5=02f2ea14deec82cd4d708cae373baec2</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1109071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1109071%26sid%3Dliteratum%253Aachs%26aulast%3DFleischmann%26aufirst%3DR.%26aulast%3DKremer%26aufirst%3DJ.%26aulast%3DCush%26aufirst%3DJ.%26aulast%3DSchulze-Koops%26aufirst%3DH.%26aulast%3DConnell%26aufirst%3DC.%2BA.%26aulast%3DBradley%26aufirst%3DJ.%2BD.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DWallenstein%26aufirst%3DG.%2BV.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DKanik%26aufirst%3DK.%2BS.%26atitle%3DPlacebo-controlled%2520trial%2520of%2520tofacitinib%2520monotherapy%2520in%2520rheumatoid%2520arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26issue%3D6%26spage%3D495%26epage%3D507%26doi%3D10.1056%2FNEJMoa1109071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kremer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleischmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Mola, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaacs, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koncz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riese, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, J.</span><span> </span><span class="NLM_article-title">Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">159</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">253</span><span class="NLM_x">â</span> <span class="NLM_lpage">261</span><span class="refDoi">Â DOI: 10.7326/0003-4819-159-4-201308200-00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.7326%2F0003-4819-159-4-201308200-00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=24026258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A280%3ADC%252BC3sbntl2qsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2013&pages=253-261&issue=4&author=J.+Kremerauthor=Z.-G.+Liauthor=S.+Hallauthor=R.+Fleischmannauthor=M.+Genoveseauthor=E.+Martin-Molaauthor=J.+D.+Isaacsauthor=D.+Grubenauthor=G.+Wallensteinauthor=S.+Krishnaswamiauthor=S.+H.+Zwillichauthor=T.+Konczauthor=R.+Rieseauthor=J.+Bradley&title=Tofacitinib+in+combination+with+nonbiologic+disease-modifying+antirheumatic+drugs+in+patients+with+active+rheumatoid+arthritis%3A+a+randomized+trial&doi=10.7326%2F0003-4819-159-4-201308200-00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4c</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial</span></div><div class="casAuthors">Kremer Joel; Li Zhan-Guo; Hall Stephen; Fleischmann Roy; Genovese Mark; Martin-Mola Emilio; Isaacs John D; Gruben David; Wallenstein Gene; Krishnaswami Sriram; Zwillich Samuel H; Koncz Tamas; Riese Richard; Bradley John</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">253-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Many patients with rheumatoid arthritis (RA) do not achieve adequate and safe responses with disease-modifying antirheumatic drugs (DMARDs).  Tofacitinib is a novel, oral, Janus kinase inhibitor that treats RA.  OBJECTIVE:  To evaluate the efficacy and safety of tofacitinib in combination with nonbiologic DMARDs.  DESIGN:  1-year, double-blind, randomized trial (ClinicalTrials.gov: NCT00856544).  SETTING:  114 centers in 19 countries.  PATIENTS:  792 patients with active RA despite nonbiologic DMARD therapy.  INTERVENTION:  Patients were randomly assigned 4:4:1:1 to oral tofacitinib, 5 mg or 10 mg twice daily, or placebo advanced to tofacitinib, 5 mg or 10 mg twice daily.  MEASUREMENTS:  Primary end points were 20% improvement in American College of Rheumatology (ACR20) criteria; Disease Activity Score for 28-joint counts based on the erythrocyte sedimentation rate (DAS28-4[ESR]) of less than 2.6; DAS28-4(ESR)-defined remission, change in Health Assessment Questionnaire Disability Index (HAQ-DI) score, and safety assessments.  RESULTS:  Mean treatment differences for ACR20 response rates (month 6) for the 5-mg and 10-mg tofacitinib groups compared with the combined placebo groups were 21.2% (95% CI, 12.2% to 30.3%; P < 0.001) and 25.8% (CI, 16.8% to 34.8%; P < 0.001), respectively.  The HAQ-DI scores (month 3) and DAS28-4(ESR) less than 2.6 response rates (month 6) were also superior in the tofacitinib groups versus placebo.  The incidence rates of serious adverse events for patients receiving 5-mg tofacitinib, 10-mg tofacitinib, or placebo were 6.9, 7.3, or 10.9 events per 100 patient-years of exposure, respectively.  In the tofacitinib groups, 2 cases of tuberculosis, 2 cases of other opportunistic infections, 3 cardiovascular events, and 4 deaths occurred.  Neutrophil counts decreased, hemoglobin and low- and high-density lipoprotein cholesterol levels increased, and serum creatinine levels had small increases in the tofacitinib groups.  LIMITATIONS:  Placebo groups were smaller and of shorter duration.  Patients received primarily methotrexate.  The ability to assess drug combinations other than tofacitinib plus methotrexate was limited.  CONCLUSION:  Tofacitinib improved disease control in patients with active RA despite treatment with nonbiologic DMARDs, primarily methotrexate.  PRIMARY FUNDING SOURCE:  Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQtavUaLESyEFMGsG_HTXYFfW6udTcc2eYgTgJcrddba7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbntl2qsg%253D%253D&md5=3751f0ebd16a232dce5f09b124c8c55c</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-159-4-201308200-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-159-4-201308200-00006%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.-G.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DFleischmann%26aufirst%3DR.%26aulast%3DGenovese%26aufirst%3DM.%26aulast%3DMartin-Mola%26aufirst%3DE.%26aulast%3DIsaacs%26aufirst%3DJ.%2BD.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DWallenstein%26aufirst%3DG.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DKoncz%26aufirst%3DT.%26aulast%3DRiese%26aufirst%3DR.%26aulast%3DBradley%26aufirst%3DJ.%26atitle%3DTofacitinib%2520in%2520combination%2520with%2520nonbiologic%2520disease-modifying%2520antirheumatic%2520drugs%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%253A%2520a%2520randomized%2520trial%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2013%26volume%3D159%26issue%3D4%26spage%3D253%26epage%3D261%26doi%3D10.7326%2F0003-4819-159-4-201308200-00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Lee, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleischmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koncz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Vollenhoven, R. F.</span><span> </span><span class="NLM_article-title">Tofacitinib versus methotrexate in rheumatoid arthritis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x"> (</span><span class="NLM_issue">25</span><span class="NLM_x">) </span> <span class="NLM_fpage">2377</span><span class="NLM_x">â</span> <span class="NLM_lpage">2386</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1310476</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1056%2FNEJMoa1310476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=24941177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ajtL%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=2377-2386&issue=25&author=E.+B.+Leeauthor=R.+Fleischmannauthor=S.+Hallauthor=B.+Wilkinsonauthor=J.+D.+Bradleyauthor=D.+Grubenauthor=T.+Konczauthor=S.+Krishnaswamiauthor=G.+V.+Wallensteinauthor=C.+Zangauthor=S.+H.+Zwillichauthor=R.+F.+van+Vollenhoven&title=Tofacitinib+versus+methotrexate+in+rheumatoid+arthritis&doi=10.1056%2FNEJMoa1310476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4dR"><div class="casContent"><span class="casTitleNuber">4d</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib versus methotrexate in rheumatoid arthritis</span></div><div class="casAuthors">Lee, Eun Bong; Fleischmann, Roy; Hall, Stephen; Wilkinson, Bethanie; Bradley, John D.; Gruben, David; Koncz, Tamas; Krishnaswami, Sriram; Wallenstein, Gene V.; Zang, Chuanbo; Zwillich, Samuel H.; van Vollenhoven, Ronald F.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2377-2386, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Methotrexate is the most frequently used first-line antirheumatic drug.  We report the findings of a phase 3 study of monotherapy with tofacitinib, an oral Janus kinase inhibitor, as compared with methotrexate monotherapy in patients with rheumatoid arthritis who had not previously received methotrexate or therapeutic doses of methotrexate. methods We randomly assigned 958 patients to receive 5 mg or 10 mg of tofacitinib twice daily or methotrexate at a dose that was incrementally increased to 20 mg per wk over 8 wk; 956 patients received a study drug.  The coprimary end points at month 6 were the mean change from baseline in the van der Heijde modified total Sharp score (which ranges from 0 to 448, with higher scores indicating greater structural joint damage) and the proportion of patients with an American College of Rheumatol. (ACR) 70 response (â¥70% redn. in the no. of both tender and swollen joints and â¥70% improvement in three of five other criteria: the patient's assessment of pain, level of disability, C-reactive protein level or erythrocyte sedimentation rate, global assessment of disease by the patient, and global assessment of disease by the physician). results Mean changes in the modified total Sharp score from baseline to month 6 were significantly smaller in the tofacitinib groups than in the methotrexate group, but changes were modest in all three groups (0.2 points in the 5-mg tofacitinib group and <0.1 point in the 10-mg tofacitinib group, as compared with 0.8 points in the methotrexate group [P<0.001 for both comparisons]).  Among the patients receiving tofacitinib, 25.5% in the 5-mg group and 37.7% in the 10-mg group had an ACR 70 response at month 6, as compared with 12.0% of patients in the methotrexate group (P<0.001 for both comparisons).  Herpes zoster developed in 31 of 770 patients who received tofacitinib (4.0%) and in 2 of 186 patients who received methotrexate (1.1%).  Confirmed cases of cancer (including three cases of lymphoma) developed in 5 patients who received tofacitinib and in 1 patient who received methotrexate.  Tofacitinib was assocd. with increases in creatinine levels and in low-d. and high-d. lipoprotein cholesterol levels. conclusions In patients who had not previously received methotrexate or therapeutic doses of methotrexate, tofacitinib monotherapy was superior to methotrexate in reducing signs and symptoms of rheumatoid arthritis and inhibiting the progression of structural joint damage.  The benefits of tofacitinib need to be considered in the context of the risks of adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeTn9l50rIrrVg90H21EOLACvtfcHk0ljZIgClrCD1yg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ajtL%252FM&md5=8b8058a1091555f957b4da7ae6e95db4</span></div><a href="/servlet/linkout?suffix=cit4d&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1310476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1310476%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DFleischmann%26aufirst%3DR.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DBradley%26aufirst%3DJ.%2BD.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKoncz%26aufirst%3DT.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DWallenstein%26aufirst%3DG.%2BV.%26aulast%3DZang%26aufirst%3DC.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3Dvan%2BVollenhoven%26aufirst%3DR.%2BF.%26atitle%3DTofacitinib%2520versus%2520methotrexate%2520in%2520rheumatoid%2520arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26issue%3D25%26spage%3D2377%26epage%3D2386%26doi%3D10.1056%2FNEJMoa1310476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">van der Heijde, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleischmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keystone, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kremer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerbini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardiel, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nash, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tegzova, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyman, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benda, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connell, C. A.</span><span> </span><span class="NLM_article-title">Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">559</span><span class="NLM_x">â</span> <span class="NLM_lpage">570</span><span class="refDoi">Â DOI: 10.1002/art.37816</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1002%2Fart.37816" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=23348607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtlGqsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=559-570&issue=3&author=D.+van+der+Heijdeauthor=Y.+Tanakaauthor=R.+Fleischmannauthor=E.+Keystoneauthor=J.+Kremerauthor=C.+Zerbiniauthor=M.+H.+Cardielauthor=S.+Cohenauthor=P.+Nashauthor=Y.-W.+Songauthor=D.+Tegzovaauthor=B.+T.+Wymanauthor=D.+Grubenauthor=B.+Bendaauthor=G.+Wallensteinauthor=S.+Krishnaswamiauthor=S.+H.+Zwillichauthor=J.+D.+Bradleyauthor=C.+A.+Connell&title=Tofacitinib+%28CP-690%2C550%29+in+patients+with+rheumatoid+arthritis+receiving+methotrexate%3A+twelve-month+data+from+a+twenty-four-month+phase+III+randomized+radiographic+study&doi=10.1002%2Fart.37816"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4eR"><div class="casContent"><span class="casTitleNuber">4e</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study</span></div><div class="casAuthors">van der Heijde, Desiree; Tanaka, Yoshiya; Fleischmann, Roy; Keystone, Edward; Kremer, Joel; Zerbini, Cristiano; Cardiel, Mario H.; Cohen, Stanley; Nash, Peter; Song, Yeong-Wook; Tegzova, Dana; Wyman, Bradley T.; Gruben, David; Benda, Birgitta; Wallenstein, Gene; Krishnaswami, Sriram; Zwillich, Samuel H.; Bradley, John D.; Connell, Carol A.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">559-570</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: The purpose of this 24-mo phase III study was to examine structural preservation with tofacitinib in patients with rheumatoid arthritis (RA) with an inadequate response to methotrexate (MTX).  Data from a planned 12-mo interim anal. are reported.  Methods: In this double-blind, parallel-group, placebo-controlled study, patients receiving background MTX were randomized 4:4:1:1 to tofacitinib at 5 mg twice daily, tofacitinib at 10 mg twice daily, placebo to tofacitinib at 5 mg twice daily, and placebo to tofacitinib at 10 mg twice daily.  At month 3, nonresponder placebo-treated patients were advanced in a blinded manner to receive tofacitinib as indicated above; remaining placebo-treated patients were advanced at 6 mo.  Four primary efficacy end points were all analyzed in a step-down procedure.  Results: At month 6, response rates according to the American College of Rheumatol. 20% improvement criteria for tofacitinib at 5 mg and 10 mg twice daily were higher than those for placebo (51.5% and 61.8%, resp., vs. 25.3%; both P < 0.0001).  At month 6, least squares mean (LSM) changes in total modified Sharp/van der Heijde score for tofacitinib at 5 mg and 10 mg twice daily were 0.12 and 0.06, resp., vs. 0.47 for placebo (P = 0.0792 and P â¤ 0.05, resp.).  At month 3, LSM changes in the Health Assessment Questionnaire disability index score for tofacitinib at 5 mg and 10 mg twice daily were -0.40 (significance not declared due to step-down procedure) and -0.54 (P < 0.0001), resp., vs. -0.15 for placebo.  At month 6, rates of remission (defined as a value <2.6 for the 4-variable Disease Activity Score in 28 joints using the erythrocyte sedimentation rate) for tofacitinib at 5 mg and 10 mg twice daily were 7.2% (significance not declared due to step-down procedure) and 16.0% (P < 0.0001), resp., vs. 1.6% for placebo.  The safety profile was consistent with findings in previous studies.  Conclusion: Data from this 12-mo interim anal. demonstrate that tofacitinib inhibits progression of structural damage and improves disease activity in patients with RA who are receiving MTX.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo13qQ8LjyKorVg90H21EOLACvtfcHk0ljZIgClrCD1yg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtlGqsrg%253D&md5=0d30a733a323fb11fc65b0f1d0b638bc</span></div><a href="/servlet/linkout?suffix=cit4e&amp;dbid=16384&amp;doi=10.1002%2Fart.37816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.37816%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BHeijde%26aufirst%3DD.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DFleischmann%26aufirst%3DR.%26aulast%3DKeystone%26aufirst%3DE.%26aulast%3DKremer%26aufirst%3DJ.%26aulast%3DZerbini%26aufirst%3DC.%26aulast%3DCardiel%26aufirst%3DM.%2BH.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DNash%26aufirst%3DP.%26aulast%3DSong%26aufirst%3DY.-W.%26aulast%3DTegzova%26aufirst%3DD.%26aulast%3DWyman%26aufirst%3DB.%2BT.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DBenda%26aufirst%3DB.%26aulast%3DWallenstein%26aufirst%3DG.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DBradley%26aufirst%3DJ.%2BD.%26aulast%3DConnell%26aufirst%3DC.%2BA.%26atitle%3DTofacitinib%2520%2528CP-690%252C550%2529%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%2520receiving%2520methotrexate%253A%2520twelve-month%2520data%2520from%2520a%2520twenty-four-month%2520phase%2520III%2520randomized%2520radiographic%2520study%26jtitle%3DArthritis%2520Rheum.%26date%3D2013%26volume%3D65%26issue%3D3%26spage%3D559%26epage%3D570%26doi%3D10.1002%2Fart.37816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">van Vollenhoven, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleischmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijide, J. A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forejtova, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koncz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B.</span><span> </span><span class="NLM_article-title">Tofacitinib or adalimumab versus placebo in rheumatoid arthritis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">508</span><span class="NLM_x">â</span> <span class="NLM_lpage">519</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1112072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1056%2FNEJMoa1112072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=22873531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1SisrbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=508-519&issue=6&author=R.+F.+van+Vollenhovenauthor=R.+Fleischmannauthor=S.+Cohenauthor=E.+B.+Leeauthor=J.+A.+G.+Meijideauthor=S.+Wagnerauthor=S.+Forejtovaauthor=S.+H.+Zwillichauthor=D.+Grubenauthor=T.+Konczauthor=G.+V.+Wallensteinauthor=S.+Krishnaswamiauthor=J.+D.+Bradleyauthor=B.+Wilkinson&title=Tofacitinib+or+adalimumab+versus+placebo+in+rheumatoid+arthritis&doi=10.1056%2FNEJMoa1112072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4fR"><div class="casContent"><span class="casTitleNuber">4f</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib or adalimumab versus placebo in rheumatoid arthritis</span></div><div class="casAuthors">van Vollenhoven, Ronald F.; Fleischmann, Roy; Cohen, Stanley; Lee, Eun Bong; Meijide, Juan A. Garcia; Wagner, Sylke; Forejtova, Sarka; Zwillich, Samuel H.; Gruben, David; Koncz, Tamas; Wallenstein, Gene V.; Krishnaswami, Sriram; Bradley, John D.; Wilkinson, Bethanie</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">508-519</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BAckground: Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being investigated for the treatment of rheumatoid arthritis.  Methods: In this 12-mo, phase 3 trial, 717 patients who were receiving stable doses of methotrexate were randomly assigned to 5 mg of tofacitinib twice daily, 10 mg of tofacitinib twice daily, 40 mg of adalimumab once every 2 wk, or placebo.  At month 3, patients in the placebo group who did not have a 20% redn. from baseline in the no. of swollen and tender joints were switched in a blinded fashion to either 5 mg or 10 mg of tofacitinib twice daily; at month 6, all patients still receiving placebo were switched to tofacitinib in a blinded fashion.  The three primary outcome measures were a 20% improvement at month 6 in the American College of Rheumatol. scale (ACR 20); the change from baseline to month 3 in the score on the Health Assessment Questionnaire-Disability Index (HAQ-DI) (which ranges from 0 to 3, with higher scores indicating greater disability); and the percentage of patients at month 6 who had a Disease Activity Score for 28-joint counts based on the erythrocyte sedimentation rate (DAS28-4[ESR]) of less than 2.6 (with scores ranging from 0 to 9.4 and higher scores indicating greater disease activity).  Results: At month 6, ACR 20 response rates were higher among patients receiving 5 mg or 10 mg of tofacitinib (51.5% and 52.6%, resp.) and among those receiving adalimumab (47.2%) than among those receiving placebo (28.3%) (P<0.001 for all comparisons).  There were also greater redns. in the HAQ-DI score at month 3 and higher percentages of patients with a DAS28-4(ESR) below 2.6 at month 6 in the active-treatment groups than in the placebo group.  Adverse events occurred more frequently with tofacitinib than with placebo, and pulmonary tuberculosis developed in two patients in the 10-mg tofacitinib group.  Tofacitinib was assocd. with an increase in both low-d. and high-d. lipoprotein cholesterol levels and with redns. in neutrophil counts.  Conclusions: In patients with rheumatoid arthritis receiving background methotrexate, tofacitinib was significantly superior to placebo and was numerically similar to adalimumab in efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA_VjQtntrVLVg90H21EOLACvtfcHk0lhriKO0uqRBRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1SisrbJ&md5=b241cdff1346e5ddb295369dabb6092c</span></div><a href="/servlet/linkout?suffix=cit4f&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1112072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1112072%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BVollenhoven%26aufirst%3DR.%2BF.%26aulast%3DFleischmann%26aufirst%3DR.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DMeijide%26aufirst%3DJ.%2BA.%2BG.%26aulast%3DWagner%26aufirst%3DS.%26aulast%3DForejtova%26aufirst%3DS.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKoncz%26aufirst%3DT.%26aulast%3DWallenstein%26aufirst%3DG.%2BV.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DBradley%26aufirst%3DJ.%2BD.%26aulast%3DWilkinson%26aufirst%3DB.%26atitle%3DTofacitinib%2520or%2520adalimumab%2520versus%2520placebo%2520in%2520rheumatoid%2520arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26issue%3D6%26spage%3D508%26epage%3D519%26doi%3D10.1056%2FNEJMoa1112072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bachelez, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van de Kerkhof, P. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strohal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubanov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenzuela, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakusevich, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chimenti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papacharalambous, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proulx, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tawadrous, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdez, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolk, R.</span><span> </span><span class="NLM_article-title">Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">386</span><span class="NLM_x"> (</span><span class="NLM_issue">9993</span><span class="NLM_x">) </span> <span class="NLM_fpage">552</span><span class="NLM_x">â</span> <span class="NLM_lpage">561</span><span class="refDoi">Â DOI: 10.1016/S0140-6736(14)62113-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1016%2FS0140-6736%2814%2962113-9" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2015&pages=552-561&issue=9993&author=H.+Bachelezauthor=P.+C.+M.+van+de+Kerkhofauthor=R.+Strohalauthor=A.+Kubanovauthor=F.+Valenzuelaauthor=J.-H.+Leeauthor=V.+Yakusevichauthor=S.+Chimentiauthor=J.+Papacharalambousauthor=J.+Proulxauthor=P.+Guptaauthor=H.+Tanauthor=M.+Tawadrousauthor=H.+Valdezauthor=R.+Wolk&title=Tofacitinib+versus+etanercept+or+placebo+in+moderate-to-severe+chronic+plaque+psoriasis%3A+a+phase+3+randomised+non-inferiority+trial&doi=10.1016%2FS0140-6736%2814%2962113-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2962113-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252962113-9%26sid%3Dliteratum%253Aachs%26aulast%3DBachelez%26aufirst%3DH.%26aulast%3Dvan%2Bde%2BKerkhof%26aufirst%3DP.%2BC.%2BM.%26aulast%3DStrohal%26aufirst%3DR.%26aulast%3DKubanov%26aufirst%3DA.%26aulast%3DValenzuela%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DJ.-H.%26aulast%3DYakusevich%26aufirst%3DV.%26aulast%3DChimenti%26aufirst%3DS.%26aulast%3DPapacharalambous%26aufirst%3DJ.%26aulast%3DProulx%26aufirst%3DJ.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DTawadrous%26aufirst%3DM.%26aulast%3DValdez%26aufirst%3DH.%26aulast%3DWolk%26aufirst%3DR.%26atitle%3DTofacitinib%2520versus%2520etanercept%2520or%2520placebo%2520in%2520moderate-to-severe%2520chronic%2520plaque%2520psoriasis%253A%2520a%2520phase%25203%2520randomised%2520non-inferiority%2520trial%26jtitle%3DLancet%26date%3D2015%26volume%3D386%26issue%3D9993%26spage%3D552%26epage%3D561%26doi%3D10.1016%2FS0140-6736%2814%2962113-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bissonnette, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iversen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sofen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, C. E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romiti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachinsky, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottinghaus, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proulx, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdez, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallbris, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolk, R.</span><span> </span><span class="NLM_article-title">Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial</span> <span class="citation_source-journal">Br. J. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">172</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">1395</span><span class="NLM_x">â</span> <span class="NLM_lpage">1406</span><span class="refDoi">Â DOI: 10.1111/bjd.13551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1111%2Fbjd.13551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=25418186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlChsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=1395-1406&issue=5&author=R.+Bissonnetteauthor=L.+Iversenauthor=H.+Sofenauthor=C.+E.+M.+Griffithsauthor=P.+Foleyauthor=R.+Romitiauthor=M.+Bachinskyauthor=S.+T.+Rottinghausauthor=H.+Tanauthor=J.+Proulxauthor=H.+Valdezauthor=P.+Guptaauthor=L.+Mallbrisauthor=R.+Wolk&title=Tofacitinib+withdrawal+and+retreatment+in+moderate-to-severe+chronic+plaque+psoriasis%3A+a+randomized+controlled+trial&doi=10.1111%2Fbjd.13551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial</span></div><div class="casAuthors">Bissonnette, R.; Iversen, L.; Sofen, H.; Griffiths, C. E. M.; Foley, P.; Romiti, R.; Bachinsky, M.; Rottinghaus, S. T.; Tan, H.; Proulx, J.; Valdez, H.; Gupta, P.; Mallbris, L.; Wolk, R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1395-1406</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Tofacitinib is an oral Janus kinase inhibitor being investigated for the treatment of moderate-to-severe plaque psoriasis.  Objectives : To compare outcomes following tofacitinib withdrawal with outcomes of continuation.  Methods : In this phase 3 study (NCT01186744), patients received tofacitinib 5 mg (n = 331) or 10 mg (n = 335) twice daily for 24 wk.  The patients who achieved both â¥ 75% redn. in Psoriasis Area and Severity Index (PASI 75) score from baseline and Physician's Global Assessment (PGA) of 'clear' or 'almost clear' (PGA response) received a placebo (withdrawal) or the previous dose.  At relapse (> 50% redn. in the PASI improvement during initial treatment) or week 40, the patients received the initial dose.  Results : Initial treatment: 33Â·5% and 55Â·2% achieved both PASI 75 and PGA responses with tofacitinib 5 and 10 mg twice daily, resp., making them eligible for the treatment-withdrawal period.  Withdrawal: 56Â·2%, 62Â·3%, 23Â·3% and 26Â·1% maintained PASI 75 responses with tofacitinib 5, 10 mg, placebo (5 mg) and placebo (10 mg) twice daily, resp.; 49Â·9%, 63Â·9%, 22Â·9% and 18Â·0% maintained PGA responses; and 92Â·3%, 93Â·0%, 32Â·8% and 42Â·9% did not relapse.  Elevations in low-d. lipoprotein-cholesterol levels following initial treatment (mean increase: 8Â·71 mg dL-1 with 5 mg twice daily, 10Â·26 mg dL-1 with 10 mg twice daily) were reversed upon withdrawal.  Retreatment: 36Â·8% and 61Â·0% of patients who relapsed achieved PASI 75 responses with tofacitinib 5 or 10 mg after 16 wk; 44Â·8% and 57Â·1% regained PGA responses.  Conclusions : Patients who received continuous treatment maintained a response more effectively when compared with placebo recipients.  Safety profiles were comparable in both the continuous treatment group and retreatment group.  Of those patients who relapsed, up to 60% recaptured a response with tofacitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohd8n-cEliL7Vg90H21EOLACvtfcHk0lh76dBxzZY0Kw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlChsLY%253D&md5=8b0331613f87c7e7030996c4ab1477d2</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1111%2Fbjd.13551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.13551%26sid%3Dliteratum%253Aachs%26aulast%3DBissonnette%26aufirst%3DR.%26aulast%3DIversen%26aufirst%3DL.%26aulast%3DSofen%26aufirst%3DH.%26aulast%3DGriffiths%26aufirst%3DC.%2BE.%2BM.%26aulast%3DFoley%26aufirst%3DP.%26aulast%3DRomiti%26aufirst%3DR.%26aulast%3DBachinsky%26aufirst%3DM.%26aulast%3DRottinghaus%26aufirst%3DS.%2BT.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DProulx%26aufirst%3DJ.%26aulast%3DValdez%26aufirst%3DH.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DMallbris%26aufirst%3DL.%26aulast%3DWolk%26aufirst%3DR.%26atitle%3DTofacitinib%2520withdrawal%2520and%2520retreatment%2520in%2520moderate-to-severe%2520chronic%2520plaque%2520psoriasis%253A%2520a%2520randomized%2520controlled%2520trial%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2015%26volume%3D172%26issue%3D5%26spage%3D1395%26epage%3D1406%26doi%3D10.1111%2Fbjd.13551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Papp, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thaci, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torii, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyring, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mebus, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallbris, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatulych, S.</span><span> </span><span class="NLM_article-title">Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study</span> <span class="citation_source-journal">J. Am. Acad. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">841</span><span class="NLM_x">â</span> <span class="NLM_lpage">850</span><span class="refDoi">Â DOI: 10.1016/j.jaad.2016.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1016%2Fj.jaad.2016.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=26899199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC28XivVCitbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2016&pages=841-850&issue=5&author=K.+A.+Pappauthor=J.+G.+Kruegerauthor=S.+R.+Feldmanauthor=R.+G.+Langleyauthor=D.+Thaciauthor=H.+Toriiauthor=S.+Tyringauthor=R.+Wolkauthor=A.+Gardnerauthor=C.+Mebusauthor=H.+Tanauthor=Y.+Luoauthor=P.+Guptaauthor=L.+Mallbrisauthor=S.+Tatulych&title=Tofacitinib%2C+an+oral+Janus+kinase+inhibitor%2C+for+the+treatment+of+chronic+plaque+psoriasis%3A+Long-term+efficacy+and+safety+results+from+2+randomized+phase-III+studies+and+1+open-label+long-term+extension+study&doi=10.1016%2Fj.jaad.2016.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study</span></div><div class="casAuthors">Papp, Kim A.; Krueger, James G.; Feldman, Steven R.; Langley, Richard G.; Thaci, Diamant; Torii, Hideshi; Tyring, Stephen; Wolk, Robert; Gardner, Annie; Mebus, Charles; Tan, Huaming; Luo, Yingchun; Gupta, Pankaj; Mallbris, Lotus; Tatulych, Svitlana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">841-850</span>CODEN:
                <span class="NLM_cas:coden">JAADDB</span>;
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis.  We sought to report longer-term tofacitinib efficacy and safety in patients with moderate to severe psoriasis.  Data from 2 identical phase-III studies, Oral-treatment Psoriasis Trial Pivotal 1 and 2, were pooled with data from these patients in an ongoing open-label long-term extension study.  Patients (n = 1861) were randomized 2:2:1 to tofacitinib 5 mg, 10 mg, or placebo twice daily (BID).  At week 16, placebo patients were rerandomized to tofacitinib.  Pivotal study participants could enroll into the long-term extension where they received tofacitinib at 10 mg BID for 3 mo, after which dosing could be 5 or 10 mg BID.  At week 28, the proportions of patients randomized to tofacitinib 5 and 10 mg BID achieving 75% or greater redn. in Psoriasis Area and Severity Index score from baseline were 55.6% and 68.8%, and achieving Physician Global Assessment of clear or almost clear were 54.7% and 65.9%.  Efficacy was maintained in most patients through 24 mo.  Serious adverse events and discontinuations because of adverse events were reported in less than 11% of patients over 33 mo of tofacitinib exposure.  There was no dose comparison beyond week 52.  Oral tofacitinib demonstrated sustained efficacy in patients with psoriasis through 2 years, with 10 mg BID providing greater efficacy than 5 mg BID.  No unexpected safety findings were obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhj8uGmv-7pLVg90H21EOLACvtfcHk0lgzSwRozTywgw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivVCitbo%253D&md5=242e57c6682bc3fefb55057cd45274db</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2016.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2016.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DKrueger%26aufirst%3DJ.%2BG.%26aulast%3DFeldman%26aufirst%3DS.%2BR.%26aulast%3DLangley%26aufirst%3DR.%2BG.%26aulast%3DThaci%26aufirst%3DD.%26aulast%3DTorii%26aufirst%3DH.%26aulast%3DTyring%26aufirst%3DS.%26aulast%3DWolk%26aufirst%3DR.%26aulast%3DGardner%26aufirst%3DA.%26aulast%3DMebus%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DMallbris%26aufirst%3DL.%26aulast%3DTatulych%26aufirst%3DS.%26atitle%3DTofacitinib%252C%2520an%2520oral%2520Janus%2520kinase%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520chronic%2520plaque%2520psoriasis%253A%2520Long-term%2520efficacy%2520and%2520safety%2520results%2520from%25202%2520randomized%2520phase-III%2520studies%2520and%25201%2520open-label%2520long-term%2520extension%2520study%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2016%26volume%3D74%26issue%3D5%26spage%3D841%26epage%3D850%26doi%3D10.1016%2Fj.jaad.2016.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Papp, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menter, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elewski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottlieb, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thaci, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buonanno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proulx, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolk, R.</span><span> </span><span class="NLM_article-title">Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials</span> <span class="citation_source-journal">Br. J. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">173</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">949</span><span class="NLM_x">â</span> <span class="NLM_lpage">961</span><span class="refDoi">Â DOI: 10.1111/bjd.14018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1111%2Fbjd.14018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=26149717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyns73E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2015&pages=949-961&issue=4&author=K.+A.+Pappauthor=M.+A.+Menterauthor=M.+Abeauthor=B.+Elewskiauthor=S.+R.+Feldmanauthor=A.+B.+Gottliebauthor=R.+Langleyauthor=T.+Lugerauthor=D.+Thaciauthor=M.+Buonannoauthor=P.+Guptaauthor=J.+Proulxauthor=S.+Lanauthor=R.+Wolk&title=Tofacitinib%2C+an+oral+Janus+kinase+inhibitor%2C+for+the+treatment+of+chronic+plaque+psoriasis%3A+results+from+two+randomized%2C+placebo-controlled%2C+phase+III+trials&doi=10.1111%2Fbjd.14018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5dR"><div class="casContent"><span class="casTitleNuber">5d</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials</span></div><div class="casAuthors">Papp, K. A.; Menter, M. A.; Abe, M.; Elewski, B.; Feldman, S. R.; Gottlieb, A. B.; Langley, R.; Luger, T.; Thaci, D.; Buonanno, M.; Gupta, P.; Proulx, J.; Lan, S.; Wolk, R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">949-961</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis.  Objectives : To det. the 16-wk efficacy and safety of two oral tofacitinib doses vs. placebo in patients with moderate-to-severe chronic plaque psoriasis.  Methods : Patients in two similarly designed phase III studies (OPT Pivotal 1, NCT01276639, n = 901; OPT Pivotal 2, NCT01309737, n = 960) were initially randomized 2 : 2 : 1 to tofacitinib 10 or 5 mg or placebo, twice daily.  Coprimary efficacy end points (week 16) included the proportion of patients achieving Physician's Global Assessment (PGA) of 'clear' or 'almost clear' (PGA response) and the proportion achieving â¥ 75% redn. in Psoriasis Area and Severity Index (PASI 75).  Results : Across OPT Pivotal 1 and OPT Pivotal 2, 745 patients received tofacitinib 5 mg, 741 received tofacitinib 10 mg and 373 received placebo.  At week 16, a greater proportion of patients achieved PGA responses with tofacitinib 5 and 10 mg twice daily vs. placebo (OPT Pivotal 1, 41Â·9% and 59Â·2% vs. 9Â·0%; OPT Pivotal 2, 46Â·0% and 59Â·1% vs. 10Â·9%; all P < 0Â·001).  Higher PASI 75 rates were obsd. with tofacitinib vs. placebo (OPT Pivotal 1, 39Â·9%, 59Â·2% and 6Â·2%, resp., for tofacitinib 5 and 10 mg twice daily and placebo; OPT Pivotal 2, 46Â·0%, 59Â·6% and 11Â·4%; all P < 0Â·001 vs. placebo).  Adverse event (AE) rates appeared generally similar across groups; rates of serious AEs, infections, malignancies and discontinuations due to AEs were low.  Twelve patients reported herpes zoster across the tofacitinib treatment groups in both studies vs. none in the resp. placebo groups.  The most common AE across groups was nasopharyngitis.  Conclusions : Oral tofacitinib demonstrated significant efficacy vs. placebo during the initial 16 wk of treatment in patients with moderate-to-severe psoriasis.  Safety findings were consistent with prior studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTWaBXP7bJbLVg90H21EOLACvtfcHk0lgzSwRozTywgw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyns73E&md5=2029ed12ccdeaeb36ab87425a8c534c1</span></div><a href="/servlet/linkout?suffix=cit5d&amp;dbid=16384&amp;doi=10.1111%2Fbjd.14018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.14018%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DMenter%26aufirst%3DM.%2BA.%26aulast%3DAbe%26aufirst%3DM.%26aulast%3DElewski%26aufirst%3DB.%26aulast%3DFeldman%26aufirst%3DS.%2BR.%26aulast%3DGottlieb%26aufirst%3DA.%2BB.%26aulast%3DLangley%26aufirst%3DR.%26aulast%3DLuger%26aufirst%3DT.%26aulast%3DThaci%26aufirst%3DD.%26aulast%3DBuonanno%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DProulx%26aufirst%3DJ.%26aulast%3DLan%26aufirst%3DS.%26aulast%3DWolk%26aufirst%3DR.%26atitle%3DTofacitinib%252C%2520an%2520oral%2520Janus%2520kinase%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520chronic%2520plaque%2520psoriasis%253A%2520results%2520from%2520two%2520randomized%252C%2520placebo-controlled%252C%2520phase%2520III%2520trials%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2015%26volume%3D173%26issue%3D4%26spage%3D949%26epage%3D961%26doi%3D10.1111%2Fbjd.14018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sandborn, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vranic, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rousell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niezychowski, W.</span><span> </span><span class="NLM_article-title">Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">616</span><span class="NLM_x">â</span> <span class="NLM_lpage">624</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1112168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1056%2FNEJMoa1112168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=22894574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Chu77K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=616-624&issue=7&author=W.+J.+Sandbornauthor=S.+Ghoshauthor=J.+Panesauthor=I.+Vranicauthor=C.+Suauthor=S.+Rousellauthor=W.+Niezychowski&title=Tofacitinib%2C+an+oral+Janus+kinase+inhibitor%2C+in+active+ulcerative+colitis&doi=10.1056%2FNEJMoa1112168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis</span></div><div class="casAuthors">Sandborn, William J.; Ghosh, Subrata; Panes, Julian; Vranic, Ivana; Su, Chinyu; Rousell, Samantha; Niezychowski, Wojciech</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">616-624</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Ulcerative colitis is a chronic inflammatory disease of the colon for which current treatments are not universally effective.  One addnl. treatment may be tofacitinib (CP-690,550), an oral inhibitor of Janus kinases 1, 2, and 3 with in vitro functional specificity for kinases 1 and 3 over kinase 2, which is expected to block signaling involving gamma chain-contg. cytokines including interleukins 2, 4, 7, 9, 15, and 21.  These cytokines are integral to lymphocyte activation, function, and proliferation.  Methods: In a double-blind, placebo-controlled, phase 2 trial, we evaluated the efficacy of tofacitinib in 194 adults with moderately to severely active ulcerative colitis.  Patients were randomly assigned to receive tofacitinib at a dose of 0.5 mg, 3 mg, 10 mg, or 15 mg or placebo twice daily for 8 wk.  The primary outcome was a clin. response at 8 wk, defined as an abs. decrease from baseline in the score on the Mayo scoring system for assessment of ulcerative colitis activity (possible score, 0 to 12, with higher scores indicating more severe disease) of 3 or more and a relative decrease from baseline of 30% or more with an accompanying decrease in the rectal bleeding subscore of 1 point or more or an abs. rectal bleeding subscore of 0 or 1.  Results: The primary outcome, clin. response at 8 wk, occurred in 32%, 48%, 61%, and 78% of patients receiving tofacitinib at a dose of 0.5 mg (P = 0.39), 3 mg (P = 0.55), 10 mg (P = 0.10), and 15 mg (P<0.001), resp., as compared with 42% of patients receiving placebo.  Clin. remission (defined as a Mayo score â¤2, with no subscore >1) at 8 wk occurred in 13%, 33%, 48%, and 41% of patients receiving tofacitinib at a dose of 0.5 mg (P = 0.76), 3 mg (P = 0.01), 10 mg (P<0.001), and 15 mg (P<0.001), resp., as compared with 10% of patients receiving placebo.  There was a dose-dependent increase in both low-d. and high-d. lipoprotein cholesterol.  Three patients treated with tofacitinib had an abs. neutrophil count of less than 1500.  Conclusions: Patients with moderately to severely active ulcerative colitis treated with tofacitinib were more likely to have clin. response and remission than those receiving placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ_Al47Ev_6rVg90H21EOLACvtfcHk0liDJCN_RhdFNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Chu77K&md5=1ae8898c6de9bd24113b1f0a8e7fbed8</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1112168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1112168%26sid%3Dliteratum%253Aachs%26aulast%3DSandborn%26aufirst%3DW.%2BJ.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DPanes%26aufirst%3DJ.%26aulast%3DVranic%26aufirst%3DI.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DRousell%26aufirst%3DS.%26aulast%3DNiezychowski%26aufirst%3DW.%26atitle%3DTofacitinib%252C%2520an%2520oral%2520Janus%2520kinase%2520inhibitor%252C%2520in%2520active%2520ulcerative%2520colitis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26issue%3D7%26spage%3D616%26epage%3D624%26doi%3D10.1056%2FNEJMoa1112168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sandborn, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâHaens, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vermeir, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danese, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faegan, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinisch, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niezychowski, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawendy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodworth, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukherjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healey, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span> </span><span class="NLM_article-title">Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate-to-severe ulcerative colitis: results from 2 phase 3 randomised controlled trials</span> <span class="citation_source-journal">J. Crohn's Colitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">OP019</span><span class="NLM_x">) </span> <span class="NLM_fpage">S15</span><span class="refDoi">Â DOI: 10.1093/ecco-jcc/jjw019.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1093%2Fecco-jcc%2Fjjw019.018" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=S15&issue=OP019&author=W.+J.+Sandbornauthor=G.+D%E2%80%99Haensauthor=S.+Vermeirauthor=S.+Schreiberauthor=S.+Daneseauthor=J.+Panesauthor=B.+G.+Faeganauthor=W.+Reinischauthor=W.+Niezychowskiauthor=G.+Friedmanauthor=N.+Lawendyauthor=D.+Yuauthor=D.+Woodworthauthor=A.+Mukherjeeauthor=P.+Healeyauthor=H.+Zhangauthor=C.+Su&title=Efficacy+and+safety+of+oral+tofacitinib+as+induction+therapy+in+patients+with+moderate-to-severe+ulcerative+colitis%3A+results+from+2+phase+3+randomised+controlled+trials&doi=10.1093%2Fecco-jcc%2Fjjw019.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1093%2Fecco-jcc%2Fjjw019.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fecco-jcc%252Fjjw019.018%26sid%3Dliteratum%253Aachs%26aulast%3DSandborn%26aufirst%3DW.%2BJ.%26aulast%3DD%25E2%2580%2599Haens%26aufirst%3DG.%26aulast%3DVermeir%26aufirst%3DS.%26aulast%3DSchreiber%26aufirst%3DS.%26aulast%3DDanese%26aufirst%3DS.%26aulast%3DPanes%26aufirst%3DJ.%26aulast%3DFaegan%26aufirst%3DB.%2BG.%26aulast%3DReinisch%26aufirst%3DW.%26aulast%3DNiezychowski%26aufirst%3DW.%26aulast%3DFriedman%26aufirst%3DG.%26aulast%3DLawendy%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DWoodworth%26aufirst%3DD.%26aulast%3DMukherjee%26aufirst%3DA.%26aulast%3DHealey%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSu%26aufirst%3DC.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520oral%2520tofacitinib%2520as%2520induction%2520therapy%2520in%2520patients%2520with%2520moderate-to-severe%2520ulcerative%2520colitis%253A%2520results%2520from%25202%2520phase%25203%2520randomised%2520controlled%2520trials%26jtitle%3DJ.%2520Crohn%2527s%2520Colitis%26date%3D2016%26volume%3D10%26issue%3DOP019%26spage%3DS15%26doi%3D10.1093%2Fecco-jcc%2Fjjw019.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">DâHaens, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feagan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moscariello, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healey, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niezychowski, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marren, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maller, E.</span><span> </span><span class="NLM_article-title">Efficacy and safety of oral tofacitinib for maintenance therapy in patients with moderate-to-severe Crohnâs disease: results of a Phase 2b randomised placebo-controlled trial</span> <span class="citation_source-journal">J. Crohns Colitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">OP021</span><span class="NLM_x">) </span> <span class="NLM_fpage">S17</span><span class="refDoi">Â DOI: 10.1093/ecco-jcc/jjw019.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1093%2Fecco-jcc%2Fjjw019.020" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=S17&issue=OP021&author=G.+D%E2%80%99Haensauthor=P.+Higginsauthor=J.+Colombelauthor=B.+Feaganauthor=M.+Moscarielloauthor=G.+Chanauthor=P.+Healeyauthor=W.+Niezychowskiauthor=W.+Wangauthor=A.+Marrenauthor=E.+Maller&title=Efficacy+and+safety+of+oral+tofacitinib+for+maintenance+therapy+in+patients+with+moderate-to-severe+Crohn%E2%80%99s+disease%3A+results+of+a+Phase+2b+randomised+placebo-controlled+trial&doi=10.1093%2Fecco-jcc%2Fjjw019.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1093%2Fecco-jcc%2Fjjw019.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fecco-jcc%252Fjjw019.020%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Haens%26aufirst%3DG.%26aulast%3DHiggins%26aufirst%3DP.%26aulast%3DColombel%26aufirst%3DJ.%26aulast%3DFeagan%26aufirst%3DB.%26aulast%3DMoscariello%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DHealey%26aufirst%3DP.%26aulast%3DNiezychowski%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DMarren%26aufirst%3DA.%26aulast%3DMaller%26aufirst%3DE.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520oral%2520tofacitinib%2520for%2520maintenance%2520therapy%2520in%2520patients%2520with%2520moderate-to-severe%2520Crohn%25E2%2580%2599s%2520disease%253A%2520results%2520of%2520a%2520Phase%25202b%2520randomised%2520placebo-controlled%2520trial%26jtitle%3DJ.%2520Crohns%2520Colitis%26date%3D2016%26volume%3D10%26issue%3DOP021%26spage%3DS17%26doi%3D10.1093%2Fecco-jcc%2Fjjw019.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Panes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bushmakin, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappelleri, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamolo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healey, P.</span><span> </span><span class="NLM_article-title">Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes</span> <span class="citation_source-journal">BMC Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">14</span><span class="refDoi">Â DOI: 10.1186/s12876-015-0239-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1186%2Fs12876-015-0239-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=25651782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtlKmsLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=14&author=J.+Panesauthor=C.+Suauthor=A.+G.+Bushmakinauthor=J.+C.+Cappelleriauthor=C.+Mamoloauthor=P.+Healey&title=Randomized+trial+of+tofacitinib+in+active+ulcerative+colitis%3A+analysis+of+efficacy+based+on+patient-reported+outcomes&doi=10.1186%2Fs12876-015-0239-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes</span></div><div class="casAuthors">Panes, Julian; Su, Chinyu; Bushmakin, Andrew G.; Cappelleri, Joseph C.; Mamolo, Carla; Healey, Paul</div><div class="citationInfo"><span class="NLM_cas:title">BMC Gastroenterology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14</span>CODEN:
                <span class="NLM_cas:coden">BGMABE</span>;
        ISSN:<span class="NLM_cas:issn">1471-230X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Tofacitinib, a novel, oral Janus kinase inhibitor, demonstrated a dose-dependent efficacy for induction of clin. response and remission in patients with active ulcerative colitis (UC).  The objective of the current study was to det. the effect of tofacitinib on patient-reported outcomes (PROs).  Methods: Eligible patients (â¥18 years of age) with a diagnosis of active UC (total Mayo score of 6-12 points and moderately-to-severely active disease on sigmoidoscopy) were randomized in a 2:2:2:3:3 ratio to receive oral tofacitinib 0.5 mg, 3 mg, 10 mg, or 15 mg, or placebo twice daily (BID) for 8 wk.  PROs were assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ) and the Inflammatory Bowel Disease Patient-Reported Treatment Impact (IBD PRTI) survey.  Results: At Week 8, mean IBDQ total scores had improved relative to baseline across all five treatment groups (baseline range 123.2-134.5; Week 8 range 149.6-175.4).  Improvement from baseline was significantly greater (P = 0.001) for tofacitinib 15 mg BID vs. placebo.  For tofacitinib 15 mg BID, most patients reported satisfaction or extreme satisfaction, definite preference for tofacitinib, and definite willingness to use tofacitinib again on the IBD PRTI at week 8.  Patients achieving endoscopic remission (Mayo endoscopy score of 0) had significantly higher IBDQ scores and favorable PRTI scores than those not achieving endoscopic remission.  Conclusions: Short-term treatment with tofacitinib BID was assocd. with dose-dependent improvement in health-related quality of life and patient preferences for tofacitinib.  The results complement previously reported efficacy and safety data for the Phase II study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra9eRYjzZ9yrVg90H21EOLACvtfcHk0ljmDoeP6HLxzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtlKmsLs%253D&md5=fbcbe109b8c2f64ccfa78e022cee507c</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1186%2Fs12876-015-0239-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12876-015-0239-9%26sid%3Dliteratum%253Aachs%26aulast%3DPanes%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DBushmakin%26aufirst%3DA.%2BG.%26aulast%3DCappelleri%26aufirst%3DJ.%2BC.%26aulast%3DMamolo%26aufirst%3DC.%26aulast%3DHealey%26aufirst%3DP.%26atitle%3DRandomized%2520trial%2520of%2520tofacitinib%2520in%2520active%2520ulcerative%2520colitis%253A%2520analysis%2520of%2520efficacy%2520based%2520on%2520patient-reported%2520outcomes%26jtitle%3DBMC%2520Gastroenterol.%26date%3D2015%26volume%3D15%26spage%3D14%26doi%3D10.1186%2Fs12876-015-0239-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Sandborn, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vranic, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niezychowski, W.</span><span> </span><span class="NLM_article-title">A Phase 2 study of tofacitinib, an oral janus kinase inhibitor, in patients with Crohnâs disease</span> <span class="citation_source-journal">Clin. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1485</span><span class="NLM_x">â</span> <span class="NLM_lpage">1493</span><span class="refDoi">Â DOI: 10.1016/j.cgh.2014.01.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1016%2Fj.cgh.2014.01.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=24480677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvV2ktb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=1485-1493&issue=9&author=W.+J.+Sandbornauthor=S.+Ghoshauthor=J.+Panesauthor=I.+Vranicauthor=W.+Wangauthor=W.+Niezychowski&title=A+Phase+2+study+of+tofacitinib%2C+an+oral+janus+kinase+inhibitor%2C+in+patients+with+Crohn%E2%80%99s+disease&doi=10.1016%2Fj.cgh.2014.01.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn's Disease</span></div><div class="casAuthors">Sandborn, William J.; Ghosh, Subrata; Panes, Julian; Vranic, Ivana; Wang, Wenjin; Niezychowski, Wojciech</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Gastroenterology and Hepatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1485-1493.e2</span>CODEN:
                <span class="NLM_cas:coden">CGHLAW</span>;
        ISSN:<span class="NLM_cas:issn">1542-3565</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Tofacitinib, an orally administered Janus kinase inhibitor, blocks signaling through Î³-chain-contg. cytokines (interleukins 2, 4, 7, 9, 15, and 21).  We performed a phase 2 trial to measure its efficacy in patients with moderate-to-severe active Crohn's disease.Patients (N = 139; age, â¥18 y) with moderate-to-severe active Crohn's disease were assigned randomly to groups given 1 mg (n = 36), 5 mg (n = 34), or 15 mg (n = 35) tofacitinib or placebo (n = 34), twice daily for 4 wk, at 48 centers in 12 countries.  The primary end point was the proportion of clin. responders at week 4 (decrease from baseline in the Crohn's Disease Activity Index score of â¥70 points [Response-70]).  Secondary end points included clin. remission (Crohn's Disease Activity Index score of <150 points) at week 4.A clin. response was obsd. in 36% (P = .467), 58% (P = .466), and 46% (P â¥ .999) of patients given the 1-, 5-, and 15-mg doses of tofacitinib, compared with 47% of patients given placebo.  Clin. remission was obsd. in 31% (P = .417), 24% (P = .776), and 14% (P = .540) of patients given the 1-, 5-, and 15-mg doses of tofacitinib, compared with 21% of patients given placebo.  The 15-mg dose of tofacitinib reduced levels of C-reactive protein and fecal calprotectin from baseline.  Adverse and serious adverse events were similar among groups.  Dose-dependent increases in low- and high-d. lipoprotein cholesterol were obsd. in patients given the 5- or 15-mg doses of tofacitinib.There were no significant differences in the percentage of patients with moderate-to-severe active Crohn's disease who achieved clin. responses (Response-70) or clin. remission after 4 wk' administration of tofacitinib (1, 5, or 15 mg) or placebo twice daily.  However, a large percentage of patients given placebo achieved Response-70 or remission.  Redns. in C-reactive protein and fecal calprotectin levels among patients given the 15-mg dose of tofacitinib indicate its biol. activity.  ClinicalTrials.gov no.: NCT00615199.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqonzbSQIILgLVg90H21EOLACvtfcHk0ljmDoeP6HLxzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvV2ktb4%253D&md5=f8ea15cbaa9b3d0809f667c7d46ead14</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1016%2Fj.cgh.2014.01.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cgh.2014.01.029%26sid%3Dliteratum%253Aachs%26aulast%3DSandborn%26aufirst%3DW.%2BJ.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DPanes%26aufirst%3DJ.%26aulast%3DVranic%26aufirst%3DI.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DNiezychowski%26aufirst%3DW.%26atitle%3DA%2520Phase%25202%2520study%2520of%2520tofacitinib%252C%2520an%2520oral%2520janus%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520Crohn%25E2%2580%2599s%2520disease%26jtitle%3DClin.%2520Gastroenterol.%2520Hepatol.%26date%3D2014%26volume%3D12%26issue%3D9%26spage%3D1485%26epage%3D1493%26doi%3D10.1016%2Fj.cgh.2014.01.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span>Pfizer press release: Pfizer announces positive top-line results from second phase 3 trial of oral Xeljanz (tofacitinib citrate) in adults with psoriatic arthritis. June 7,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="http://www.pfizer.com" class="extLink">www.pfizer.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pfizer+press+release%3A+Pfizer+announces+positive+top-line+results+from+second+phase+3+trial+of+oral+Xeljanz+%28tofacitinib+citrate%29+in+adults+with+psoriatic+arthritis.+June+7%2C+2016%3B+www.pfizer.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">van der Heijde, D. D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drescher, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleishaker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrikx, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanik, K.</span><span> </span><span class="NLM_article-title">Tofacitinib in patients with ankylosing spondylitis: a phase 2, 16-week, randomized, placebo-controlled, dose-ranging study</span> <span class="citation_source-journal">Arthritis Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">5L</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=5L&author=D.+D.+A.+van+der+Heijdeauthor=J.+C.+Weiauthor=E.+Drescherauthor=D.+Fleishakerauthor=T.+Hendrikxauthor=D.+Liauthor=S.+Menonauthor=K.+Kanik&title=Tofacitinib+in+patients+with+ankylosing+spondylitis%3A+a+phase+2%2C+16-week%2C+randomized%2C+placebo-controlled%2C+dose-ranging+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BHeijde%26aufirst%3DD.%2BD.%2BA.%26aulast%3DWei%26aufirst%3DJ.%2BC.%26aulast%3DDrescher%26aufirst%3DE.%26aulast%3DFleishaker%26aufirst%3DD.%26aulast%3DHendrikx%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DKanik%26aufirst%3DK.%26atitle%3DTofacitinib%2520in%2520patients%2520with%2520ankylosing%2520spondylitis%253A%2520a%2520phase%25202%252C%252016-week%252C%2520randomized%252C%2520placebo-controlled%252C%2520dose-ranging%2520study%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2015%26volume%3D67%26spage%3D5L" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Wollenhaupt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverfield, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nduaka, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benda, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komuro, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riese, R. J.</span><span> </span><span class="NLM_article-title">Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies</span> <span class="citation_source-journal">J. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">837</span><span class="NLM_x">â</span> <span class="NLM_lpage">852</span><span class="refDoi">Â DOI: 10.3899/jrheum.130683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.3899%2Fjrheum.130683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=24692527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyiurbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2014&pages=837-852&issue=5&author=J.+Wollenhauptauthor=J.+Silverfieldauthor=E.+B.+Leeauthor=J.+R.+Curtisauthor=S.+P.+Woodauthor=K.+Somaauthor=C.+I.+Nduakaauthor=B.+Bendaauthor=D.+Grubenauthor=H.+Nakamuraauthor=Y.+Komuroauthor=S.+H.+Zwillichauthor=L.+Wangauthor=R.+J.+Riese&title=Safety+and+efficacy+of+tofacitinib%2C+an+oral+janus+kinase+inhibitor%2C+for+the+treatment+of+rheumatoid+arthritis+in+open-label%2C+longterm+extension+studies&doi=10.3899%2Fjrheum.130683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies</span></div><div class="casAuthors">Wollenhaupt, Juergen; Silverfield, Joel; Lee, Eun Bong; Curtis, Jeffrey R.; Wood, Susan P.; Soma, Koshika; Nduaka, Chudy I.; Benda, Birgitta; Gruben, David; Nakamura, Hiroyuki; Komuro, Yoshihiro; Zwillich, Samuel H.; Wang, Lisy; Riese, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">837-852</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">Objective: To describe the longterm safety and efficacy profile of tofacitinib in patients with moderate to severe active rheumatoid arthritis (RA).  Methods: Data were pooled from 2 open-label studies (NCT00413699, NCT00661661) involving patients who had participated in qualifying phase I, II, or III index studies of tofacitinib.  Safety data included over 60 mo of observation; efficacy data are reported up to Month 48.  Treatment was initiated with tofacitinib 5 or 10 mg twice daily.  Primary endpoints were adverse events (AE) and lab. safety data.  Secondary endpoints included American College of Rheumatol. (ACR) response rates, and Disease Activity Score (28 joints) (DAS28)-4[erythrocyte sedimentation rate (ESR)] and Health Assessment Questionnaire-Disability Index (HAQ-DI) assessments.  Results: Overall, 4102 patients were treated for 5963 patient-years; mean (max.) treatment duration was 531 (1844) days; 20.8% of patients discontinued treatment over 60 mo.  The most common AE were nasopharyngitis (12.7%) and upper respiratory tract infection (10.5%).  Serious AE were reported in 15.4% of patients with an exposure-estd. incidence rate of 11.1 events/100 patient-years.  Serious infections were reported in 4.5% of patients with an exposure-estd. incidence rate of 3.1 events/100 patient-years (95% CI: 2.66-3.55).  Mean values for lab. variables were stable over time and consistent with phase II and III studies.  Persistent efficacy was demonstrated through Month 48, as measured by ACR response rate (ACR20/50/70) DAS28-4-ESR, and HAQ-DI.  Safety and efficacy were similar for patients receiving tofacitinib as monotherapy or with background nonbiol. disease-modifying antirheumatic drugs.  Conclusion: Tofacitinib demonstrated consistent safety and persistent efficacy over 48 mo in patients with RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-Scjk1FOYMrVg90H21EOLACvtfcHk0ljWDJAI_KtHrw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyiurbJ&md5=0c8cf68569627b3948b6c275ec69d8df</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.130683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.130683%26sid%3Dliteratum%253Aachs%26aulast%3DWollenhaupt%26aufirst%3DJ.%26aulast%3DSilverfield%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DCurtis%26aufirst%3DJ.%2BR.%26aulast%3DWood%26aufirst%3DS.%2BP.%26aulast%3DSoma%26aufirst%3DK.%26aulast%3DNduaka%26aufirst%3DC.%2BI.%26aulast%3DBenda%26aufirst%3DB.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DKomuro%26aufirst%3DY.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRiese%26aufirst%3DR.%2BJ.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520tofacitinib%252C%2520an%2520oral%2520janus%2520kinase%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%2520in%2520open-label%252C%2520longterm%2520extension%2520studies%26jtitle%3DJ.%2520Rheumatol.%26date%3D2014%26volume%3D41%26issue%3D5%26spage%3D837%26epage%3D852%26doi%3D10.3899%2Fjrheum.130683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Coe, J. W.; Dehnhardt, C. M.; Jones, P.; Kortum, S. W.; Sabnis, Y. A.; Wakenhut, F. M.; Whitlock, G. A.</span><span> </span><span class="NLM_article-title">Indazoles</span>. WO2013014567 A1,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=J.+W.+Coe&author=C.+M.+Dehnhardt&author=P.+Jones&author=S.+W.+Kortum&author=Y.+A.+Sabnis&author=F.+M.+Wakenhut&author=G.+A.+Whitlock&title=Indazoles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCoe%26aufirst%3DJ.%2BW.%26atitle%3DIndazoles%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><div class="note"><p class="first last">Compound <b>2</b> (catalog no. PZ0324) is available from Sigma Aldrich.</p></div>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Compound+2+%28catalog+no.+PZ0324%29+is+available+from+Sigma+Aldrich.."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Barnes, P. J.</span><span> </span><span class="NLM_article-title">New anti-inflammatory targets for chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">543</span><span class="NLM_x">â</span> <span class="NLM_lpage">59</span><span class="refDoi">Â DOI: 10.1038/nrd4025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1038%2Fnrd4025" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=543-59&issue=7&author=P.+J.+Barnes&title=New+anti-inflammatory+targets+for+chronic+obstructive+pulmonary+disease&doi=10.1038%2Fnrd4025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd4025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4025%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DNew%2520anti-inflammatory%2520targets%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26issue%3D7%26spage%3D543%26epage%3D59%26doi%3D10.1038%2Fnrd4025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jones, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coghlan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Entwistle, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeder, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenyon, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selby, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevethick, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span> </span><span class="NLM_article-title">Inhalation by design: dual pharmacology Î²-2 agonists/M3 antagonists for the treatment of COPD</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">2759</span><span class="NLM_x">â</span> <span class="NLM_lpage">2763</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2010.10.132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1016%2Fj.bmcl.2010.10.132" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2759-2763&issue=9&author=L.+H.+Jonesauthor=H.+Baldockauthor=M.+E.+Bunnageauthor=J.+Burrowsauthor=N.+Clarkeauthor=M.+Coghlanauthor=D.+Entwistleauthor=D.+Fairmanauthor=N.+Feederauthor=C.+Fultonauthor=L.+Hiltonauthor=K.+Jamesauthor=R.+M.+Jonesauthor=A.+S.+Kenyonauthor=S.+Marshallauthor=S.+D.+Newmanauthor=R.+Osborneauthor=S.+Patelauthor=M.+D.+Selbyauthor=E.+F.+Stuartauthor=M.+A.+Trevethickauthor=K.+N.+Wrightauthor=D.+A.+Price&title=Inhalation+by+design%3A+dual+pharmacology+%CE%B2-2+agonists%2FM3+antagonists+for+the+treatment+of+COPD&doi=10.1016%2Fj.bmcl.2010.10.132"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.10.132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.10.132%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DBaldock%26aufirst%3DH.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DClarke%26aufirst%3DN.%26aulast%3DCoghlan%26aufirst%3DM.%26aulast%3DEntwistle%26aufirst%3DD.%26aulast%3DFairman%26aufirst%3DD.%26aulast%3DFeeder%26aufirst%3DN.%26aulast%3DFulton%26aufirst%3DC.%26aulast%3DHilton%26aufirst%3DL.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DR.%2BM.%26aulast%3DKenyon%26aufirst%3DA.%2BS.%26aulast%3DMarshall%26aufirst%3DS.%26aulast%3DNewman%26aufirst%3DS.%2BD.%26aulast%3DOsborne%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DSelby%26aufirst%3DM.%2BD.%26aulast%3DStuart%26aufirst%3DE.%2BF.%26aulast%3DTrevethick%26aufirst%3DM.%2BA.%26aulast%3DWright%26aufirst%3DK.%2BN.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26atitle%3DInhalation%2520by%2520design%253A%2520dual%2520pharmacology%2520%25CE%25B2-2%2520agonists%252FM3%2520antagonists%2520for%2520the%2520treatment%2520of%2520COPD%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26issue%3D9%26spage%3D2759%26epage%3D2763%26doi%3D10.1016%2Fj.bmcl.2010.10.132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hilton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenyon, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coghlan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Entwistle, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeder, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laouar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lunn, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selby, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spence, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Summerhill, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevethick, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeadon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L. H.</span><span> </span><span class="NLM_article-title">Optimized glucuronidation of dual pharmacology Î²-2 agonists/M3 antagonists for the treatment of COPD</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">870</span><span class="NLM_x">â</span> <span class="NLM_lpage">876</span><span class="refDoi">Â DOI: 10.1039/c1md00140j</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1039%2Fc1md00140j" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=870-876&author=L.+Hiltonauthor=R.+Osborneauthor=A.+S.+Kenyonauthor=H.+Baldockauthor=M.+E.+Bunnageauthor=J.+Burrowsauthor=N.+Clarkeauthor=M.+Coghlanauthor=D.+Entwistleauthor=D.+Fairmanauthor=N.+Feederauthor=K.+Jamesauthor=R.+M.+Jonesauthor=N.+Laouarauthor=G.+Lunnauthor=S.+Marshallauthor=S.+D.+Newmanauthor=S.+Patelauthor=M.+D.+Selbyauthor=F.+Spenceauthor=E.+F.+Stuartauthor=S.+Summerhillauthor=M.+A.+Trevethickauthor=K.+N.+Wrightauthor=M.+Yeadonauthor=D.+A.+Priceauthor=L.+H.+Jones&title=Optimized+glucuronidation+of+dual+pharmacology+%CE%B2-2+agonists%2FM3+antagonists+for+the+treatment+of+COPD&doi=10.1039%2Fc1md00140j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1039%2Fc1md00140j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1md00140j%26sid%3Dliteratum%253Aachs%26aulast%3DHilton%26aufirst%3DL.%26aulast%3DOsborne%26aufirst%3DR.%26aulast%3DKenyon%26aufirst%3DA.%2BS.%26aulast%3DBaldock%26aufirst%3DH.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DBurrows%26aufirst%3DJ.%26aulast%3DClarke%26aufirst%3DN.%26aulast%3DCoghlan%26aufirst%3DM.%26aulast%3DEntwistle%26aufirst%3DD.%26aulast%3DFairman%26aufirst%3DD.%26aulast%3DFeeder%26aufirst%3DN.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DR.%2BM.%26aulast%3DLaouar%26aufirst%3DN.%26aulast%3DLunn%26aufirst%3DG.%26aulast%3DMarshall%26aufirst%3DS.%26aulast%3DNewman%26aufirst%3DS.%2BD.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DSelby%26aufirst%3DM.%2BD.%26aulast%3DSpence%26aufirst%3DF.%26aulast%3DStuart%26aufirst%3DE.%2BF.%26aulast%3DSummerhill%26aufirst%3DS.%26aulast%3DTrevethick%26aufirst%3DM.%2BA.%26aulast%3DWright%26aufirst%3DK.%2BN.%26aulast%3DYeadon%26aufirst%3DM.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DJones%26aufirst%3DL.%2BH.%26atitle%3DOptimized%2520glucuronidation%2520of%2520dual%2520pharmacology%2520%25CE%25B2-2%2520agonists%252FM3%2520antagonists%2520for%2520the%2520treatment%2520of%2520COPD%26jtitle%3DMedChemComm%26date%3D2011%26volume%3D2%26spage%3D870%26epage%3D876%26doi%3D10.1039%2Fc1md00140j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Glossop, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C. A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewthwaite, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeadon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perros-Huguet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevethick, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeder, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spence, F. J.</span><span> </span><span class="NLM_article-title">Inhalation by design: novel ultra-long-acting Î²2-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">6640</span><span class="NLM_x">â</span> <span class="NLM_lpage">6652</span><span class="refDoi">Â DOI: 10.1021/jm1005989</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1005989" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6640-6652&issue=18&author=P.+A.+Glossopauthor=C.+A.+L.+Laneauthor=D.+A.+Priceauthor=M.+E.+Bunnageauthor=R.+A.+Lewthwaiteauthor=K.+Jamesauthor=A.+D.+Brownauthor=M.+Yeadonauthor=C.+Perros-Huguetauthor=M.+A.+Trevethickauthor=N.+P.+Clarkeauthor=R.+Websterauthor=R.+M.+Jonesauthor=J.+L.+Burrowsauthor=N.+Feederauthor=S.+C.+J.+Taylorauthor=F.+J.+Spence&title=Inhalation+by+design%3A+novel+ultra-long-acting+%CE%B22-adrenoreceptor+agonists+for+inhaled+once-daily+treatment+of+asthma+and+chronic+obstructive+pulmonary+disease+that+utilize+a+sulfonamide+agonist+headgroup&doi=10.1021%2Fjm1005989"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1021%2Fjm1005989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1005989%26sid%3Dliteratum%253Aachs%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DLane%26aufirst%3DC.%2BA.%2BL.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DA.%2BD.%26aulast%3DYeadon%26aufirst%3DM.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DTrevethick%26aufirst%3DM.%2BA.%26aulast%3DClarke%26aufirst%3DN.%2BP.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DR.%2BM.%26aulast%3DBurrows%26aufirst%3DJ.%2BL.%26aulast%3DFeeder%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DS.%2BC.%2BJ.%26aulast%3DSpence%26aufirst%3DF.%2BJ.%26atitle%3DInhalation%2520by%2520design%253A%2520novel%2520ultra-long-acting%2520%25CE%25B22-adrenoreceptor%2520agonists%2520for%2520inhaled%2520once-daily%2520treatment%2520of%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%2520that%2520utilize%2520a%2520sulfonamide%2520agonist%2520headgroup%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D18%26spage%3D6640%26epage%3D6652%26doi%3D10.1021%2Fjm1005989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Millan, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodd, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairman, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilty, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaitre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewthwaite, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahnke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathias, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philip, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefaniak, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeadon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, C.</span><span> </span><span class="NLM_article-title">Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">7797</span><span class="NLM_x">â</span> <span class="NLM_lpage">7814</span><span class="refDoi">Â DOI: 10.1021/jm200677b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200677b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7797-7814&issue=22&author=D.+S.+Millanauthor=M.+E.+Bunnageauthor=J.+L.+Burrowsauthor=K.+J.+Butcherauthor=P.+G.+Doddauthor=T.+J.+Evansauthor=D.+A.+Fairmanauthor=S.+J.+Hughesauthor=I.+C.+Kiltyauthor=A.+Lemaitreauthor=R.+A.+Lewthwaiteauthor=A.+Mahnkeauthor=J.+P.+Mathiasauthor=J.+Philipauthor=R.+T.+Smithauthor=M.+H.+Stefaniakauthor=M.+Yeadonauthor=C.+Phillips&title=Design+and+synthesis+of+inhaled+p38+inhibitors+for+the+treatment+of+chronic+obstructive+pulmonary+disease&doi=10.1021%2Fjm200677b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=10.1021%2Fjm200677b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200677b%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DD.%2BS.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DBurrows%26aufirst%3DJ.%2BL.%26aulast%3DButcher%26aufirst%3DK.%2BJ.%26aulast%3DDodd%26aufirst%3DP.%2BG.%26aulast%3DEvans%26aufirst%3DT.%2BJ.%26aulast%3DFairman%26aufirst%3DD.%2BA.%26aulast%3DHughes%26aufirst%3DS.%2BJ.%26aulast%3DKilty%26aufirst%3DI.%2BC.%26aulast%3DLemaitre%26aufirst%3DA.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DMahnke%26aufirst%3DA.%26aulast%3DMathias%26aufirst%3DJ.%2BP.%26aulast%3DPhilip%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DR.%2BT.%26aulast%3DStefaniak%26aufirst%3DM.%2BH.%26aulast%3DYeadon%26aufirst%3DM.%26aulast%3DPhillips%26aufirst%3DC.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520inhaled%2520p38%2520inhibitors%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D22%26spage%3D7797%26epage%3D7814%26doi%3D10.1021%2Fjm200677b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="note"><p class="first last">Compound <b>3</b> (catalog no. PZ0151) is available from Sigma Aldrich.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Pan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karns, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herr, A. E.</span><span> </span><span class="NLM_article-title">Microfluidic electrophoretic mobility shift assays for quantitative biochemical analysis</span> <span class="citation_source-journal">Electrophoresis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">2078</span><span class="NLM_x">â</span> <span class="NLM_lpage">2090</span><span class="refDoi">Â DOI: 10.1002/elps.201300500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1002%2Felps.201300500" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=2078-2090&issue=15&author=Y.+Panauthor=K.+Karnsauthor=A.+E.+Herr&title=Microfluidic+electrophoretic+mobility+shift+assays+for+quantitative+biochemical+analysis&doi=10.1002%2Felps.201300500"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Felps.201300500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Felps.201300500%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DY.%26aulast%3DKarns%26aufirst%3DK.%26aulast%3DHerr%26aufirst%3DA.%2BE.%26atitle%3DMicrofluidic%2520electrophoretic%2520mobility%2520shift%2520assays%2520for%2520quantitative%2520biochemical%2520analysis%26jtitle%3DElectrophoresis%26date%3D2014%26volume%3D35%26issue%3D15%26spage%3D2078%26epage%3D2090%26doi%3D10.1002%2Felps.201300500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery?</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">1230</span><span class="NLM_x">â</span> <span class="NLM_lpage">1241</span><span class="refDoi">Â DOI: 10.1021/cb500129t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500129t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1230-1241&issue=6&author=Z.+Zhaoauthor=H.+Wuauthor=L.+Wangauthor=Y.+Liuauthor=S.+Knappauthor=Q.+Liuauthor=N.+S.+Gray&title=Exploration+of+type+II+binding+mode%3A+a+privileged+approach+for+kinase+inhibitor+focused+drug+discovery%3F&doi=10.1021%2Fcb500129t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span></div><div class="casAuthors">Zhao, Zheng; Wu, Hong; Wang, Li; Liu, Yi; Knapp, Stefan; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1230-1241</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ATP site of kinases displays remarkable conformational flexibility when accommodating chem. diverse small mol. inhibitors.  The so-called activation segment, whose conformation controls catalytic activity and access to the substrate binding pocket, can undergo a large conformational change with the active state assuming a 'DFG-in' and an inactive state assuming a 'DFG-out' conformation.  Compds. that preferentially bind to the DFG-out conformation are typically called 'type II' inhibitors in contrast to 'type I' inhibitors that bind to the DFG-in conformation.  This review surveys the large no. of type II inhibitors that have been developed and provides an anal. of their crystallog. detd. binding modes.  Using a small library of type II inhibitors, we demonstrate that more than 200 kinases can be targeted, suggesting that type II inhibitors may not be intrinsically more selective than type I inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4jYt6Db3Ap7Vg90H21EOLACvtfcHk0lhCxxYfyFeBfQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D&md5=95bf185ff7f973eda5a65f4096bfaa82</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fcb500129t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500129t%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DExploration%2520of%2520type%2520II%2520binding%2520mode%253A%2520a%2520privileged%2520approach%2520for%2520kinase%2520inhibitor%2520focused%2520drug%2520discovery%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26issue%3D6%26spage%3D1230%26epage%3D1241%26doi%3D10.1021%2Fcb500129t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Berman, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henrick, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, H.</span><span> </span><span class="NLM_article-title">Announcing the worldwide Protein Data Bank</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">980</span><span class="refDoi">Â DOI: 10.1038/nsb1203-980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1038%2Fnsb1203-980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=14634627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFOmsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2003&pages=980&author=H.+M.+Bermanauthor=K.+Henrickauthor=H.+Nakamura&title=Announcing+the+worldwide+Protein+Data+Bank&doi=10.1038%2Fnsb1203-980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Announcing the worldwide Protein Data Bank</span></div><div class="casAuthors">Berman, Helen; Henrick, Kim; Nakamura, Haruki</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">980</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplInmv2AD6cbVg90H21EOLACvtfcHk0lhCxxYfyFeBfQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFOmsbY%253D&md5=8146ff5fc67f64e31b2f8c475473879c</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1038%2Fnsb1203-980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb1203-980%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DH.%2BM.%26aulast%3DHenrick%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DH.%26atitle%3DAnnouncing%2520the%2520worldwide%2520Protein%2520Data%2520Bank%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2003%26volume%3D10%26spage%3D980%26doi%3D10.1038%2Fnsb1203-980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rose, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prlic, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bluhm, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodsell, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westbrook, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zardecki, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berman, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourne, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burley, S. K.</span><span> </span><span class="NLM_article-title">The RCSB Protein Data Bank: views of structural biology for basic and applied research and education</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">D345</span><span class="NLM_x">â</span> <span class="NLM_lpage">D356</span><span class="refDoi">Â DOI: 10.1093/nar/gku1214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1093%2Fnar%2Fgku1214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=25428375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtV2itr%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=D345-D356&author=P.+W.+Roseauthor=A.+Prlicauthor=C.+Biauthor=W.+F.+Bluhmauthor=C.+H.+Christieauthor=S.+Duttaauthor=R.+K.+Greenauthor=D.+S.+Goodsellauthor=J.+D.+Westbrookauthor=J.+Wooauthor=J.+Youngauthor=C.+Zardeckiauthor=H.+M.+Bermanauthor=P.+E.+Bourneauthor=S.+K.+Burley&title=The+RCSB+Protein+Data+Bank%3A+views+of+structural+biology+for+basic+and+applied+research+and+education&doi=10.1093%2Fnar%2Fgku1214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">The RCSB protein data bank: views of structural biology for basic and applied research and education</span></div><div class="casAuthors">Rose, Peter W.; Prlic, Andreas; Bi, Chunxiao; Bluhm, Wolfgang F.; Christie, Cole H.; Dutta, Shuchismita; Green, Rachel Kramer; Goodsell, David S.; Westbrook, John D.; Woo, Jesse; Young, Jasmine; Zardecki, Christine; Berman, Helen M.; Bourne, Philip E.; Burley, Stephen K.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D345-D356</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  The RCSB Protein Data Bank provides access to 3D structures of biol. macromols. and is one of the leading resources in biol. and biomedicine worldwide.  Our efforts over the past 2 years focused on enabling a deeper understanding of structural biol. and providing new structural views of biol. that support both basic and applied research and education.  Herein, we describe recently introduced data annotations including integration with external biol. resources, such as gene and drug databases, new visualization tools and improved support for the mobile web.  We also describe access to data files, web services and open access software components to enable software developers to more effectively mine the PDB archive and related annotations.  Our efforts are aimed at expanding the role of 3D structure in understanding biol. and medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-p1ymUjOOkrVg90H21EOLACvtfcHk0lhCxxYfyFeBfQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtV2itr%252FO&md5=fe95bef159c997e2195a9ae469d9ae4b</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgku1214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgku1214%26sid%3Dliteratum%253Aachs%26aulast%3DRose%26aufirst%3DP.%2BW.%26aulast%3DPrlic%26aufirst%3DA.%26aulast%3DBi%26aufirst%3DC.%26aulast%3DBluhm%26aufirst%3DW.%2BF.%26aulast%3DChristie%26aufirst%3DC.%2BH.%26aulast%3DDutta%26aufirst%3DS.%26aulast%3DGreen%26aufirst%3DR.%2BK.%26aulast%3DGoodsell%26aufirst%3DD.%2BS.%26aulast%3DWestbrook%26aufirst%3DJ.%2BD.%26aulast%3DWoo%26aufirst%3DJ.%26aulast%3DYoung%26aufirst%3DJ.%26aulast%3DZardecki%26aufirst%3DC.%26aulast%3DBerman%26aufirst%3DH.%2BM.%26aulast%3DBourne%26aufirst%3DP.%2BE.%26aulast%3DBurley%26aufirst%3DS.%2BK.%26atitle%3DThe%2520RCSB%2520Protein%2520Data%2520Bank%253A%2520views%2520of%2520structural%2520biology%2520for%2520basic%2520and%2520applied%2520research%2520and%2520education%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2015%26volume%3D43%26spage%3DD345%26epage%3DD356%26doi%3D10.1093%2Fnar%2Fgku1214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Kania, R. S.; Bender, S. L.; Borchardt, A. J.; Braganza, J. F.; Cripps, S. J.; Hua, Y.; Johnson, M. D.; Johnson, T. O.,  Jr.; Luu, H. T.; Palmer, C. L.; Reich, S. H.; Tempczyk-russell, A. M.; Teng, M.; Thomas, C.; Varney, M. D.; Wallace, M. B.</span><span> </span><span class="NLM_article-title">Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use</span>. WO2001002369,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=R.+S.+Kania&author=S.+L.+Bender&author=A.+J.+Borchardt&author=J.+F.+Braganza&author=S.+J.+Cripps&author=Y.+Hua&author=M.+D.+Johnson&author=T.+O.+Johnson&author=H.+T.+Luu&author=C.+L.+Palmer&author=S.+H.+Reich&author=A.+M.+Tempczyk-russell&author=M.+Teng&author=C.+Thomas&author=M.+D.+Varney&author=M.+B.+Wallace&title=Indazole+compounds+and+pharmaceutical+compositions+for+inhibiting+protein+kinases%2C+and+methods+for+their+use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKania%26aufirst%3DR.%2BS.%26atitle%3DIndazole%2520compounds%2520and%2520pharmaceutical%2520compositions%2520for%2520inhibiting%2520protein%2520kinases%252C%2520and%2520methods%2520for%2520their%2520use%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Zuccotto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angiolini, M.</span><span> </span><span class="NLM_article-title">Through the "gatekeeper door": exploiting the active kinase conformation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">2681</span><span class="NLM_x">â</span> <span class="NLM_lpage">2694</span><span class="refDoi">Â DOI: 10.1021/jm901443h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901443h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2681-2694&issue=7&author=F.+Zuccottoauthor=E.+Ardiniauthor=E.+Casaleauthor=M.+Angiolini&title=Through+the+%22gatekeeper+door%22%3A+exploiting+the+active+kinase+conformation&doi=10.1021%2Fjm901443h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm901443h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901443h%26sid%3Dliteratum%253Aachs%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DAngiolini%26aufirst%3DM.%26atitle%3DThrough%2520the%2520%2522gatekeeper%2520door%2522%253A%2520exploiting%2520the%2520active%2520kinase%2520conformation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D7%26spage%3D2681%26epage%3D2694%26doi%3D10.1021%2Fjm901443h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Thorarensen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banker, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fensome, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telliez, J.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juba, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czerwinski, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casimiro-Garcia, A.</span><span> </span><span class="NLM_article-title">ATP-mediated kinome selectivity: the missing link in understanding the contribution of individual JAK kinase isoforms to cellular signaling</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1552</span><span class="NLM_x">â</span> <span class="NLM_lpage">1558</span><span class="refDoi">Â DOI: 10.1021/cb5002125</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5002125" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1552-1558&issue=7&author=A.+Thorarensenauthor=M.+E.+Bankerauthor=A.+Fensomeauthor=J.-B.+Telliezauthor=B.+Jubaauthor=F.+Vincentauthor=R.+M.+Czerwinskiauthor=A.+Casimiro-Garcia&title=ATP-mediated+kinome+selectivity%3A+the+missing+link+in+understanding+the+contribution+of+individual+JAK+kinase+isoforms+to+cellular+signaling&doi=10.1021%2Fcb5002125"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fcb5002125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5002125%26sid%3Dliteratum%253Aachs%26aulast%3DThorarensen%26aufirst%3DA.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DJuba%26aufirst%3DB.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26atitle%3DATP-mediated%2520kinome%2520selectivity%253A%2520the%2520missing%2520link%2520in%2520understanding%2520the%2520contribution%2520of%2520individual%2520JAK%2520kinase%2520isoforms%2520to%2520cellular%2520signaling%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26issue%3D7%26spage%3D1552%26epage%3D1558%26doi%3D10.1021%2Fcb5002125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Ritchie, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, S. J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickett, S. D.</span><span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">3/4</span><span class="NLM_x">) </span> <span class="NLM_fpage">164</span><span class="NLM_x">â</span> <span class="NLM_lpage">171</span><span class="refDoi">Â DOI: 10.1016/j.drudis.2010.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1016%2Fj.drudis.2010.11.014" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=164-171&issue=3%2F4&author=T.+J.+Ritchieauthor=S.+J.+F.+MacDonaldauthor=R.+J.+Youngauthor=S.+D.+Pickett&title=The+impact+of+aromatic+ring+count+on+compound+developability%3A+further+insights+by+examining+carbo-+and+hetero-aromatic+and+-aliphatic+ring+types&doi=10.1016%2Fj.drudis.2010.11.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacDonald%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%253A%2520further%2520insights%2520by%2520examining%2520carbo-%2520and%2520hetero-aromatic%2520and%2520-aliphatic%2520ring%2520types%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26issue%3D3%252F4%26spage%3D164%26epage%3D171%26doi%3D10.1016%2Fj.drudis.2010.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Walker, M. A.</span><span> </span><span class="NLM_article-title">Novel tactics for designing water-soluble molecules in drug discovery</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1421</span><span class="NLM_x">â</span> <span class="NLM_lpage">1433</span><span class="refDoi">Â DOI: 10.1517/17460441.2014.960839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1517%2F17460441.2014.960839" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1421-1433&issue=12&author=M.+A.+Walker&title=Novel+tactics+for+designing+water-soluble+molecules+in+drug+discovery&doi=10.1517%2F17460441.2014.960839"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1517%2F17460441.2014.960839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2014.960839%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DM.%2BA.%26atitle%3DNovel%2520tactics%2520for%2520designing%2520water-soluble%2520molecules%2520in%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2014%26volume%3D9%26issue%3D12%26spage%3D1421%26epage%3D1433%26doi%3D10.1517%2F17460441.2014.960839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Lovering, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bikker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humblet, C.</span><span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">6752</span><span class="NLM_x">â</span> <span class="NLM_lpage">6756</span><span class="refDoi">Â DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&issue=21&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0ljPo2FVouTHdQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D21%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Patton, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byron, P. R.</span><span> </span><span class="NLM_article-title">Inhaling medicines: delivering drugs to the body through the lungs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">67</span><span class="NLM_x">â</span> <span class="NLM_lpage">74</span><span class="refDoi">Â DOI: 10.1038/nrd2153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1038%2Fnrd2153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=17195033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlGktbbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=67-74&issue=1&author=J.+S.+Pattonauthor=P.+R.+Byron&title=Inhaling+medicines%3A+delivering+drugs+to+the+body+through+the+lungs&doi=10.1038%2Fnrd2153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Inhaling medicines: delivering drugs to the body through the lungs</span></div><div class="casAuthors">Patton, John S.; Byron, Peter R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-74</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Remarkably, with the exception of anesthetic gases, the ancient human practice of inhaling substances into the lungs for systemic effect has only just begun to be adopted by modern medicine.  Treatment of asthma by inhaled drugs began in earnest in the 1950s, and now such 'topical' or targeted treatment with inhaled drugs is considered for treating many other lung diseases.  More recently, major advances have led to increasing interest in systemic delivery of drugs by inhalation.  Small mols. can be delivered with very rapid action, low metab. and high bioavailability; and macromols. can be delivered without injections, as highlighted by the recent approval of the first inhaled insulin product.  Here, we review these advances, and discuss aspects of lung physiol. and formulation compn. that influence the systemic delivery of inhaled therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT_qTU0rDV17Vg90H21EOLACvtfcHk0lhVXl6bwMrjsQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlGktbbL&md5=81a851de5e01f016f0978cd64fbee624</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnrd2153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2153%26sid%3Dliteratum%253Aachs%26aulast%3DPatton%26aufirst%3DJ.%2BS.%26aulast%3DByron%26aufirst%3DP.%2BR.%26atitle%3DInhaling%2520medicines%253A%2520delivering%2520drugs%2520to%2520the%2520body%2520through%2520the%2520lungs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26issue%3D1%26spage%3D67%26epage%3D74%26doi%3D10.1038%2Fnrd2153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Hsu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, A. W.</span><span> </span><span class="NLM_article-title">JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis</span> <span class="citation_source-journal">J. Immunol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">2014</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">7</span><span class="refDoi">Â DOI: 10.1155/2014/283617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1155%2F2014%2F283617" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=1-7&author=L.+Hsuauthor=A.+W.+Armstrong&title=JAK+inhibitors%3A+treatment+efficacy+and+safety+profile+in+patients+with+psoriasis&doi=10.1155%2F2014%2F283617"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1155%2F2014%2F283617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2014%252F283617%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DL.%26aulast%3DArmstrong%26aufirst%3DA.%2BW.%26atitle%3DJAK%2520inhibitors%253A%2520treatment%2520efficacy%2520and%2520safety%2520profile%2520in%2520patients%2520with%2520psoriasis%26jtitle%3DJ.%2520Immunol.%2520Res.%26date%3D2014%26volume%3D2014%26spage%3D1%26epage%3D7%26doi%3D10.1155%2F2014%2F283617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Patricelli, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szardenings, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liyanage, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomanbhoy, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aban, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozarich, J. W.</span><span> </span><span class="NLM_article-title">Functional interrogation of the kinome using nucleotide acyl phosphates</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">350</span><span class="NLM_x">â</span> <span class="NLM_lpage">358</span><span class="refDoi">Â DOI: 10.1021/bi062142x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi062142x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtlaru7rO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=350-358&issue=2&author=M.+P.+Patricelliauthor=A.+K.+Szardeningsauthor=M.+Liyanageauthor=T.+K.+Nomanbhoyauthor=M.+Wuauthor=H.+Weissigauthor=A.+Abanauthor=D.+Chunauthor=S.+Tannerauthor=J.+W.+Kozarich&title=Functional+interrogation+of+the+kinome+using+nucleotide+acyl+phosphates&doi=10.1021%2Fbi062142x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Functional Interrogation of the Kinome Using Nucleotide Acyl Phosphates</span></div><div class="casAuthors">Patricelli, Matthew P.; Szardenings, A. Katrin; Liyanage, Marek; Nomanbhoy, Tyzoon K.; Wu, Min; Weissig, Helge; Aban, Arwin; Chun, Doris; Tanner, Stephen; Kozarich, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">350-358</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The central role of protein kinases in signal transduction pathways has generated intense interest in targeting these enzymes for a wide range of therapeutic indications.  Here we report a method for identifying and quantifying protein kinases in any biol. sample or tissue from any species.  The procedure relies on acyl phosphate-contg. nucleotides, prepd. from a biotin deriv. and ATP or ADP.  The acyl phosphate probes react selectively and covalently at the ATP binding sites of at least 75% of the known human protein kinases.  Biotinylated peptide fragments from labeled proteomes are captured and then sequenced and identified using a mass spectrometry-based anal. platform to det. the kinases present and their relative levels.  Further, direct competition between the probes and inhibitors can be assessed to det. inhibitor potency and selectivity against native protein kinases, as well as hundreds of other ATPases.  The ability to broadly profile kinase activities in native proteomes offers an exciting prospect for both target discovery and inhibitor selectivity profiling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiUQQGW0LLn7Vg90H21EOLACvtfcHk0lhVXl6bwMrjsQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtlaru7rO&md5=a912b834ff5456f09f1c45ddceb15dca</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fbi062142x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi062142x%26sid%3Dliteratum%253Aachs%26aulast%3DPatricelli%26aufirst%3DM.%2BP.%26aulast%3DSzardenings%26aufirst%3DA.%2BK.%26aulast%3DLiyanage%26aufirst%3DM.%26aulast%3DNomanbhoy%26aufirst%3DT.%2BK.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DWeissig%26aufirst%3DH.%26aulast%3DAban%26aufirst%3DA.%26aulast%3DChun%26aufirst%3DD.%26aulast%3DTanner%26aufirst%3DS.%26aulast%3DKozarich%26aufirst%3DJ.%2BW.%26atitle%3DFunctional%2520interrogation%2520of%2520the%2520kinome%2520using%2520nucleotide%2520acyl%2520phosphates%26jtitle%3DBiochemistry%26date%3D2007%26volume%3D46%26issue%3D2%26spage%3D350%26epage%3D358%26doi%3D10.1021%2Fbi062142x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Siewert, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller-Esterl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starr, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaper, F.</span><span> </span><span class="NLM_article-title">Different protein turnover of interleukin-6-type cytokine signalling components</span> <span class="citation_source-journal">Eur. J. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">265</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">251</span><span class="NLM_x">â</span> <span class="NLM_lpage">257</span><span class="refDoi">Â DOI: 10.1046/j.1432-1327.1999.00719.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1046%2Fj.1432-1327.1999.00719.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10491180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADyaK1MXmsFKks7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=1999&pages=251-257&issue=1&author=E.+Siewertauthor=W.+Muller-Esterlauthor=R.+Starrauthor=P.+C.+Heinrichauthor=F.+Schaper&title=Different+protein+turnover+of+interleukin-6-type+cytokine+signalling+components&doi=10.1046%2Fj.1432-1327.1999.00719.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Different protein turnover of interleukin-6-type cytokine signalling components</span></div><div class="casAuthors">Siewert, Elmar; Muller-Esterl, Werner; Starr, Robin; Heinrich, Peter C.; Schaper, Fred</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">265</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">251-257</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Interleukin (IL)-6 and IL-6-type cytokines signal through the gp130/Jak/STAT signal transduction pathway.  The key components involved are the signal transducing receptor subunit gp130, the Janus kinases Jak1, Jak2 and Tyk2, STAT1 and STAT3 of the family of signal transducers and activators of transcription, the protein tyrosine phosphatase SHP2 and the suppressors of cytokine signalling SOCS1, SOCS2 and SOCS3.  Whereas considerable information has been accumulated concerning the time-course of activation for the individual signalling mols., data on the availability of the proteins involved in IL-6-type cytokine signal transduction are scarce.  Nevertheless, availability of these mols., detd. by the balance of protein synthesis and degrdn., also influences IL-6-type cytokine signal transduction.  Here, we present a comprehensive set of data on the half-lives of the key mols. involved in the IL-6 signal transduction pathway.  The turnover rates for the various proteins differ substantially.  Three groups of signalling proteins can be discriminated: whereas the feedback inhibitors SOCS1, SOCS2 and SOCS3 are very short-lived, STAT1, STAT3 and SHP2 have an extremely slow turnover rate.  Interestingly, the half-life of STAT3Î², a splice variant of STAT3Î±, is reduced to almost 50% of the half-life of STAT3Î±.  The Janus kinases Jak1, Jak2, Tyk2 and gp130 show intermediate half-lives.  The data imply that signalling components activated by post-translational modifications are long-lived whereas the activity of very short-lived proteins is regulated mainly at the transcriptional level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrykEOWrPY1qrVg90H21EOLACvtfcHk0ljwyazHbScGng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsFKks7g%253D&md5=9a92232aa03148d1a70e5a9c2cd89733</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1046%2Fj.1432-1327.1999.00719.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1432-1327.1999.00719.x%26sid%3Dliteratum%253Aachs%26aulast%3DSiewert%26aufirst%3DE.%26aulast%3DMuller-Esterl%26aufirst%3DW.%26aulast%3DStarr%26aufirst%3DR.%26aulast%3DHeinrich%26aufirst%3DP.%2BC.%26aulast%3DSchaper%26aufirst%3DF.%26atitle%3DDifferent%2520protein%2520turnover%2520of%2520interleukin-6-type%2520cytokine%2520signalling%2520components%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1999%26volume%3D265%26issue%3D1%26spage%3D251%26epage%3D257%26doi%3D10.1046%2Fj.1432-1327.1999.00719.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Diez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voldoire, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubiralta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segarra, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pages, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palacios, J. M.</span><span> </span><span class="NLM_article-title">Synthetic applications of 2-aryl-4-piperidones. X. Synthesis of 3-aminopiperidines, potential substances P antagonists</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">5143</span><span class="NLM_x">â</span> <span class="NLM_lpage">56</span><span class="refDoi">Â DOI: 10.1016/0040-4020(95)98710-Y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=10.1016%2F0040-4020%2895%2998710-Y" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1995&pages=5143-56&issue=17&author=A.+Diezauthor=A.+Voldoireauthor=I.+Lopezauthor=M.+Rubiraltaauthor=V.+Segarraauthor=L.+Pagesauthor=J.+M.+Palacios&title=Synthetic+applications+of+2-aryl-4-piperidones.+X.+Synthesis+of+3-aminopiperidines%2C+potential+substances+P+antagonists&doi=10.1016%2F0040-4020%2895%2998710-Y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2F0040-4020%2895%2998710-Y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4020%252895%252998710-Y%26sid%3Dliteratum%253Aachs%26aulast%3DDiez%26aufirst%3DA.%26aulast%3DVoldoire%26aufirst%3DA.%26aulast%3DLopez%26aufirst%3DI.%26aulast%3DRubiralta%26aufirst%3DM.%26aulast%3DSegarra%26aufirst%3DV.%26aulast%3DPages%26aufirst%3DL.%26aulast%3DPalacios%26aufirst%3DJ.%2BM.%26atitle%3DSynthetic%2520applications%2520of%25202-aryl-4-piperidones.%2520X.%2520Synthesis%2520of%25203-aminopiperidines%252C%2520potential%2520substances%2520P%2520antagonists%26jtitle%3DTetrahedron%26date%3D1995%26volume%3D51%26issue%3D17%26spage%3D5143%26epage%3D56%26doi%3D10.1016%2F0040-4020%2895%2998710-Y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Flohr, A.; Jakob-Roetne, R.; Norcross, R. D.; Riemer, C.</span><span> </span><span class="NLM_article-title">Imidazolyl benzothiazoles as adenosine receptor ligands, processes for their preparations, pharmaceutical formulations and uses thereof</span>. US20040229862,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=A.+Flohr&author=R.+Jakob-Roetne&author=R.+D.+Norcross&author=C.+Riemer&title=Imidazolyl+benzothiazoles+as+adenosine+receptor+ligands%2C+processes+for+their+preparations%2C+pharmaceutical+formulations+and+uses+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFlohr%26aufirst%3DA.%26atitle%3DImidazolyl%2520benzothiazoles%2520as%2520adenosine%2520receptor%2520ligands%252C%2520processes%2520for%2520their%2520preparations%252C%2520pharmaceutical%2520formulations%2520and%2520uses%2520thereof%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Ramis, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calama, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domenech, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carreno, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calaf, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordoba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alberti, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Alba, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bach, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prats, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miralpeix, M.</span><span> </span><span class="NLM_article-title">New inhaled JAK inhibitor LAS194046 inhibits allergen-induced airway inflammation in Brown Norway rats</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 58</span><span class="NLM_x">) </span> <span class="NLM_fpage">1508</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2014&pages=1508&issue=Suppl.+58&author=I.+Ramisauthor=E.+Calamaauthor=A.+Domenechauthor=C.+Carrenoauthor=E.+Calafauthor=M.+Cordobaauthor=J.+Albertiauthor=J.+De+Albaauthor=J.+Bachauthor=N.+Pratsauthor=M.+Miralpeix&title=New+inhaled+JAK+inhibitor+LAS194046+inhibits+allergen-induced+airway+inflammation+in+Brown+Norway+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRamis%26aufirst%3DI.%26aulast%3DCalama%26aufirst%3DE.%26aulast%3DDomenech%26aufirst%3DA.%26aulast%3DCarreno%26aufirst%3DC.%26aulast%3DCalaf%26aufirst%3DE.%26aulast%3DCordoba%26aufirst%3DM.%26aulast%3DAlberti%26aufirst%3DJ.%26aulast%3DDe%2BAlba%26aufirst%3DJ.%26aulast%3DBach%26aufirst%3DJ.%26aulast%3DPrats%26aufirst%3DN.%26aulast%3DMiralpeix%26aufirst%3DM.%26atitle%3DNew%2520inhaled%2520JAK%2520inhibitor%2520LAS194046%2520inhibits%2520allergen-induced%2520airway%2520inflammation%2520in%2520Brown%2520Norway%2520rats%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2014%26volume%3D44%26issue%3DSuppl.%252058%26spage%3D1508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Ritzen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soerensen, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dack, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greve, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jerre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnerup, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rytved, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagger-Bahnsen, J.</span><span> </span><span class="NLM_article-title">Fragment-based discovery of 6-arylindazole JAK inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">641</span><span class="NLM_x">â</span> <span class="NLM_lpage">646</span><span class="refDoi">Â DOI: 10.1021/acsmedchemlett.6b00087</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00087" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=641-646&issue=6&author=A.+Ritzenauthor=M.+D.+Soerensenauthor=K.+N.+Dackauthor=D.+R.+Greveauthor=A.+Jerreauthor=M.+A.+Carnerupauthor=K.+A.+Rytvedauthor=J.+Bagger-Bahnsen&title=Fragment-based+discovery+of+6-arylindazole+JAK+inhibitors&doi=10.1021%2Facsmedchemlett.6b00087"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00087%26sid%3Dliteratum%253Aachs%26aulast%3DRitzen%26aufirst%3DA.%26aulast%3DSoerensen%26aufirst%3DM.%2BD.%26aulast%3DDack%26aufirst%3DK.%2BN.%26aulast%3DGreve%26aufirst%3DD.%2BR.%26aulast%3DJerre%26aufirst%3DA.%26aulast%3DCarnerup%26aufirst%3DM.%2BA.%26aulast%3DRytved%26aufirst%3DK.%2BA.%26aulast%3DBagger-Bahnsen%26aufirst%3DJ.%26atitle%3DFragment-based%2520discovery%2520of%25206-arylindazole%2520JAK%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D6%26spage%3D641%26epage%3D646%26doi%3D10.1021%2Facsmedchemlett.6b00087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Baell, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, G. A.</span><span> </span><span class="NLM_article-title">New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">2719</span><span class="NLM_x">â</span> <span class="NLM_lpage">2740</span><span class="refDoi">Â DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&issue=7&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+substructure+filters+for+removal+of+pan+assay+interference+compounds+%28PAINS%29+from+screening+libraries+and+for+their+exclusion+in+bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0ljlmhko8Ouhgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520substructure%2520filters%2520for%2520removal%2520of%2520pan%2520assay%2520interference%2520compounds%2520%2528PAINS%2529%2520from%2520screening%2520libraries%2520and%2520for%2520their%2520exclusion%2520in%2520bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D7%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LXK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LXK','PDB','3LXK'); return false;">PDB: 3LXK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ7','PDB','5TQ7'); return false;">PDB: 5TQ7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ3','PDB','5TQ3'); return false;">PDB: 5TQ3</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ4','PDB','5TQ4'); return false;">PDB: 5TQ4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ5','PDB','5TQ5'); return false;">PDB: 5TQ5</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ8','PDB','5TQ8'); return false;">PDB: 5TQ8</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i31"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01634">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_46851"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b01634">10.1021/acs.jmedchem.6b01634</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01634/suppl_file/jm6b01634_si_001.csv">CSV</a>)</p></li><li><p class="inline">General chemistry experimental procedures; all synthetic procedures and analytical data with synthesis schemes; selected HPLC and NMR spectra of <b>2</b>; kinase inhibition panels for selected compounds and polypharmacology and broad kinase inhibition profile for <b>2</b>; biology experimental procedures; table of crystallography information (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01634/suppl_file/jm6b01634_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01634/suppl_file/jm6b01634_si_001.csv">jm6b01634_si_001.csv (1.73 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01634/suppl_file/jm6b01634_si_002.pdf">jm6b01634_si_002.pdf (2.59 MB)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes are the following: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LXK">3LXK</a> for <b>1</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ7">5TQ7</a> for <b>4</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ3">5TQ3</a> for <b>5</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ4">5TQ4</a> for <b>13</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ5">5TQ5</a> for <b>16</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TQ8">5TQ8</a> for <b>2</b>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b01634&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b01634%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-2%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b01634" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e0b9d7dafa198b","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
